Furopyridine compounds as p53 mutant stabilizer and uses thereof

Furopyridine compounds address the need for effective small molecules to stabilize and restore the wild-type function of mutant p53 proteins, particularly the Y220C mutation, providing a therapeutic option for treating cancers.

WO2024238406A1PCT designated stage expired Publication Date: 2024-11-21FRONTIER MEDICINES CORP

Patent Information

Application Number
PCT/US2024/028984
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-26
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current therapies lack effective small molecules that can bind to the Y220C mutant p53 protein with high potency to restore its wild-type function, which is crucial for treating proliferative disorders like cancer associated with p53 mutations.

Method used

Development of furopyridine compounds that bind to the mutant p53 protein, specifically designed to stabilize its conformation and restore wild-type function by modulating its structure.

Benefits of technology

The furopyridine compounds effectively stabilize and restore the wild-type function of mutant p53 proteins, offering a potential therapeutic approach for treating cancers associated with p53 mutations by targeting the Y220C mutation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000005_0001
    Figure IMGF000005_0001
Patent Text Reader

Abstract

The present disclosure relates to compounds and methods to restore wild-type function of p53 mutants and to treat proliferative disorders or cancers associated with p53 mutation.
Need to check novelty before this filing date? Find Prior Art

Description

FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority benefit of United States Provisional Patent Application No. 63 / 466,228, filed May 12, 2023, and United States Provisional Patent Application No. 63 / 558,097, filed February 26, 2024, the contents of each of which are incorporated herein by reference in their entirety.FIELD

[0002] The present disclosure in some aspects relates generally to compounds that bind to a mutant p53 protein and are capable of modulating the conformation thereof. The present disclosure in some aspects relates generally to method of restoring wild-type function of p53 mutants and treating proliferative disorders, such as cancers associated with p53 mutation.BACKGROUND

[0003] The transcription factor p53 functions as a tumor suppressor and is one of the most potent tumor suppressors in the cell, as it regulates a plethora of intracellular metabolic pathways, including DNA damage repair, apoptosis, and senescence. The gene encoding the p53 protein is the most frequently altered gene in human tumors. The loss of transcriptional functions leading to the deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 is the primary outcome of p53 mutations, and is a hallmark of most cancers.

[0004] Y220C is the most common mutation outside the DNA-binding surface and is associated with over 100,000 new cancer cases per year worldwide. The hydrophobic and “druggable” nature of the Y220C pocket offers a fruitful opportunity for targeting using small-molecule stabilizers. However, small molecules with high potency of binding to the Y220C mutation and restoring the wild-type function of p53 remain an unmet need. The present disclosure addresses this and other needs.SUMMARY

[0005] In one aspect, provided herein is a compound of Formula (O):or a salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; and wherein at least one of R1, R2, R3, and R4is RA; wherein RA, at each occurrence, is independently -ORAa, -O-(L1)n-NRw2Rw3, -SRAl, -N(Rw4)-M1-C(O)- L2-RAb, -N(Rw4)-M1-C(O)-RAb, -N(Rw4)-C(O)-L2-RAb, -N(Rw5)-C(O)-RAc, -N(Rw7)-(L3)n- C(O)-N(Rw8)-RAd, -N(Rw9)-RAe, -N(Rw10)-M2-L4-RAf, -N(Rw10)-M2-RAf, -N(Rw10)-L4-RAf,- N(Rw11)-(M3)m-Rx, -N(Rw12)-M4-L5-N(Rw13)RAg, -N(Rw12)-M4-N(Rw13)RAg, -N(Rw12)-L5- N(Rw13)RAg, -S(O)2NRw24Rw25, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, or - N(Rw14)-L6-N(Rw15)-Ry; R1, R2, R3, and R4, when present, are each independently RA, H, deuterium, halogen, -CN, - NO2, -ORw1, -N(Rw6)C(O)Rw7, -(L7)n-RAh, -NRw16Rw17, -C(O)ORw18, -C(O)RAi, -C(O)Rw19, - C(O)N(Rw20)-RAj, -C(O)N(Rw21)-L8-RAk, -C(O)N(Rw21)-M6-RAk, -C(O)N(Rw21)-L8-M6-RAk, - C(O)NRw22Rw23, -Rz, C2-C6alkenyl, or C2-C6alkynyl optionally substituted with one or more -NRw26RAm, or any two vicinal R1, R2, R3, and R4are taken together with the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl) -C(O)-M7-N(Ru5)-R5a-C(O)-N(Ru5)-L12-R5a-C(O)-M7-N(Ru5)-L12-R5a-C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl, or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl; RAa, RAb, RAc, RAd, RAe, RAf, RAg, RAh, RAi, RAj, RAk, RAl, RAm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3- C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl optionally substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or,R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more oxo, independently selected C1- C6alkyl, or independently selected C3-C6cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0006] In one aspect, provided herein is a compound of Formula (I)or a salt thereof, wherein: R1is H; deuterium; halogen; -NO2; C(O)Rw1; C1-C6 alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; C3-C14cycloalkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; or C2-C6 alkynyl, R2is -OR2a, -O-(L1)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, - N(Rx5)-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n-C(O)-N(Rx7)-R2e, -N(Rx8)-R2A, - N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3- N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -(L6)n-R2h, -C(O)R2i, -N(Rx13)-M5- L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7-N(Rx14)-R2y, or R1is taken together with R2and the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R2a, R2b, R2c, R2d, R2e, R2f, R2h, R2i, and R2j, at each occurrence, are independently 3- to 14- membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, - S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L8)n-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted with one or more R21a, C3-C6cycloalkyl optionally substituted with one or more R21a, 5- to 12-memberedmembered heterocyclyl optionally substituted with one or more R21b, orR21a, at each occurrence, is independently halogen, -ORa, - N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, 3- to 14-membered heterocyclyl, or 5- to 12-membered heteroaryl, R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6 cycloalkyl; R22, at each occurrence, is independently C1-C6 alkyl, C3-C6 cycloalkyl, -OH, - OD, -S(O)2Ra, -C(O)N(Ra)2, or -N(Ra)2; R23, at each occurrence, is independently -N(Ra)2, C1-C6 alkyl, or C3-C6 cycloalkyl; R24, at each occurrence, is independently -OH, -OD, oxo, -C(O)N(Ra)2, or - N(Ra)C(O)Ra; R2xis C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen, -ORa, -N(Ra)2, -C(O)- N(Ra)2, or -N(Ra)C(O)-Ra; R2yis C1-C6alkyl optionally substituted with one or more R26; R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)- N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L9)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R2Ais 3- to 14-membered heterocyclyl, C6-C12 aryl, 5- to 14-membered heteroaryl, or C3-C14cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, oxo, -OH, -OD, -C(O)-(L10)n-N(Ra)2, -C(O)Ra, or -N(Ra)C(O)Ra;R4is H, deuterium, -N(Ra)2, -NO2, C3-C14cycloalkyl, -C(O)ORz1, -N(Rz2)-(L11)n-R4a, -C(O)- R4b, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-L12-M6-R4d, -C(O)N(Rz4)-L12-R4d, -C(O)N(Rz4)-M6-R4d, or -C(O)NRz5Rz6, R4a, R4b, R4c, and R4d, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R41, C6-C12aryl optionally substituted with one or more R42, 5- to 14-membered heteroaryl optionally substituted with one or more R43, or C3-C14 cycloalkyl optionally substituted with one or more R44; R41, R42, R43, and R44, at each occurrence, are independently halogen, - S(O)2N(Ra)2, C1-C6 alkyl optionally substituted with one or more -ORa, or C3- C6cycloalkyl optionally substituted with one or more -ORa; R5is H, deuterium, halogen, -(L13)n-NR5AR5B, C1-C6 alkyl optionally substituted with one or more halogen, C3-C6cycloalkyl optionally substituted with one or more halogen, C2-C6alkenyl optionally substituted with one or more R5C, C2-C6alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or -C(O)-N(Ru2)-R5x; R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5a; R5C, at each occurrence, is independently -OR5C1, -N(Ra)R5C2, or R5c; R5C1and R5C2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6cycloalkyl, or C6-C12aryl; R5D, at each occurrence, is independently -N(Ra)R5D1or R5d; R5D1, at each occurrence, is independently C6-C12 aryl optionally substituted with one or more independently selected -ORa, -C(O)N(Ra)2, or -S(O)2N(Ra)2; R5a, R5c, R5d, and R5e, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12 aryl optionally substituted with one or more R52, 5- to 14-membered heteroaryl optionally substituted with one or more R53, or C3-C12cycloalkyl optionally substituted with one or more R54; R51, R52, R53, and R54, at each occurrence, are independently halogen, oxo, - CN, -C(O)Rz8, -S(O)2Ra, -C(O)-N(Ra)2, 3- to 14-membered heteroaryl, C1-C6alkyl optionally substituted one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted one or more independently selected halogen;R5xis C1-C6alkyl optionally substituted with one or more independently selected -O- (C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, and L14, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, and M6, at each occurrence, are independently C6-C12 arylene, C3-C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1; Rw1, Rx1, Rx2, Rx3, Rx4, Rx5, Rx6, Rx7, Rx8, Rx9, Rx10, Rx11, Rx12, Rx13, Rx14, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Ru1, Ru2, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0007] In some embodiments of Formula (I), R1is H, deuterium, or Br. In some embodiments of Formula (I), R2is -OR2a, -O-(L1)n-NRx1Rx2, -SR2b, -N(Rx4)-C(O)-R2c, - N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n-C(O)- N(Rx7)-R2e, -N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3- L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, - N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L7-N(Rx14)-R2y, 5- to 14- membered heterocycle optionally substituted with one or more R21, or 5- to 14-membered heteroaryl optionally substituted with one or more R23. In some embodiments of Formula (I), R2is -OR2a, -O-L1-NRx1Rx2, or -SR2b. In some embodiments of Formula (I), R2is 5- to 14- membered heteroaryl optionally substituted with one or more R23. In some embodiments of Formula (I), R2is unsubstituted 5- to 10-membered heteroaryl. In some embodiments of Formula (I), R2is -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, or -N(Rx5)- M1-C(O)-L2-R2d. In some embodiments of Formula (I), R2is -N(Rx4)-C(O)-R2c, and wherein R2cis 3- to 14-membered heterocyclyl optionally substituted with one or more R21. In some embodiments of Formula (I), R2is -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, or -N(Rx5)- M1-C(O)-L2-R2d, wherein M1 is 3- to 12-membered heterocyclylene, L2 is C1-C8 alkylene, and R2dis 3- to 14-membered heterocyclyl optionally substituted with one or more R21. InN(Rx7)-R2e. In some embodiments of Formula (I), R2is N(Rx6)-L3-C(O)-N(Rx7)-R2e, and L3is C1-C8 alkylene. In some embodiments of Formula (I), R2eis 3- to 14-membered heterocyclyl optionally substituted with one or more R21or C3-C14 cycloalkyl optionally substituted with one or more R24. In some embodiments of Formula (I), R2is -N(Rx8)-R2A. In some embodiments of Formula (I), R2Ais C6-C12aryl or C3-C14cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, oxo, -OH, -OD, -C(O)-L10-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, or -N(Ra)C(O)Ra. In some embodiments of Formula (I), R2is -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, or -N(Rx9)-M2-L4-R2f. In some embodiments of Formula (I), R2is -N(Rx9)-M2-R2f, wherein M2 is C3-C14 cycloalkylene or 3- to 14-membered heterocyclylene optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl. In some embodiments of Formula (I), R2is -N(Rx9)- M2-R2f, and R2fis C6-C12 aryl. In some embodiments of Formula (I), R2is -N(Rx9)-M2-R2f, and R2fis 5- to 14-membered heteroaryl. In some embodiments of Formula (I), R2is -N(Rx9)- M2-R2f, and R2fis C3-C14cycloalkyl. In some embodiments of Formula (I), R2is -N(Rx9)-M2- R2f, wherein R2fis 3- to 14-membered heterocyclyl optionally substituted with one or more R21, and wherein R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, - S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-L8-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, - N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted with one or more R21a, C3-C6cycloalkyl optionally substituted with one or more R21a, 5- to 14-membered heteroaryl optionally substituted with one or more Ra, C6-C12aryl, 3- to 14-membered heterocyclyl optionally substituted with one or moresome embodiments of Formula (I), R2is -N(Rx9)-M2-R2f, wherein R2fis 3- to 14-membered heterocyclyl substituted with one or more R21, and wherein R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-L8- N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted with one or more R21a, C3-C6 cycloalkyl optionally substituted with one or more R21a, or 5- to 12 membered heteroaryl substituted with one or more Ra. In some embodiments of Formula (I), R2is -N(Rx9)-M2-R2f, wherein R2fis unsubstituted 3- to 14-membered heterocyclyl. In some embodiments of Formula (I), R2is -N(Rx9)-L4-R2f, and wherein L4 is C1-C8 alkylene. In some embodiments of Formula (I), R2is -N(Rx9)-L4-R2f, and R2fis unsubstituted 3- to 14- membered heterocyclyl. In some embodiments of Formula (I), R2is -N(Rx9)-L4-R2f, and R2fisC(O)-N(Ra)2, C1-C6alkyl, or C3-C6cycloalkyl. In some embodiments of Formula (I), R2is - N(Rx9)-M2-L4-R2f. In some embodiments of Formula (I), R2is -N(Rx9)-M2-L4-R2f, wherein M2 is 3- to 14-membered heterocyclylene, and wherein L4 is C1-C6 alkylene. In some embodiments of Formula (I), R2is -N(Rx9)-M2-L4-R2f, and R2fis C6-C12aryl optionally substituted with one or more R22. In some embodiments of Formula (I), R2is -N(Rx10)-M3- N(Rx11)-R2jor -N(Rx10)-L5-N(Rx11)-R2j. In some embodiments of Formula (I), R2is -N(Rx10)- M3-N(Rx11)-R2j, and wherein M3 is 3- to 14-membered heterocyclylene or C3-C14 cycloalkylene, each of which is optionally substituted with one or more independently selected oxo, C1-C6 alkyl, or C3-C6 cycloalkyl. In some embodiments of Formula (I), R2is - N(Rx10)-L5-N(Rx11)-R2j, and wherein L5 is C1-C8 alkylene. In some embodiments of Formula (I), R2jis 3- to 14-membered heterocyclyl optionally substituted with one or more R21, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; wherein R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -N(Ra)C(O)Ra, C1-C6alkyl, or C3-C6cycloalkyl, wherein R23, at each occurrence, is independentlyC1-C6alkyl or C3-C6cycloalkyl; and wherein R24, at each occurrence, is independently oxo, halogen, -ORa, -C(O)-(L8)n-N(Ra)2, or -N(Ra)C(O)Ra. In some embodiments of Formula (I), R2is -N(Rx13)-M5-N(Rx14)-R2y, - N(Rx13)-L7-N(Rx14)-R2y, or -N(Rx13)-M5-L7-N(Rx14)-R2y. In some embodiments of Formula (I), R2is -N(Rx13)-M5-N(Rx14)-R2y, and wherein M5 is C3-C14 cycloalkylene optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl. In some embodiments of Formula (I), R2is -N(Rx13)-L7-N(Rx14)-R2y, and wherein L7is C1-C8alkylene. In some embodiments of Formula (I), R2is -N(Rx13)-M5-L7-N(Rx14)-R2y, wherein M5 is C3-C14 cycloalkylene, and wherein L7 is C1-C8 alkylene. In some embodiments of Formula (I), R2yis C1-C6alkyl optionally substituted with one or more R26, and R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)-N(Ra)2; -N(Ra)C(O)-Ra; - N(Ra)C(O)-(C6-C12 aryl); -N(Ra)C(O)-(C1-C6 alkylene)-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6alkyl, or C3-C6 cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD. In some embodiments of Formula (I), R2yis C1-C6alkyl optionally substituted with one or more R26, and R26, at each occurrence, is independently -ORa; -N(Ra)2; -C(O)-N(Ra)2; -N(Ra)C(O)-Ra; - N(Ra)C(O)-(C6-C12aryl); -N(Ra)C(O)-(C1-C6alkylene)-(C6-C12aryl); 3- to 10-memberedor C3-C6cycloalkyl; or 3 to 10-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments of Formula (I), R2is -N(Rx12)-R2xor -N(Rx12)-M4-R2x. In some embodiments of Formula (I), R2is -N(Rx12)- R2x. In some embodiments of Formula (I), R2is -N(Rx12)-M4-R2x, and wherein M4is C3-C14cycloalkylene or 3- to 14-membered heterocyclylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2. In some embodiments of Formula (I), R2xis C1-C6 alkyl optionally substituted with one or more R25, and wherein R25, at each occurrence, is independently halogen, -OH, -OD, -OCH3, or -N(CH3)2. In some embodiments of Formula (I), In some embodiments of Formula (I), R2is -C(O)ORx3, -C(O)R2i, -L6-R2h, 3- to 14- membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, or C3-C14 cycloalkyl optionally substituted with one or more R24. In some embodiments of Formula (I), R2is -C(O)ORx3, and wherein Rx3is H, D, C1-C3alkyl, or C3-C6cycloalkyl. In some embodiments of Formula (I), R2is -C(O)R2i, and wherein R2iis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments of Formula (I), R2is -L6-R2h, wherein L6is C1-C8alkylene, and wherein R2his 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3alkyl or C3-C6 cycloalkyl, each of which is optionally substituted with one or more independently selected -OH, -OD, halogen, or -N(Ra)2. In some embodiments of Formula (I), R2is 3- to 14- membered heterocyclyl optionally substituted with one or more independently selected C1-C3alkyl or C3-C6 cycloalkyl, each of which is optionally substituted with one or more independently selected -OH, -OD, halogen, or -N(Ra)2.

[0008] In some embodiments of Formula (I), R1is taken together with R2and the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b. In some embodiments of Formula (I), R1b, at each occurrence, is independently 3- to 14-membered heterocyclyl or -N(Ra)-(3- to 14- membered heterocyclyl), wherein any 3- to 14-membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl.

[0009] In some embodiments of Formula (I), R4is H or deuterium. In some embodiments of Formula (I), R4is -N(Ra)2 or -NO2, wherein each Rais independently H or D. In some embodiments of Formula (I), R4is unsubstituted C3-C14cycloalkyl. In some embodiments ofN(Rz4)-M6-R4d, -C(O)-N(Rz4)-L12-R4d, or -C(O)NRz5Rz6. In some embodiments of Formula (I), R4is -C(O)N(Rz3)-R4c, and wherein R4cis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected halogen, or C6-C12 aryl optionally substituted with one or more -S(O)2N(Ra)2, wherein each Rais independently H or D. In some embodiments of Formula (I), R4is -C(O)-N(Rz4)-L12-M6-R4d, -C(O)-N(Rz4)-M6-R4d, or - C(O)-N(Rz4)-L12-R4d, wherein R4dis 3- to 14-membered heterocyclyl optionally substituted with one or more R41, C6-C12 aryl optionally substituted with one or more R42, 5- to 14- membered heteroaryl optionally substituted with one or more R43, or C3-C14cycloalkyl optionally substituted with one or more R44. In some embodiments of Formula (I), R4is - C(O)NRz5Rz6. In some embodiments of Formula (I), R4is -N(Rz2)-L11-R4aor -N(Rz2)-R4a, and wherein R4ais C6-C12aryl optionally substituted with one or more R42.

[0010] In some embodiments of Formula (I), R5is H or deuterium. In some embodiments of Formula (I), R5is -L13-NR5AR5Bor -NR5AR5B, wherein R5Aand R5Bare independently C2- C6alkynyl or C6-C12aryl. In some embodiments of Formula (I), In some embodiments of Formula (I), R5is C2-C6alkenyl optionally substituted with one or more R5C, and wherein R5C, at each occurrence, is independently -OH, -OD, -OCH3, -O-(C6-C12 aryl), -NH-(C6-C12 aryl), -ND-(C6-C12aryl), C3-C12cycloalkyl, or C6-C12aryl. In some embodiments of Formula (I), R5is C2-C6alkynyl optionally substituted with one or more R5D, and wherein R5D, at each occurrence, is independently C6-C12aryl, -NH-(C6-C12aryl),. some embodiments of Formula (I), R5is -C(O)-N(Ru1)-L14- R5eor -C(O)-N(Ru1)-R5e, wherein R5eis 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12 aryl optionally substituted with one or more R52, 5- to 14-membered heteroaryl optionally substituted with one or more R53, or C3-C12 cycloalkyl optionally substituted with one or more R54. In some embodiments of Formula (I), R5is- C(O)-N(Ru2)-R5x, and wherein R5xis C1-C6 alkyl optionally substituted with one or more - OCF3.

[0011] In some embodiments of Formula (I)R1is H, deuterium, halogen, or C1-C6alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; R2is -SR2b, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, - N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5- N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, - (L6)n-R2h, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7- N(Rx14)-R2y, R4is H, D, C3-C14cycloalkyl, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-(L12)n-(M6)m-R4d, or - C(O)NRz5Rz6; and R5is H, deuterium, C2-C6 alkenyl optionally substituted with one or more R5C, C2-C6 alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or - C(O)-N(Ru2)-R5x.

[0012] In some embodiments of Formula (I), provided herein is a compound selected from compounds in Table 1 or Table 1A, or a pharmaceutically acceptable salt thereof.

[0013] In another aspect, provided herein is a compound of Formula (II)or a salt thereof, wherein: R1is H, deuterium, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, -N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, C1-C6alkyl optionally substituted with one or more independently selected halogen, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen, or C2-C6 alkynyl optionally substituted with one or more independently selected -N(Rw9)R1f, R3is H, deuterium, -N(Ry3)-R3a, -C(O)ORy4, -N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, or - S(O)2NRy8Ry9; R4is H, deuterium, halogen, -N(Rz1)Rz2, -N(Rz3)-(L4)n-R4a, -N(Rz4)-C(O)-(L5)n-R4b, - C(O)ORz5, -C(O)N(Rz6)R4c, C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, or C2-C6alkynyl optionally substituted with one or more independently selected -NRz7R4d,R5is H, deuterium, Br, I, -ORu1, -O-(C2-C6alkynyl), -C(O)NRu2Ru3, -C(O)-M1-N(Ry1)-R5a, - C(O)-N(Ry1)-L6-R5a, -C(O)-M1-N(Ry1)-L6-R5a, -N(Ru6)-(L7)n-R5b, C1-C6 alkyl optionally substituted with one or more -OR5A, C3-C6 cycloalkyl optionally substituted with one or more -OR5A, C2-C6alkenyl optionally substituted with one or more R5B, C2-C6alkynyl optionally substituted with one or more -NRu7R5c, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5C, R5A, at each occurrence, is independently selected from the group consisting of H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl, and C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; R5B, at each occurrence, is independently -ORa, -N(Ra)2, or C6-C12aryl; and R5C, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R3a, R3b, R4a, R4b, R4c, R4d, R5a, R5b, and R5c, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl optionally substituted with one or more independently selected -ORa, C(O)N(Ra)2, or -S(O)2N(Ra)2; or C3-C14cycloalkyl; M1 is C6-C12 arylene, C3-C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14- membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or - C(O)-N(Ra)2; L1, L2, L3, L4, L5, L6, and L7, at each occurrence, are independently C1-C8 alkylene; n, at each occurrence, is independently 0 or 1; Rw1, Rw2, Rw3, Rw4, Rw5, Rw6, Rw7, Rw8, Rw9, Ry1, Ry3, Ry4, Ry5, Ry6, Ry7, Ry8, Ry9, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Rz7, Ru1, Ru2, Ru3, Ru6, Ru7, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen; provided that, when R5is unsubstituted C1-C6alkyl or -ORu1, or when R4is Br, R3is not H; and at least one of R1, R3, R4, and R5is not H.

[0014] In some embodiments of Formula (II), R1is H, D, -N(Rw1)-(L1)n-R1a, -N(Rw4)-C(O)-with one or more independently selected halogen, C3-C6cycloalkyl optionally substituted with one or more independently selected halogen, or C2-C6 alkynyl optionally substituted with one or more independently selected -N(Rw9)R1f. In some embodiments of Formula (II), R1is -N(Rw1)-L1-R1a, wherein L1is C1-C6alkylene, and wherein R1ais 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6 cycloalkyl.

[0015] In some embodiments of Formula (II), R3is H or D. In some embodiments of Formula (II), R3is -N(Ry3)-R3a, -C(O)ORy4, or -N(Ry7)C(O)R3b, wherein R3aand R3bare each independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl.

[0016] In some embodiments of Formula (II), R4is halogen. In some embodiments of Formula (II), R4is C2-C6 alkenyl or C2-C6 alkynyl optionally substituted with.

[0017] In some embodiments of Formula (II), R5is H, deuterium, or Br. In some embodiments of Formula (II), R5is -O-(C1-C6haloalkyl), -C(O)NRu2Ru3, -C(O)-M1-N(Ry1)- R5a, -C(O)-N(Ry1)-L6-R5a, -C(O)-M1-N(Ry1)-L6-R5a, C2-C6 alkenyl optionally substituted with one or more R5B, or C2-C6 alkynyl optionally substituted with one or moreembodiments of Formula (II), M1is 3- to 14-membered heterocyclylene.

[0018] In some embodiments of Formula (II), the compound is selected from compounds in Table 2, or a salt thereof.

[0019] In yet another aspect, provided herein is a compound of Formula (III)or a salt thereof, wherein:R2is halogen, -N(Rx1)Rx2, -N(Rx3)R2a, -C(O)N(Rx4)R2b, -N(Rx5)C(O)Rx6, -N(Rx7)C(O)R2c, or -N(Rx8)C(O)N(Rx9)R2d, R3is H, deuterium, halogen, or -CN; R4is H or deuterium; R5is H, deuterium, halogen, -OH, -OD, -NRu1Ru2, -N(Ru3)C(O)ORu4, -N(Ru5)-C(O)-(L1)n- R5a, -N(Ru6)C(O)NRu7Ru8, -N(Ru9)-C(O)-N(Ru10)-(L2)n-R5b, -(L3)n-COORu11, -(L4)n- C(O)NRu12Ru13, or C2-C6 alkynyl optionally substituted with one or more -NRu14R5c, R2a, R2b, R2c, R2d, R5a, R5b, and R5c, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl, C3- C6cycloalkyl, or -C(O)ORa; or C6-C12aryl optionally substituted with one or more independently selected -ORaor -S(O)2N(Ra)2; n, at each occurrence, is independently 0 or 1; L1, L2, L3, L4, at each occurrence, are independently C1-C8alkylene;, Ru10, Ru11, Ru12, Ru13, Ru14, and Ra, at each occurrence, are independently H, deuterium, C1- C6alkyl, or C3-C6cycloalkyl.

[0020] In some embodiments of Formula (III), R2is -N(Rx1)Rx2, -N(Rx3)R2a, - N(Rx7)C(O)R2c, -N(Rx5)C(O)Rx6, or -N(Rx8)C(O)N(Rx9)R2d. In some embodiments of Formula (III), R2is -N(Rx3)R2aor -N(Rx8)C(O)N(Rx9)R2d, and wherein R2aand R2dare each independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)ORa.

[0021] In some embodiments of Formula (III), R3is H, deuterium, or F.

[0022] In some embodiments of Formula (III), R5is H, deuterium, -NH2, -NHD, -ND2, - N(Ru56 alkynyl optionally substituted with one or more.

[0023] In some embodiments of Formula (III), the compound is selected from compounds in Table 3, or a pharmaceutically acceptable salt thereof.

[0024] In yet another aspect, provided herein is a compound of Formula (IV)or a salt thereof, wherein: R1is H, deuterium, or halogen; R2is -N(Rx1)-R2a, -OR2b, or -SR2c; R3is H, deuterium, -C(O)NRy1Ry2, or -C(O)N(Ry3)-L1-R2d; R2a, R2b, R2c, and R2dare each independently 3- to 14-membered heterocyclyl, C6-C12 aryl, 5- to 14-membered heteroaryl, or C3-C14cycloalkyl, each of which is independently substituted with one or more Ra; L1 is C1-C6 alkylene; Rx1, Ry1, Ry2, Ry3, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl, or C3-C6 cycloalkyl.

[0025] In some embodiments of Formula (IV), R1is Br. In some embodiments of Formula (IV), R2is -N(Rx1)-R2a, and R2ais 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments of Formula (IV), the compound is selected from compounds Table 4, or a pharmaceutically acceptable salt thereof.

[0026] In yet another aspect, provided herein is a pharmaceutical formulation comprising a compound of any one of Formula (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the Formula (I), (II), (III), (IV) are as defined herein, and a pharmaceutically acceptable carrier or excipient.

[0027] In yet another aspect, provided herein is a method of modulating the conformation of a mutant p53 protein, comprising contacting the mutant p53 protein with an effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof wherein:each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0028] In some embodiments, the mutant p53 protein comprises a Y220C mutation.

[0029] In yet another aspect, provided herein is a method of restoring wild-type function of a mutant p53 protein, comprising contacting the mutant p53 protein with an effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0030] In some embodiments, the mutant p53 protein comprises a Y220C mutation.

[0031] In yet another aspect, provided herein is a method of treating a proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein:each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0032] In some embodiments, the proliferative disorder is associated with a mutant p53 protein. In some embodiments, the mutant p53 protein comprises a Y220C mutation. In some embodiments, the proliferative disorder is cancer.

[0033] In yet another aspect, provided herein is a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0034] In some embodiments, the cancer is associated with a p53 protein comprising a Y220C mutation.

[0035] In some embodiments, J and K are both C. In some embodiments, r and s are each 1 and q is 2. In some embodiments, one of r and s is 1 and the other is 2. In some embodiments, q is 1. In some embodiments, q is 2.

[0036] In some embodiments of the method described herein, the compound is of Formula (Z)or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently C(Rz), N, N(Rz), O, or S; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; each Rz, when present, is independently H, deuterium, halogen, -CN, -NO2, -ORza, -ORw1, - O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2-Rzb, - N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw9)-Rze, -N(Rw10)- M2-L4-Rzf, -N(Rw10)-M2-Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw11)-Rx, -N(Rw12)-M4-L5- N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, -C(O)ORw18, - C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)-M6-Rzk, - C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26Rzmor two vicinal Rzgroups are taken together with the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally b tit t d ith i d d tl l t d h l OR5CC C l lk loptionally substituted with one or more independently selected halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, or C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rxand Ry, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25;R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl; C6-C12aryl; and C3-C14cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected- OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12 arylene, C3- C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen; and wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Z) is aromatic.

[0037] In some embodiments of the method described herein, the compound is of Formula (A)or a pharmaceutically acceptable salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; R1to R4, when present, are each independently H, deuterium, halogen, -CN, -NO2, -ORza, - ORw1, -O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2- Rzb, -N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw9)-Rze, - N(Rw10)-M2-L4-Rzf, -N(Rw10)-M2-Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw11)-Rx, - N(Rw12)-M4-L5-N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5- L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, - C(O)ORw18, -C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)- M6-Rzk, -C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6 alkenyl, or C2-C6alkynyl optionally substituted with one or more -NRw26Rzmor R1is taken together with R2, and the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e;R5C, at each occurrence, is independently H; deuterium; or C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12aryl); 3- to 14-memberedC6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12 arylene, C3- C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0038] In some embodiments, the compound of Formula (A) is a compound of Formula (B)or a pharmaceutically acceptable salt thereof, A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; R1, when present, is H, deuterium, halogen, -NO2, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, - N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, -independently selected halogen or -OH, C3-C6cycloalkyl optionally substituted with one or more groups independently selected from the group consisting of halogen and -OH, or C2-C6 alkynyl optionally substituted with one or more independently selected -NRw10R1f, R2, when present, is H, halogen, -OR2a, -O-(L4)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)- R2c, -N(Rx5)-M1-C(O)-L5-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L5-R2d, -N(Rx6)-(L6)n- C(O)-N(Rx7)-R2e, -N(Rx8)-M3-L7-N(Rx9)R2f, -N(Rx8)-M3-N(Rx9)R2f, -N(Rx8)-L7-N(Rx9)R2f, - N(Rx10)-R2g, -N(Rx11)-M2-L8-R2h, -N(Rx11)-M2-R2h, -N(Rx11)-L8-R2h, -N(Rx12)-(M4)m-R2x, - (L9)n-R2i, -C(O)R2j, -N(Rx13)-M5-L10-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L10- N(Rx14)-R2y, -R2z, -C(O)N(Rx15)-R2k, or -N(Rx16)C(O)Rx17, or R1is taken together with R2, and the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R3, when present, is H, deuterium, halogen, -CN, -N(Ry1)Ry2, -N(Ry3)-R3a, -C(O)ORy4, - N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, -C(O)NRy8Ry9, or -S(O)2NRy10Ry11; R4, when present, is H, deuterium, halogen, -N(Rz1)Rz2, -NO2, -C(O)ORz3, -N(Rz4)-(L11)n-R4a, -N(Rz5)-C(O)-(L12)n-R4b, -C(O)-R4c, -C(O)N(Rz3)-R4d, -C(O)N(Rz4)-L13-M6-R4e, - C(O)N(Rz4)-L13-R4e, -C(O)N(Rz4)-M6-R4e, -C(O)NRz5Rz6, C3-C14 cycloalkyl, C1-C6 alkyl, C2- C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more independently selected NRz7R4f, R5is H, deuterium, halogen, -(L14)n-NR5AR5B, -(L15)n-COORu1, -(L16)n-C(O)NRu2Ru3, -ORu4, -O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-L17-R5a, -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L17-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)ORu11, -N(Ru12)-C(O)- (L18)n-R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L19)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6C2-C6alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5f, or R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2j, R2k, R3a, R3b, R4a, R4b, R4c, R4d, R4e, R4f, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L20)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl;R2x, R2y, and R2z, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L21)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14cycloalkyl optionally substituted with one or more -OH or -OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, and L21at each occurrence, are independently selected C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently selected C6-C12arylene, C3-C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rx10, Rx11, Rx12, Rx13, Rx14, Rx15, Rx16, Rx17, Ry1, Ry2, Ry3, Ry4, Ry5, Ry6, Ry7, Ry8, Ry9, Ry10, Ry11, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, is independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen; or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen.

[0039] In some embodiments of the method described herein, the compound is of any one of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the forgoing Formulae are as defined herein or any variation thereof.

[0040] In some embodiments, provided herein is a pharmaceutical formulation comprising a compound of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), or (B), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier orFormula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), or (B), Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, or a pharmaceutically acceptable salt thereof, wherein the composition is sterile.

[0041] In yet another aspect, provided herein is a composition comprising a mutant p53 protein and a p53 stabilizer having a covalent bond to the mutant p53 protein, wherein the mutant p53 protein comprises a Y220C mutation, and the covalent bond is formed between a -CN group of the p53 stabilizer and the cysteine at position 220 in the mutant p53 protein. In some embodiments of the foregoing, the mutant p53 protein has greater wild-type function compared to a composition comprising the mutant p53 protein without the p53 stabilizer having a covalent bond to the mutant p53 protein. In some embodiments of the foregoing, the mutant p53 protein has a greater wild-type conformation compared to a composition comprising the mutant p53 protein without the p53 stabilizer having a covalent bond to the mutant p53 protein. In some embodiments of the foregoing, the p53 stabilizer is a compound of any one of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, or a stereoisomer thereof, or a salt (e.g., a pharmaceutically acceptable salt) thereof. DETAILED DESCRIPTION

[0042] The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that the description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments. I. Definition

[0043] For use herein, unless clearly indicated otherwise, use of the terms “a”, “an” and the like refers to one or more.

[0044] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.

[0045] “Alkyl” as used herein refers to and includes, unless otherwise stated, a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., C1-C10means one to ten carbon atoms). Particular alkyl groups are those having 1 to 20 carbon atoms (a “C1-C20alkyl”) having 1 to10 carbon atoms (a “C1-C10alkyl”), having 6 to 10 carbon atoms (a “C6-C10alkyl”), having 1 to 6 carbon atoms (a “C1-C6 alkyl”), having 2 to 6 carbon atoms (a “C2-C6 alkyl”), or having 1 to 4 carbon atoms (a “C1-C4 alkyl”). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n- pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

[0046] “Alkylene” as used herein refers to the same residues as alkyl, but having bivalency. Particular alkylene groups are those having 1 to 20 carbon atoms (a “C1-C20 alkylene”), having 1 to 10 carbon atoms (a “C1-C10alkylene”), having 6 to 10 carbon atoms (a “C6-C10alkylene”), having 1 to 6 carbon atoms (a “C1-C6 alkylene”), 1 to 5 carbon atoms (a “C1-C5 alkylene”), 1 to 4 carbon atoms (a “C1-C4 alkylene”) or 1 to 3 carbon atoms (a “C1-C3 alkylene”). Examples of alkylene include, but are not limited to, groups such as methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), isopropylene (-CH2CH(CH3)-), butylene (-CH2(CH2)2CH2-), isobutylene (-CH2CH(CH3)CH2-), pentylene (-CH2(CH2)3CH2-), hexylene (-CH2(CH2)4CH2-), heptylene (-CH2(CH2)5CH2-), octylene (-CH2(CH2)6CH2-), and the like.

[0047] “Haloalkyl”, as used herein refers to the same residues as alkyl, but having at least one (e.g., 1, 2, 3, 4, 5, or 6) hydrogens replaced with halogen, including F, Cl, Br, and I. When more than one hydrogen is replaced by halogen, each halogen is independently selected from F, Cl, Br, and I. For example, an alkyl can be substituted with one F group and one Br group, with two F groups, with one Cl group and one Br group, or with one Br group and one I group. Examples of haloalkyl include trifluoromethyl, difluoromethyl, 2- fluoroethyl, penta-fluoroethyl, and 3-bromo-1-fluoro-butyl.

[0048] “Alkenyl” as used herein refers to and includes, unless otherwise stated, an unsaturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C) and having the number of carbon atoms designated (i.e., C2-C10 means two to ten carbon atoms). An alkenyl group may have “cis” or “trans” configurations, or alternatively have “E” or “Z” configurations. Particular alkenyl groups are those having 2 to 20 carbon atoms (a “C2-C20 alkenyl”), having 6 to 10 carbon atoms (a “C6-C10 alkenyl”), having 2 to 8 carbon atoms (a “C2-C8alkenyl”), having 2 to 6 carbon atoms (a “C2-C6alkenyl”), or having 2 to 4 carbon atoms (a “C2-C4alkenyl”). Alkenyl groups also include dienes, including cumulated dienes (i.e., two C=C share a common carbon), conjugated dienes (i.e., two conjugated C=C separated by a single bond), and unconjugated dienes (i.e.,are not limited to, groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), 2- methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3- dienyl, pent-1-enyl, pent-2-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, 1,2-propadiene, 2- methyl-1,3-butadiene, and the like.

[0049] “Alkenylene” as used herein refers to the same residues as alkenyl, but having bivalency. Particular alkenylene groups are those having 2 to 20 carbon atoms (a “C2-C20 alkenylene”), having 2 to 10 carbon atoms (a “C2-C10 alkenylene”), having 6 to 10 carbon atoms (a “C6-C10alkenylene”), having 2 to 6 carbon atoms (a “C2-C6alkenylene”), 2 to 4 carbon atoms (a “C2-C4 alkenylene”) or 2 to 3 carbon atoms (a “C2-C3 alkenylene”). Examples of alkenylene include, but are not limited to, groups such as ethenylene (or vinylene) (-CH=CH-), propenylene (-CH=CHCH2-), 1,4-but-1-enylene (-CH=CH-CH2CH2-), 1,4-but-2-enylene (-CH2CH=CHCH2-), 1,6-hex-1-enylene (-CH=CH-(CH2)3CH2-), and the like.

[0050] “Alkynyl” as used herein refers to and includes, unless otherwise stated, an unsaturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C≡C) and having the number of carbon atoms designated (i.e., C2-C10means two to ten carbon atoms). Particular alkynyl groups are those having 2 to 20 carbon atoms (a “C2- C20 alkynyl”), having 6 to 10 carbon atoms (a “C6-C10 alkynyl”), having 2 to 8 carbon atoms (a “C2-C8alkynyl”), having 2 to 6 carbon atoms (a “C2-C6alkynyl”), or having 2 to 4 carbon atoms (a “C2-C4alkynyl”). Examples of alkynyl groups include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2- ynyl, but-3-ynyl, and the like.

[0051] “Alkynylene” as used herein refers to the same residues as alkynyl, but having bivalency. Particular alkynylene groups are those having 2 to 20 carbon atoms (a “C2-C20 alkynylene”), having 2 to 10 carbon atoms (a “C2-C10 alkynylene”), having 6 to 10 carbon atoms (a “C6-C10alkynylene”), having 2 to 6 carbon atoms (a “C2-C6alkynylene”), 2 to 4 carbon atoms (a “C2-C4 alkynylene”) or 2 to 3 carbon atoms (a “C2-C3 alkynylene”). Examples of alkynylene include, but are not limited to, groups such as ethynylene (or acetylenylene) (-C≡C-), propynylene (-C≡CCH2-), and the like.

[0052] “Cycloalkyl” as used herein refers to and includes, unless otherwise stated, saturated cyclic univalent hydrocarbon structures, having the number of carbon atoms designated (i.e., C3-C10means three to ten carbon atoms). Cycloalkyl can consist of one ring,one ring may be fused, spiro, or bridged, or combinations thereof. Particular cycloalkyl groups are those having from 3 to 14 annular carbon atoms, from 3 to 13 annular carbon atoms, or from 3 to 6 annular carbon atoms. A particular cycloalkyl is a cyclic hydrocarbon having from 3 to 14 annular carbon atoms (a "C3-C14cycloalkyl"), 3 to 13 annular carbon atoms (a "C3-C13cycloalkyl"), having 3 to 6 annular carbon atoms (a “C3-C6cycloalkyl”), or having from 3 to 4 annular carbon atoms (a "C3-C4 cycloalkyl"). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.

[0053] “Cycloalkylene” as used herein refers to the same residues as cycloalkyl, but having bivalency. Cycloalkylene can consist of one ring or multiple rings which may be fused, spiro, or bridged, or combinations thereof. Particular cycloalkylene groups are those having from 3 to 12 annular carbon atoms. A particular cycloalkylene is a cyclic hydrocarbon having from 3 to 4 annular carbon atoms (a "C3-C14 cycloalkylene"), from 3 to 13 annular carbon atoms (a "C3-C13cycloalkylene"), having 3 to 6 carbon atoms (a “C3-C6cycloalkylene”), or having from 3 to 4 annular carbon atoms (a "C3-C4cycloalkylene"). Examples of cycloalkylene include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, norbornylene, and the like. A cycloalkylene may attach to the remaining structures via the same ring carbon atom or different ring carbon atoms. When a cycloalkylene attaches to the remaining structures via two different ring carbon atoms, the connecting bonds may be cis- or trans- to each other. For example, cyclopropylene may include 1,1-cyclopropylene and 1,2-cyclopropylene (e.g., cis-1,2-cyclopropylene or trans-1,2- cyclopropylene), or a mixture thereof.

[0054] “Cycloalkenyl” refers to and includes, unless otherwise stated, an unsaturated cyclic non-aromatic univalent hydrocarbon structure, having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C) and having the number of carbon atoms designated (i.e., C3-C10 means three to ten carbon atoms). Cycloalkenyl can consist of one ring, such as cyclohexenyl, or multiple rings, such as norbornenyl. A particular cycloalkenyl is an unsaturated cyclic hydrocarbon having from 3 to 13 annular carbon atoms (a “C3-C13 cycloalkenyl”). Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, norbornenyl, and the like.

[0055] “Cycloalkenylene” as used herein refers to the same residues as cycloalkenyl, but having bivalency.

[0056] “Aryl” or “Ar” as used herein refers to an unsaturated aromatic carbocyclic groupwhich condensed rings may or may not be aromatic. Particular aryl groups are those having from 6 to 14 annular carbon atoms (a “C6-C14 aryl”). In some instances, all rings of a polycyclic aryl group are aromatic (e.g., naphthyl). In other instances, polycyclic aryl groups may include a non-aromatic ring fused to an aromatic ring. An aryl group having more than one ring where at least one ring is non-aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, an aryl group having more than one ring where at least one ring is non-aromatic is connected to the parent structure at an aromatic ring position.

[0057] “Arylene” as used herein refers to the same residues as aryl, but having bivalency. Particular arylene groups are those having from 6 to 14 annular carbon atoms (a “C6-C14 arylene”).

[0058] “Heteroaryl” as used herein refers to an aromatic cyclic group having from 1 to 14 annular carbon atoms and at least one annular heteroatom, including but not limited to heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl), provided the entire group is aromatic. Particular heteroaryl groups are 5 to 14-membered rings having 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 5 to 10-membered rings having 1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 5, 6 or 7-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, particular heteroaryl groups are monocyclic aromatic 5-, 6- or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, particular heteroaryl groups are polycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0059] “Heteroarylene” as used herein refers to the same residues as heteroaryl, but having bivalency.

[0060] “Heterocycle”, “heterocyclic”, or “heterocyclyl” as used herein refers to a saturated or a partially unsaturated non-aromatic cyclic group having a single ring or multiple condensed rings (e.g., fused rings, bridged rings, spiro rings, or any combination thereof), and having from 1 to 14 annular carbon atoms and from 1 to 6 annular heteroatoms, such asfused, bridged, or spiro, or any combination thereof, but excludes heteroaryl groups. A heterocyclyl group may comprise multiple rings, wherein at least one of the condensed rings is not aromatic, and the remaining ring(s) can be aromatic or non-aromatic. When a heterocyclyl group comprises at least one ring that is aromatic and at least one ring that is non-aromatic, the annular heteroarom(s) may be present in an aromatic ring, in a non- aromatic ring, or in both aromatic and non-aromatic rings. A heterocyclyl group having more than one ring where at least one ring is non-aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a heterocyclyl group having more than one ring where at least one ring is non-aromatic is connected to the parent structure at an aromatic ring position. A heterocyclyl group may be connected to the parent structure via either a heteroatom or a carbon atom. Particular heterocyclyl groups are 3 to 14-membered rings having 1 to 13 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 12- membered rings having 1 to 11 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 10-membered rings having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 8-membered rings having 1 to 7 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 3 to 6- membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, heterocyclyl includes monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annular carbon atoms and 1 to 2, 1 to 3, or 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, heterocyclyl includes polycyclic non-aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0061] “Heterocyclylene” as used herein refers to the same residues as heterocyclyl, but having bivalency. In some variations, heterocyclylene comprises more than one ring provided that at least one ring is non-aromatic, and a heterocyclylene may be connected to the parent structure at two aromatic ring positions, at two non-aromatic ring positions, or at an aromatic ring position and at a non-aromatic ring position.

[0062] “Halo” or “halogen” refers to elements of the Group 17 series having atomic number 9 to 85. Preferred halo groups include the radicals of fluorine, chlorine, bromine and iodine. Where a residue is substituted with more than one halogen, it may be referred to bydihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be but are not necessarily the same halogen; thus 4-chloro-3- fluorophenyl is within the scope of dihaloaryl. An alkyl group in which each hydrogen is replaced with a halo group is referred to as a “perhaloalkyl.” A preferred perhaloalkyl group is trifluoromethyl (-CF3). Similarly, “perhaloalkoxy” refers to an alkoxy group in which a halogen takes the place of each H in the hydrocarbon making up the alkyl moiety of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (–OCF3).

[0063] “Oxo” refers to the moiety =O.

[0064] “Optionally substituted” unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group in which the substituents may be the same or different. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In some embodiments, an optionally substituted group has more than one substituents, wherein each substituent is independently selected. In another embodiment, an optionally substituted group has four substituents. In some embodiments, an optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents. In one embodiment, an optionally substituted group is unsubstituted.

[0065] It is understood that an optionally substituted moiety can be substituted with more than five substituents, if permitted by the number of valences available for substitution on the moiety. For example, a propyl group can be substituted with seven halogen atoms to provide a perhalopropyl group. The substituents may be the same or different. Where there are multiple substituents within a moiety or compound, it is to be understood that each substituent may be selected independently of each other substituent.

[0066] Unless clearly indicated otherwise, “an individual” or “a subject” as used herein intends a mammal, including but not limited to a primate, human, bovine, horse, feline, canine, or rodent. In one variation, the individual is a human.

[0067] As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired results include, but are not limited to, one or more of the following: decreasing one more symptoms resulting from the disease, diminishing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread of the disease, delaying the occurrence or recurrence of the disease, delay or slowing the progression of thedisease, decreasing the dose of one or more other medications required to treat the disease, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival. Also encompassed by “treatment” is a reduction of pathological consequence of cancer. The methods provided herein contemplate any one or more of these aspects of treatment.

[0068] In certain instances, the terms "prevention", "prophylaxis" and "preclusion" are used synonymously and refer to the avoidance or reduction of the risk of contracting, experiencing, suffering from or having a disease, a condition, a disorder (e.g., a proliferative disorder), a symptom or a health problem, or a development or advancement of such states and / or the symptoms of such states. In certain instances, prevention means delaying the development of a disease or any symptom thereof. For example, prevention of a proliferative disorder means to delay, defer, hinder, slow, retard, stabilize, and / or postpone development of the disorder or any symptom thereof. This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant prevention or delay can, in effect, result in that the individual does not develop the disease. A method that prevents development of a proliferative disorder (e.g., cancer) is a method that reduces probability of disease development in a given time frame and / or reduces the extent of the disorder in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a statistically significant number of subjects. Cancer development can be detectable using standard methods, such as routine physical exams, mammography, imaging, or biopsy. Development may also refer to disease progression that may be initially undetectable and includes occurrence, recurrence, and onset. The treatment or prevention of a disease, a condition, a disorder, an injury or a health problem may be partial or complete.

[0069] The term “effective amount” as used herein, refers to a sufficient amount of at least one agent being administered to achieve a desired result, e.g., to induce apoptosis in at least one abnormally proliferating cell or to relieve to some extent one or more symptoms of a disease or condition being treated. In certain instances, the method is in vitro, and the desired result may comprise certain desired alteration of cells or biological processes. In certain instances, the method is in vivo, and the result may comprise a reduction and / or alleviation of the signs, symptoms, or causes of a disease, such as cancer. In certain instances, the result is a death of or decrease in the growth of at least one abnormally proliferating cell, e.g., a cancer cell. As is understood in the art, an effective amount may be in one or more doses, i.e., aeffective amount may be considered in the context of administering one or more therapeutic agents (e.g., a compound, or pharmaceutically acceptable salt thereof), and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any of the co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.

[0070] In certain instances, an “effective amount” is considered in the context of therapeutical uses and may be optionally referred to as “therapeutically effective amount”. A “therapeutically effective amount” refers to an amount of the compound or the composition comprising a compound or salt thereof as set forth herein sufficient to produce a desired therapeutic outcome and / or required to provide a clinically significant decrease in a disease. An appropriate “effective” or “therapeutically effective” amount in any individual case is determined using any suitable technique, such as a dose escalation study. In various embodiments, an effective amount or a therapeutically effective amount of the compound may (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent, and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of a tumor; and / or (vii) relieve to some extent one or more of the symptoms associated with the cancer. In various embodiments, the amount is sufficient to ameliorate, palliate, lessen, and / or delay one or more of symptoms of cancer.

[0071] As used herein, “unit dosage form” refers to physically discrete units, suitable as unit dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Unit dosage forms may contain a single or a combination therapy.

[0072] As used herein, the term “controlled release” refers to a drug-containing formulation or fraction thereof in which release of the drug is not immediate, i.e., with a “controlled release” formulation, administration does not result in immediate release of the drug into an absorption pool. The term encompasses depot formulations designed to gradually release the drug compound over an extended period of time. Controlled release formulations can include a wide variety of drug delivery systems, generally involving mixing the drug compound with carriers, polymers or other compounds having the desired release characteristics (e.g., pH- dependent or non-pH-dependent solubility, different degrees of water solubility, and the like)and formulating the mixture according to the desired route of delivery (e.g., coated capsules, implantable reservoirs, injectable solutions containing biodegradable capsules, and the like).

[0073] As used herein, by “pharmaceutically acceptable” or “pharmacologically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. Pharmaceutically acceptable carriers or excipients have in some embodiments met the required standards of toxicological and manufacturing testing and / or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.

[0074] “Pharmaceutically acceptable salts” are those salts which retain at least some of the biological activity of the free (non-salt) compound and which can be administered as drugs or pharmaceuticals to an individual. Such salts, for example, include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like; (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification. In some embodiments, the pharmaceutically acceptable salt is a TFA, formate, or hydrochloride (HCl) salt. In some embodiments, the pharmaceutically acceptable salt is a TFA or hydrochloride (HCl) salt. In some embodiments, the compounds described herein are in free form.

[0075] The term “excipient” as used herein means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound provided herein as an active ingredient. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, solutions for parenteralagent, or wet granulation agent. Binders include, e.g., carbomers, povidone, xanthan gum, etc.; coatings include, e.g., cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, etc.; compression / encapsulation aids include, e.g., calcium carbonate, dextrose, fructose dc (dc = “directly compressible”), honey dc, lactose (anhydrate or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.; disintegrants include, e.g., croscarmellose sodium, gellan gum, sodium starch glycolate, etc.; creams or lotions include, e.g., maltodextrin, carrageenans, etc.; lubricants include, e.g., magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; materials for chewable tablets include, e.g., dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.; suspending / gelling agents include, e.g., carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulation agents include, e.g., calcium carbonate, maltodextrin, microcrystalline cellulose, etc.

[0076] Unless otherwise stated, "substantially pure" intends a composition that contains no more than 10% impurity, such as a composition comprising less than 9%, 7%, 5%, 3%, 1%, 0.5%, 0.1% impurity.

[0077] It is understood that aspects and embodiments described herein as “comprising” include “consisting of” and “consisting essentially of” embodiments.

[0078] In the descriptions herein (e.g., Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), or (IV)) it is understood that every description, variation, embodiment or aspect of a moiety may be combined with every description, variation, embodiment or aspect of other moieties the same as if each and every combination of descriptions is specifically and individually listed. For example, every description, variation, embodiment or aspect provided herein with respect to R1of Formula (I) may be combined with every description, variation, embodiment or aspect of R2of Formula (I) the same as if each and every combination were specifically and individually listed.

[0079] Provided herein are all salts of compounds referred to herein, such as pharmaceutically acceptable salts. Also provided herein are any or all of the stereochemical forms, including any enantiomeric or diastereomeric forms, and any tautomers or other forms of the compounds described. Unless stereochemistry is explicitly indicated in a chemical structure or name, the structure or name is intended to embrace all possible stereoisomers of a compound depicted. When a specific stereo configuration is indicated at certain positions of aat any other positions without specified stereo configuration. In some embodiments, the compound described herein may be described as “trans” or “mixture of trans-isomers”, and these terms encompass trans isomers with any absolute stereo configurations and any mixture of them. For example, cyclobutyl labeled with “trans racemic” may refer. Likewise, “cis” or “mixture of cis-isomers” encompasses any cis isomers with any absolute stereo configurations, and any mixture of them. In addition, where a specific stereochemical form is depicted, it is understood that other stereochemical forms are also described and embraced by the disclosure. All forms of the compounds are also provided herein, such as crystalline or non-crystalline forms of the compounds. It is also understood that prodrugs, solvates and metabolites of the compounds are provided herein. Compositions comprising a compound described herein are also provided herein, such as a composition of substantially pure compound, including a specific stereochemical form thereof. Compositions comprising a mixture of compounds described herein in any ratio are also provided herein, including mixtures of two or more stereochemical forms of a compound in any ratio, such that racemic, non-racemic, enantioenriched and scalemic mixtures of a compound are embraced. Where one or more tertiary amine moiety is present in the compound, the N- oxides are also provided and described.

[0080] The disclosure also includes isotopically-labeled and / or isotopically-enriched forms of compounds described herein. The compounds herein may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. In some embodiments, the compound is isotopically-labeled, such as an isotopically-labeled compound of Formula (O), Formula (I), Formula (II), Formula (III), Formula (IV), Formula (Y), Formula (Z), Formula (A), and Formula (B), or variations thereof described herein, where one or more atoms are replaced by an isotope of the same element. Exemplary isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, chlorine, such as2H,3H,11C,13C,14C13N,15O,17O,35S,18F,36Cl. Incorporation of heavier isotopes such as deuterium (2H or D) can afford certain therapeutic advantages resulting from greater metabolic stability, for example,some instances. As used herein, each instance of enrichment, substitution, or replacement of an atom with corresponding isotope of that atom encompasses isotopic enrichment levels of one of about: 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99,6%, 99.7%, 99.8%, 99.9%, or 100%, or a range between any two of the preceding percentages.

[0081] Isotopically-labeled compounds of the present disclosure can generally be prepared by standard methods and techniques known to those skilled in the art or by procedures similar to those described in the accompanying Examples substituting appropriate isotopically- labeled reagents in place of the corresponding non-labeled reagent.

[0082] It should be understood that the chemical structures, formulae, and descriptions set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts. The descriptions of compounds are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and / or would not be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. In some embodiments, the substituents for rings (e.g. cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylene, heterocyclylene, arylene, or heteroarylene), unless otherwise specified, may be attached to any of the ring atoms (obeying the rules of chemical valency). When a ring is substituted with multiple substituents, unless otherwise specified, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may be independently selected and optionally be different. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the substitution positions on the ring, fused rings, or spirocyclic rings are not specified, the substituents (including, but not limited to, points of attachment to the remainder of the molecule or other substituents) may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with one or more substituent, unless otherwise specified, the substituent can be understood to replace the hydrogen, including the hydrogen on the heteroatom, while obeying the rules of chemical valency.II. Compounds Compounds of Formula (Y)

[0083] In one aspect, provided herein is a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0084] In some embodiments of Formula (Y), J and K are both C. In some embodiments, r and s are each 1 and q is 2. In some embodiments, one of r and s is 1 and the other is 2. In some embodiments, r is 1, s is 2, and q is 1. In some embodiments, r is 1, s is 2, and q is 2. In some embodiments, r is 2, s is 1, and q is 2. In some embodiments, r is 2, s is 1, and q is 2.

[0085] In some embodiments, provided herein is a compound of Formula (Za):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently C(Rz), N, N(Rz), O, or S; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and h f d ieach Rz, when present, is independently H, deuterium, halogen, -CN, -NO2, -ORza, -ORw1, - O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2-Rzb, - N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw5)-M1-M2-C(O)- Rzd, -N(Rw9)-Rze, -N(Rw5)-M1-M2-C(O)-N(Rw7)-(L3)n-Rze, -N(Rw10)-M2-L4-Rzf, -N(Rw10)-M2- Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw12)-M4-M5-C(O)-N(Rw13)-Rx, -N(Rw11)-Rx, - N(Rw12)-M4-L5-N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5- L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, - C(O)ORw18, -C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)- M6-Rzk, -C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26Rzmor two vicinal Rzgroups are taken together with the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, or C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h;R5D1and R5D2, at each occurrence, are independently H, C1-C6alkyl, C3-C6cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, C6-C12aryl optionally substituted with one or more independently selected –(C1-C6 alkylene)-OH, 3- to 14- membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rxand Ry, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl optionally substituted with one or more independently selected CN or C1-C6alkoxy; and C3-C14cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected- OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen; and wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Z) is aromatic.

[0086] In some embodiments, provided herein is a compound of Formula (Z):or a pharmaceutically acceptable salt thereof, wherein: wherein: each A, B, D, G, and H is independently C(Rz), N, N(Rz), O, or S; J and K are each independently C or N;at least one of r and s is 1; and the sum of r, s and q is 4 or 5; each Rz, when present, is independently H, deuterium, halogen, -CN, -NO2, -ORza, -ORw1, - O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2-Rzb, - N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw9)-Rze, -N(Rw10)- M2-L4-Rzf, -N(Rw10)-M2-Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw11)-Rx, -N(Rw12)-M4-L5- N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, -C(O)ORw18, - C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)-M6-Rzk, - C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6 alkenyl, or C2-C6alkynyl optionally substituted with one or more -NRw26Rzmor two vicinal Rzgroups are taken together with the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, or C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i;R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; Rxand Ry, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl; C6-C12aryl; and C3-C14cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected-M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen; and wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Z) is aromatic.

[0087] In some embodiments, the compound of Formula (Y) is a compound of Formula (Z), Formula (A), Formula (B), Formula (O), Formula (I), Formula (II), Formula (III), or Formula (IV). In some embodiments, the compound of Formula (Za) is a compound of Formula (Aa), Formula (A), Formula (Ba), Formula (B), Formula (Oa), Formula (O), Formula (Ia), Formula (I), Formula (II), Formula (III), or Formula (IV). In some embodiments, the compound of Formula (Z) is a compound of Formula (A), Formula (B), Formula (O), Formula (I), Formula (II), Formula (III), or Formula (IV). Compounds of Formula (Aa), (A), (Ba), (B), (Oa), and (O)

[0088] In one aspect, provided herein is a compound of Formula (Aa):or a pharmaceutically acceptable salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N;R1to R4, when present, are each independently H, deuterium, halogen, -CN, -NO2, -ORza, - ORw1, -O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2- Rzb, -N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw5)-M1-M2- C(O)-Rzd, -N(Rw9)-Rze, -N(Rw5)-M1-M2-C(O)-N(Rw7)-(L3)n-Rze,-N(Rw10)-M2-L4-Rzf, - N(Rw10)-M2-Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw11)-Rx, -N(Rw12)-M4-M5-C(O)- N(Rw13)-Rx, -N(Rw12)-M4-L5-N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, - NRw16Rw17, -C(O)ORw18, -C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, - C(O)N(Rw21)-M6-Rzk, -C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, - Rzm, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26Rzmor R1is taken together with R2, and the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; or C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl; or C3-C6cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl;R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, C6-C12aryl optionally substituted with one or more independently selected –(C1-C6 alkylene)-OH, 3- to 14- membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl optionally substituted with one or more independently selected CN or C1-C6alkoxy; or C3-C14cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0089] In one aspect, provided herein is a compound of Formula (A):or a pharmaceutically acceptable salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; R1to R4, when present, are each independently H, deuterium, halogen, -CN, -NO2, -ORza, - ORw1, -O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2- Rzb, -N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw9)-Rze, - N(Rw10) M L RzfN(Rw10) M RzfN(Rw10) L RzfN(Rw11) M RxN(Rw11) RxN(Rw12)-M4-L5-N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5- L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, - C(O)ORw18, -C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)- M6-Rzk, -C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6alkenyl, or C2-C6alkynyl optionally substituted with one or more -NRw26Rzmor R1is taken together with R2, and the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6cycloalkyl optionally substituted with one or more halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; or C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl;Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24,occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen;M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0090] In some embodiments, the compound of Formula (Aa) is a compound of Formula (Ba):or a pharmaceutically acceptable salt thereof, wherein exactly oneR1, when present, is H, deuterium, halogen, -NO2, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, - N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, - C(O)Rw9, C3-C14cycloalkyl, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OH, C3-C6 cycloalkyl optionally substituted with one or more groups independently selected from the group consisting of halogen and -OH, or C2-C6 alkynyl optionally substituted with one or more independently selected -NRw10R1f, R2, when present, is H, halogen, -OR2a, -O-(L4)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)- R2c, -N(Rx5)-M1-C(O)-L5-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L5-R2d, -N(Rx5)-M1-M2- C(O)-R2d, -N(Rx6)-(L6)n-C(O)-N(Rx7)-R2e, -N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2e, -N(Rx8)- M3-L7-N(Rx9)R2f, -N(Rx8)-M3-N(Rx9)R2f, -N(Rx8)-L7-N(Rx9)R2f, -N(Rx10)-R2g, -N(Rx11)-M2-N(Rx13)-R2x, -(L9)n-R2i, -C(O)R2j, -N(Rx13)-M5-L10-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, - N(Rx13)-L10-N(Rx14)-R2y, -R2z, -C(O)N(Rx15)-R2k, or -N(Rx16)C(O)Rx17, or R1is taken together with R2, and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R3, when present, is H, deuterium, halogen, -CN, -N(Ry1)Ry2, -N(Ry3)-R3a, -C(O)ORy4, - N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, -C(O)NRy8Ry9, or -S(O)2NRy10Ry11; R4, when present, is H, deuterium, halogen, -N(Rz1)Rz2, -NO2, -C(O)ORz3, -N(Rz4)-(L11)n-R4a, -N(Rz5)-C(O)-(L12)n-R4b, -C(O)-R4c, -C(O)N(Rz3)-R4d, -C(O)N(Rz4)-L13-M6-R4e, - C(O)N(Rz4)-L13-R4e, -C(O)N(Rz4)-M6-R4e, -C(O)NRz5Rz6, C3-C14cycloalkyl, C1-C6alkyl, C2- C6alkenyl, or C2-C6alkynyl optionally substituted with one or more independently selected NRz7R4f, R5is H, deuterium, halogen, -(L14)n-NR5AR5B, -(L15)n-COORu1, -(L16)n-C(O)NRu2Ru3, -ORu4, -O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-L17-R5a, -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L17-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)ORu11, -N(Ru12)-C(O)- (L18)n-R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L19)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6-R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5f, or R5g; R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2j, R2k, R3a, R3b, R4a, R4b, R4c, R4d, R4e, R4f, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L20)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, C6-C12 aryl optionally substituted with one or more independently selected –(C1-C6alkylene)-OH3- to 14- membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; R2x, R2y, and R2z, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L21)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; C6-C12aryloptionally substituted with one or more independently selected CN or C1-C6alkoxy; or C3-C14 cycloalkyl optionally substituted with one or more -OH or -OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, and L21at each occurrence, are independently selected C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently selected C6-C12arylene, C3-C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)- N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rx10, Rx11, Rx12, Rx13, Rx14, Rx15, Rx16, Rx17, Ry1, Ry2, Ry3, Ry4, Ry5, Ry6, Ry7, Ry8, Ry9, Ry10, Ry11, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, is independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen; or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0091] In some embodiments, the compound of Formula (A) is a compound of Formula (B):or a pharmaceutically acceptable salt thereof, wherein: wherein exactly oneR1, when present, is H, deuterium, halogen, -NO2, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, - N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, - C(O)Rw9, C3-C14 cycloalkyl, C1-C6 alkyl optionally substituted with one or moremore groups independently selected from the group consisting of halogen and -OH, or C2-C6alkynyl optionally substituted with one or more independently selected -NRw10R1f, R2, when present, is H, halogen, -OR2a, -O-(L4)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)- R2c, -N(Rx5)-M1-C(O)-L5-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L5-R2d, -N(Rx6)-(L6)n- C(O)-N(Rx7)-R2e, -N(Rx8)-M3-L7-N(Rx9)R2f, -N(Rx8)-M3-N(Rx9)R2f, -N(Rx8)-L7-N(Rx9)R2f, - N(Rx10)-R2g, -N(Rx11)-M2-L8-R2h, -N(Rx11)-M2-R2h, -N(Rx11)-L8-R2h, -N(Rx12)-(M4)m-R2x, - (L9)n-R2i, -C(O)R2j, -N(Rx13)-M5-L10-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L10- N(Rx14)-R2y, -R2z, -C(O)N(Rx15)-R2k, or -N(Rx16)C(O)Rx17, or R1is taken together with R2, and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R3, when present, is H, deuterium, halogen, -CN, -N(Ry1)Ry2, -N(Ry3)-R3a, -C(O)ORy4, - N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, -C(O)NRy8Ry9, or -S(O)2NRy10Ry11; R4, when present, is H, deuterium, halogen, -N(Rz1)Rz2, -NO2, -C(O)ORz3, -N(Rz4)-(L11)n-R4a, -N(Rz5)-C(O)-(L12)n-R4b, -C(O)-R4c, -C(O)N(Rz3)-R4d, -C(O)N(Rz4)-L13-M6-R4e, - C(O)N(Rz4)-L13-R4e, -C(O)N(Rz4)-M6-R4e, -C(O)NRz5Rz6, C3-C14cycloalkyl, C1-C6alkyl, C2- C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more independently selected NRz7R4f, R5is H, deuterium, halogen, -(L14)n-NR5AR5B, -(L15)n-COORu1, -(L16)n-C(O)NRu2Ru3, -ORu4, -O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-L17-R5a, -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L17-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)ORu11, -N(Ru12)-C(O)- (L18)n-R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L19)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C,substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl; or C3-C6cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5f, or R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2j, R2k, R3a, R3b, R4a, R4b, R4c, R4d, R4e, R4f, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L20)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; R2x, R2y, and R2z, at each occurrence, are independently C1-C6alkyl optionally substitutedR25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L21)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; C6-C12aryl; or C3-C14 cycloalkyl optionally substituted with one or more -OH or -OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, and L21 at each occurrence, are independently selected C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently selected C6-C12 arylene, C3-C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rx10, Rx11, Rx12, Rx13, Rx14, Rx15, Rx16, Rx17, Ry1, Ry2, Ry3, Ry4, Ry5, Ry6, Ry7, Ry8, Ry9, Ry10, Ry11, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, is independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen; or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0092] In one aspect, provided herein is a compound of Formula (Oa)or a salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; and wherein at least one of R1, R2, R3, and R4is RA; whereinRA, at each occurrence, is independently -ORAa, -O-(L1)n-NRw2Rw3, -SRAl, -N(Rw4)-M1-C(O)- L2-RAb, -N(Rw4)-M1-C(O)-RAb, -N(Rw4)-C(O)-L2-RAb, -N(Rw5)-C(O)-RAc, -N(Rw7)-(L3)n- C(O)-N(Rw8)-RAd, -N(Rw5)-M1-M2-C(O)-RAd, -N(Rw9)-RAe, -N(Rw5)-M1-M2-C(O)-N(Rw7)- (L3)n-RAe, -N(Rw10)-M2-L4-RAf, -N(Rw10)-M2-RAf, -N(Rw10)-L4-RAf,-N(Rw11)-(M3)m-Rx, - N(Rw12)-M4-M5-C(O)-N(Rw13)-Rx, -N(Rw12)-M4-L5-N(Rw13)RAg, -N(Rw12)-M4-N(Rw13)RAg, - N(Rw12)-L5-N(Rw13)RAg, -S(O)2NRw24Rw25, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5- N(Rw15)-Ry, or -N(Rw14)-L6-N(Rw15)-Ry; R1, R2, R3, and R4, when present, are each independently RA, H, deuterium, halogen, -CN, - NO2, -ORw1, -N(Rw6)C(O)Rw7, -(L7)n-RAh, -NRw16Rw17, -C(O)ORw18, -C(O)RAi, -C(O)Rw19, - C(O)N(Rw20)-RAj, -C(O)N(Rw21)-L8-RAk, -C(O)N(Rw21)-M6-RAk, -C(O)N(Rw21)-L8-M6-RAk, - C(O)NRw22Rw23, -Rz, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26RAm, or any two vicinal R1, R2, R3, and R4are taken together with the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e;R5C, at each occurrence, is independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl, or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; RAa, RAb, RAc, RAd, RAe, RAf, RAg, RAh, RAi, RAj, RAk, RAl, RAm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3- C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl optionally substituted with one or more Ra, C6-C12aryl optionally substituted with one or more independently selected –(C1-C6 alkylene)-OH, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25;R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more oxo, independently selected C1- C6alkyl, or independently selected C3-C6cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl; C6-C12aryl optionally substituted with one or more independently selected CN or C1-C6 alkoxy; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw17, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0093] In one aspect, provided herein is a compound of Formula (O)or a pharmaceutically acceptable salt thereof, wherein:A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; and wherein at least one of R1, R2, R3, and R4is RA; wherein RA, at each occurrence, is independently -ORAa, -O-(L1)n-NRw2Rw3, -SRAl, -N(Rw4)-M1-C(O)- L2-RAb, -N(Rw4)-M1-C(O)-RAb, -N(Rw4)-C(O)-L2-RAb, -N(Rw5)-C(O)-RAc, -N(Rw7)-(L3)n- C(O)-N(Rw8)-RAd, -N(Rw9)-RAe, -N(Rw10)-M2-L4-RAf, -N(Rw10)-M2-RAf, -N(Rw10)-L4-RAf,- N(Rw11)-(M3)m-Rx, -N(Rw12)-M4-L5-N(Rw13)RAg, -N(Rw12)-M4-N(Rw13)RAg, -N(Rw12)-L5- N(Rw13)RAg, -S(O)2NRw24Rw25, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, or - N(Rw14)-L6-N(Rw15)-Ry; R1, R2, R3, and R4, when present, are each independently RA, H, deuterium, halogen, -CN, - NO2, -ORw1, -N(Rw6)C(O)Rw7, -(L7)n-RAh, -NRw16Rw17, -C(O)ORw18, -C(O)RAi, -C(O)Rw19, - C(O)N(Rw20)-RAj, -C(O)N(Rw21)-L8-RAk, -C(O)N(Rw21)-M6-RAk, -C(O)N(Rw21)-L8-M6-RAk, - C(O)NRw22Rw23, -Rz, C2-C6alkenyl, or C2-C6alkynyl optionally substituted with one or more -NRw26RAm, or any two vicinal R1, R2, R3, and R4are taken together with the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, C1-C6alkyl optionallycycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; RAa, RAb, RAc, RAd, RAe, RAf, RAg, RAh, RAi, RAj, RAk, RAl, RAm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3- C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl optionally substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more oxo, independently selected C1- C6 alkyl, or independently selected C3-C6 cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl; C6-C12aryl; or C3-C14cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw17, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0094] In some embodiments, the compound of Formula (Aa) is a compound of Formula (A), (Ba), (B), (Oa), (O), (Ia), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the Formula (A), (Ba), (B), (Oa), (O), (Ia), (I), (II), (III), (IV) are as defined herein. In some embodiments, the compound of Formula (Ba) is a compound of Formula (B), (Oa), (O), (Ia), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the Formula (B), (Oa), (O), (Ia), (I), (II), (III), (IV) are as defined herein. In some embodiments, the compound of Formula (Aa) or Formula (Ba) is a compound of (Ia), (I), (II), (III), or (IV), or a compound selected from Compounds 2, 3, 5, 6, 9, and 11-972 in Table 1, Compounds 978-1034 in Table 1A, Compounds 2-2 to 2-88, Compounds 3-1 to 3-25, and Compound 4-1 to 4-4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the Formula (Ia), (I), (II), (III), (IV) are as defined herein.

[0095] In some embodiments, the compound of Formula (A) is a compound of Formulastereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the Formula (I), (II), (III), (IV) are as defined herein. In some embodiments, the compound of Formula (B) is a compound of Formula (O), (I), (II), (III), (IV), a compound of Table 1, Table 2, Table 3, Table 4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the Formula (I), (II), (III), (IV) are as defined herein. In some embodiments, the compound of Formula (A) or Formula (B) is a compound of (I), (II), (III), or (IV), or a compound selected from Compounds 2, 3, 5, 6, 9, and 11-972 in Table 1, Compounds 2-2 to 2-88, Compounds 3-1 to 3-25, and Compound 4-1 to 4-4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the Formula (I), (II), (III), (IV) are as defined herein. Compounds of Formula (Ia) and (I)

[0096] In one aspect, provided herein is a compound of Formula (Ia)or a salt thereof, wherein: R1is H; deuterium; halogen; -NO2; C(O)Rw1; C1-C6 alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; C3-C14cycloalkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; or C2-C6alkynyl, R2is -OR2a, -O-(L1)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, - N(Rx5)-M1-M2-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n- C(O)-N(Rx7)-R2e, -N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2e, -N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, - N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, - N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -N(Rx12)-M4-M5-C(O)-N(Rx13)-R2x, -(L6)n-R2h, - C(O)R2i, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7-N(Rx14)-R2y,or R1is taken together with R2and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R2a, R2b, R2c, R2d, R2e, R2f, R2h, R2i, and R2j, at each occurrence, are independently 3- to 14- membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, - S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L8)n-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted with one or more R21a, C3-C6cycloalkyl optionally substituted with one or more R21a, 5- to 12-membered heteroaryl optionally substituted with one or more Ra, C6-C12aryl optionally substituted with one or more independently selected –(C1-C6alkylene)-OH, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, orR21a, at each occurrence, is independently halogen, -ORa, - N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, 3- to 14-membered heterocyclyl, C6-C12 aryl, or 5- to 12-membered heteroaryl, R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6cycloalkyl; R22, at each occurrence, is independently C1-C6 alkyl, C3-C6 cycloalkyl, -OH, - OD, -S(O)2Ra, -C(O)N(Ra)2, or -N(Ra)2; R23, at each occurrence, is independently -N(Ra)2, C1-C6alkyl, or C3-C6cycloalkyl; R24, at each occurrence, is independently -OH, -OD, oxo, -(C1-C6 alkylene)- C(O)N(Ra)2, -C(O)N(Ra)2, or -N(Ra)C(O)Ra;R2xis C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen, -ORa, -N(Ra)2, -C(O)- N(Ra)2, or -N(Ra)C(O)-Ra; R2yis C1-C6alkyl optionally substituted with one or more R26; R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)- N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L9)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl optionally substituted with one or more independently selected CN or C1-C6alkoxy; or C3-C14cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R2Ais 3- to 14-membered heterocyclyl, C6-C12aryl, 5- to 14-membered heteroaryl, or C3-C14cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, -N(Ra)2, oxo, -OH, -OD, -C(O)-(L10)n-N(Ra)2, - C(O)Ra, or -N(Ra)C(O)Ra; R4is H, deuterium, -N(Ra)2, -NO2, C3-C14cycloalkyl, -C(O)ORz1, -N(Rz2)-(L11)n-R4a, -C(O)- )N(Rz4)-L12-M6-R4d, -C(O)N(Rz4)-L12-R4d, -C(O)N(Rz4)-M6-R4d,d, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R41, C6-C12aryl optionally substituted with one or more R42, 5- to 14-membered heteroaryl optionally substituted with one or more R43, or C3-C14 cycloalkyl optionally substituted with one or more R44; R41, R42, R43, and R44, at each occurrence, are independently halogen, - S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more -ORa, or C3-C6 cycloalkyl optionally substituted one or more -ORa; R5is H, deuterium, halogen, -(L13)n-NR5AR5B, C1-C6alkyl optionally substituted with one oralkenyl optionally substituted with one or more R5C, C2-C6alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or -C(O)-N(Ru2)-R5x; R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5a; R5C, at each occurrence, is independently -OR5C1, -N(Ra)R5C2, or R5c; R5C1and R5C2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6 cycloalkyl, or C6-C12 aryl; R5D, at each occurrence, is independently -N(Ra)R5D1or R5d; R5D1, at each occurrence, is independently C6-C12aryl optionally substituted with one or more independently selected -ORa, -C(O)N(Ra)2, or -S(O)2N(Ra)2; R5a, R5c, R5d, and R5e, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12aryl optionally substituted with one or more R52, 5- to 14-membered heteroaryl optionally substituted with one or more R53, or C3-C12 cycloalkyl optionally substituted with one or more R54; R51, R52, R53, and R54, at each occurrence, are independently halogen, oxo, - CN, -C(O)Rz8, -S(O)2Ra, -C(O)-N(Ra)2, 3- to 14-membered heteroaryl, C1-C6 alkyl optionally substituted one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted one or more independently selected halogen; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O- (C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, and L14, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, and M6, at each occurrence, are independently C6-C12 arylene, C3-C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1; Rw1, Rx1, Rx2, Rx3, Rx4, Rx5, Rx6, Rx7, Rx8, Rx9, Rx10, Rx11, Rx12, Rx13, Rx14, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Ru1, Ru2, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyloptionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

[0097] In one aspect, provided herein is a compound of Formula (I)or a pharmaceutically acceptable salt thereof, wherein: R1is H; deuterium; halogen; -NO2; C(O)Rw1; C1-C6 alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; or C2-C6alkynyl, R2is -OR2a, -O-(L1)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, - N(Rx5)-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n-C(O)-N(Rx7)-R2e, -N(Rx8)-R2A, - N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3- N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -(L6)n-R2h, -C(O)R2i, -N(Rx13)-M5- L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7-N(Rx14)-R2y, or R1is taken together with R2and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R2a, R2b, R2c, R2d, R2e, R2f, R2h, R2i, and R2j, at each occurrence, are independently 3- to 14- membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, - S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L8)n-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted with one or more R21a, C3-C6cycloalkyl optionally substituted with one or more R21a, 5- to 12-memberedmembered heterocyclyl optionally substituted with one or more R21b, orR21a, at each occurrence, is independently halogen, -ORa, - N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, 3- to 14-membered heterocyclyl, or 5- to 12-membered heteroaryl, R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6 cycloalkyl; R22, at each occurrence, is independently C1-C6 alkyl, C3-C6 cycloalkyl, -OH, - OD, -S(O)2Ra, -C(O)N(Ra)2, or -N(Ra)2; R23, at each occurrence, is independently -N(Ra)2, C1-C6 alkyl, or C3-C6 cycloalkyl; R24, at each occurrence, is independently -OH, -OD, oxo, -C(O)N(Ra)2, or - N(Ra)C(O)Ra; R2xis C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen, -ORa, -N(Ra)2, -C(O)- N(Ra)2, or -N(Ra)C(O)-Ra; R2yis C1-C6 alkyl optionally substituted with one or more R26; R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)- N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L9)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R2Ais 3- to 14-membered heterocyclyl, C6-C12 aryl, 5- to 14-membered heteroaryl, or C3-C14 cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, oxo, -OH, -OD, -C(O)-(L10)n-N(Ra)2, -C(O)Ra, or -N(Ra)C(O)Ra; R4is H, deuterium, -N(Ra)2, -NO2, C3-C14 cycloalkyl, -C(O)ORz1, -N(Rz2)-(L11)n-R4a, -C(O)- R4b, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-L12-M6-R4d, -C(O)N(Rz4)-L12-R4d, -C(O)N(Rz4)-M6-R4d,R4a, R4b, R4c, and R4d, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R41, C6-C12 aryl optionally substituted with one or more R42, 5- to 14-membered heteroaryl optionally substituted with one or more R43, or C3-C14cycloalkyl optionally substituted with one or more R44; R41, R42, R43, and R44, at each occurrence, are independently halogen, - S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more -ORa, or C3-C6 cycloalkyl optionally substituted one or more -ORa; R5is H, deuterium, halogen, -(L13)n-NR5AR5B, C1-C6 alkyl optionally substituted with one or more halogen, C3-C6 cycloalkyl optionally substituted with one or more halogen, C2-C6 alkenyl optionally substituted with one or more R5C, C2-C6alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or -C(O)-N(Ru2)-R5x; R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5a; R5C, at each occurrence, is independently -OR5C1, -N(Ra)R5C2, or R5c; R5C1and R5C2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6 cycloalkyl, or C6-C12 aryl; R5D, at each occurrence, is independently -N(Ra)R5D1or R5d; R5D1, at each occurrence, is independently C6-C12aryl optionally substituted with one or more independently selected -ORa, -C(O)N(Ra)2, or -S(O)2N(Ra)2; R5a, R5c, R5d, and R5e, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12aryl optionally substituted with one or more R52, 5- to 14-membered heteroaryl optionally substituted with one or more R53, or C3-C12 cycloalkyl optionally substituted with one or more R54; R51, R52, R53, and R54, at each occurrence, are independently halogen, oxo, - CN, -C(O)Rz8, -S(O)2Ra, -C(O)-N(Ra)2, 3- to 14-membered heteroaryl, C1-C6 alkyl optionally substituted one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted one or more independently selected halogen; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O- (C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, and L14, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selectedM1, M2, M3, M4, M5, and M6, at each occurrence, are independently C6-C12arylene, C3-C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1; Rw1, Rx1, Rx2, Rx3, Rx4, Rx5, Rx6, Rx7, Rx8, Rx9, Rx10, Rx11, Rx12, Rx13, Rx14, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Ru1, Ru2, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen.

[0098] In some embodiments of Formula (I), R1is H, D, or halogen. In some embodiments of Formula (I), R1is F, Cl, Br, or I. In some embodiments of Formula (I), R1is H, D, or Br. In some embodiments of Formula (I), R1is -NO2. In some embodiments, R1is C(O)Rw1, wherein Rw1is H, D, C1-C3alkyl, or C3-C6cycloalkyl. In some embodiments, R1is C(O)Rw1, wherein Rw1is H or C1-C3 alkyl. In some embodiments, R1is C3-C6 cycloalkyl optionally substituted with one or more independently selected -OH or halogen. In some embodiments, R1is C1-C6alkyl optionally substituted with one or more independently selected -OH or halogen. In some embodiments, R1is C1-C6 alkyl optionally substituted with one or more F or -OH. In some embodiments, R1is C3-C14cycloalkyl. In some embodiments, R1is C3-C10cycloalkyl. In some embodiments, R1is cyclopropyl. In some embodiments, R1is C2-C6alkynyl. In some embodiments, R1is ethynyl.

[0099] In some embodiments of Formula (Ia), R2is R2is -OR2a, -O-(L1)n-NRx1Rx2, -SR2b, - N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-M1-M2-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, - N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n-C(O)-N(Rx7)-R2e, -N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n- R2e, -N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5- N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-M4-M5-C(O)-N(Rx13)- R2x, -N(Rx12)-(M4)m-R2x, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)- L7-N(Rx14)-R2y, 5- to 14-membered heterocycle optionally substituted with one or more R21, or 5- to 14-membered heteroaryl optionally substituted with one or more R23.

[0100] In some embodiments, R2is -N(Rx5)-M1-M2-C(O)-R2d, -N(Rx5)-M1-M2-C(O)- N(Rx7)-(L3)n-R2e, or -N(Rx12)-M4-M5-C(O)-N(Rx13)-R2x.

[0101] In some embodiments, R2is -N(Rx5)-M1-M2-C(O)-R2d. In some embodiments, M1iscycloalkylene. In some embodiments, M1is cyclohexylene. In some embodiments, M2is 3- to 14-membered heterocyclylene, 3- to 10-membered heterocyclylene, 5- to 10-membered heterocyclylene, or 5- to 8-membered heterocyclylene. In some embodiments, M2 is 5- to 8- membered heterocyclylene. In some embodiments, R2is -N(Rx5)-M1-M2-C(O)-R2dand R2dis 4- to 6-membered heterocycle, optionally substituted with one or more R21. In some embodiments, R2dis 4- to 6-membered heterocyclyl (e.g., 4 to 6-membered heterocyclyl comprising at least one annular nitrogen) optionally substituted with one, two, or three -CN or -OH. In some embodiments, R2dis connected to the rest of the molecule via a heteroatom, such as an annular nitrogen atom.

[0102] In some embodiments, R2is -N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2e. In some embodiments, M1is C3-C14cycloalkylene, such as C3-C10cycloalkylene, C5-C14cycloalkylene, or C5-C6 cycloalkylene. In some embodiments, M1 is cyclohexylene. In some embodiments, M2 is 3- to 14-membered heterocyclylene, 3- to 10-membered heterocyclylene, 5- to 10-membered heterocyclylene, or 5- to 8-membered heterocyclylene. In some embodiments, M2is 5- to 8-membered heterocyclylene. In some embodiments, L3is C1-C8alkylene, such as C1-C6 alkylene, C1-C3 alkylene, methylene, or ethylene. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, R2eis 5- to 6- membered heteroaryl (e.g., 5 or 6-membered heteroaryl comprising at least one annular nitrogen) optionally substituted with one or more R23, C3-C6 cycloalkyl optionally substituted with one or more R24, or 3- to 6-membered heterocyclyl (e.g., 5 or 10-membered heterocyclyl comprising one, two, or three annular nitrogen) optionally substituted with one or more R21. In some embodiments, R2eis 5- to 10-membered heterocyclyl optionally substituted with one or more R21. In some embodiments, R2eis 5- to 10-membered heterocyclyl, wherein the heterocyclyl comprises one or two annular nitrogen, and wherein the heterocyclyl is optionally substituted with oxo. In some embodiments, R2eis 5- to 6-membered heteroaryl, wherein the heteroaryl comprises one or two annular nitrogen, and wherein the heteroaryl is optionally substituted with C1-C3alkyl, or -N(C1-C3alkyl)2.

[0103] In some embodiments, R2is -N(Rx12)-M4-M5-C(O)-N(Rx13)-R2x. In some embodiments, M4 is C3-C14 cycloalkylene, such as C3-C10 cycloalkylene, C5-C14 cycloalkylene, or C5-C6cycloalkylene. In some embodiments, M4is cyclohexylene. In some embodiments, M5is 3- to 14-membered heterocyclylene, 3- to 10-membered heterocyclylene, 5- to 10-membered heterocyclylene, or 5- to 8-membered heterocyclylene. In some embodiments, M5is 5- to 8-membered heterocyclylene. In some embodiments, R2xis C1-C6

[0104] In some embodiments of Formula (I), R2is -OR2a, -O-(L1)n-NRx1Rx2, -SR2b, - N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, - N(Rx6)-(L3)n-C(O)-N(Rx7)-R2e, -N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4- R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)- (M4)m-R2x, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L7-N(Rx14)-R2y, or 5- to 14-membered heteroaryl optionally substituted with one or more independently selected R23. In some embodiments of Formula (I), R2is -OR2a, -O-L1-NRx1Rx2, or -SR2b. In some embodiments of Formula (I), R2is -OR2a, wherein R2ais 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments of Formula (I), R2is -OR2a, wherein R2ais 5- to 6- membered heterocyclyl (e.g., piperidine, tetrahydropyridine, tetrahydropyran, dihydropyridine, pyrrolidine, tetrahydrofuran) optionally substituted with one or more independently selected C1-C3 alkyl (e.g., substituted with one methyl, substituted with one methyl and one ethyl, substituted with two methyl). In some embodiments, R2ais piperidinyl optionally substituted with one to three methyl. In some embodiments of Formula (I), R2is - O-L1-NRx1Rx2, wherein L1 is C1-C8 alkylene (e.g., methylene, ethylene, or propylene), and - NRx1Rx2is -N(C1-C3alkyl)2. In some embodiments of Formula (I), R2is -SR2b, wherein R2bis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments of Formula (I), R2is -SR2b, wherein R2bis 5- to 6-membered heterocyclyl (e.g., piperidine, tetrahydropyridine, tetrahydropyran, dihydropyridine, pyrrolidine, tetrahydrofuran) optionally substituted with one or more independently selected C1-C3 alkyl (e.g., substituted with one methyl, substituted with one methyl and one ethyl, substituted with two methyl). In some embodiments, R2bis piperidinyl optionally substituted with one to three methyl.

[0105] In some embodiments of Formula (I), R2is 5- to 14-membered heterocycle optionally substituted with one or more R21or 5- to 14-membered heteroaryl optionally substituted with one or more R23. In some embodiments of Formula (I), R2is 5- to 14- membered heterocycle optionally substituted with one or more R21. In some embodiments of Formula (I), R2is 5- to 14-membered heterocycle optionally substituted with one or more C1- C6alkyl, wherein the C1-C6alkyl is optionally substituted with one, two, or three -OH or - OD. In some embodiments, R2is azaspiro[3.5]nonane optionally substituted with one or more methyl, wherein the methyl is optionally substituted with one -OH or -OD, and wherein R2can be connected the rest of the structure via any annular position, as valency permits. Inmore R23. In some embodiments, the 5- to 14-membered heteroaryl comprises at least one annular S. In some embodiments, R2is 5- to 6-membered heteroaryl (e.g., thiophene or thiazole) which is unsubstituted or substituted with one or more -NH2, wherein R2can be connected the rest of the structure via any annular position, as valency permits.

[0106] In some embodiments of Formula (I), R2is -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)- R2d, -N(Rx5)-C(O)-L2-R2d, or -N(Rx5)-M1-C(O)-L2-R2d. In some embodiments, R2is -N(Rx4)- C(O)-R2c, and wherein R2cis 3- to 14-membered heterocyclyl optionally substituted with one or more R21. In some embodiments of Formula (I), R2cis 5- to 6-membered heterocyclyl (e.g., piperidine), which is unsubstituted or substituted with one, two, or three independently selected C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments of Formula (I), R2cis 5- to 6- membered heterocyclyl (e.g., piperidine), which is unsubstituted or substituted with one methyl.

[0107] In some embodiments of Formula (I), R2is -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2- R2d, or -N(Rx5)-M1-C(O)-L2-R2d, wherein M1is 3- to 12-membered heterocyclylene, L2is C1- C8alkylene, and R2dis 3- to 14-membered heterocyclyl optionally substituted with one or more R21. In some embodiments of Formula (I), R2is -N(Rx5)-M1-C(O)-R2d, wherein M1 is 3- to 10-membered heterocyclylene. In some embodiments, M1is 5- to 10-membered heterocyclylene comprising at least one annular N, such as azaspiro[3.3]heptane. In some embodiments, R2is -N(Rx5)-M1-C(O)-R2d, wherein R2dis 4- to 6-membered heterocyclyl optionally substituted with one, two, or three independently selected C1-C3alkyl or C3-C6cycloalkyl. In some embodiments, R2dis 5- to 6-membered heterocyclyl (e.g., pyrrolidine or piperidine) optionally substituted with one methyl. In some embodiments, R2is -N(Rx5)- C(O)-L2-R2d, wherein L2 is C1-C8 alkylene, such as C1-C6 alkylene, C1-C3 alkylene, methylene, or ethylene. In some embodiments, R2is -N(Rx5)-C(O)-L2-R2d, wherein R2dis 4- to 6-membered heterocyclyl optionally substituted with one, two, or three independently selected C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments, R2is -N(Rx5)-C(O)-L2-R2d, wherein R2dis 4- to 6-membered heterocyclyl (e.g., piperidine or azetidine) optionally substituted with one methyl.

[0108] In some embodiments of Formula (I), R2is -N(Rx6)-C(O)-N(Rx7)-R2e, or -N(Rx6)- L3-C(O)-N(Rx7)-R2e. In some embodiments, R2is N(Rx6)-L3-C(O)-N(Rx7)-R2e, and L3is C1- C8alkylene (e.g., methylene, ethylene, or propylene). In some embodiments, R2is -N(Rx6)- C(O)-N(Rx7)-R2eor N(Rx6)-L3-C(O)-N(Rx7)-R2e, and R2eis 3- to 14-membered heterocyclyl optionally substituted with one or more R21or C3-C14cycloalkyl optionally substituted with(e.g., piperidine, tetrahydropyridine, dihydropyridine, or pyrrolidine) optionally substituted with one or more independently selected R21. In some embodiments, R21, at each occurrence, is independently C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments, R21, at each occurrence, is independently C1-C6alkyl (e.g., methyl, ethyl, propyl, or butyl). In some embodiments of Formula (I), R2eis C5-C10cycloalkyl (e.g., cyclopentyl or cyclohexyl) substituted with one or more R24. In some embodiments of the foregoing, R24, at each occurrence, is independently -ORa(e.g., -OH or -OD). In some embodiments, R2eis cyclopentyl optionally substituted with one to three -OH.

[0109] In some embodiments of Formula (I), R2is -N(Rx8)-R2A. In some embodiments of the foregoing, R2Ais 3- to 14-membered heterocyclyl, C6-C12 aryl, 5- to 14-membered heteroaryl, or C3-C14cycloalkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, -CN, oxo, -OH, -OD, - C(O)-L10-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, and -N(Ra)C(O)Ra. In some embodiments, R2Ais C6-C12aryl or C3-C14cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, -N(Ra)2, oxo, -OH, -OD, -C(O)-L10-N(Ra)2, -C(O)- N(Ra)2, -C(O)Ra, or -N(Ra)C(O)Ra. In some embodiments of Formula (I), R2Ais 3- to 14- membered heterocyclyl (e.g. piperidine, dihydropyridine, pyrrolidine, 1,3- diazaspiro[4.5]decane, hexahydropyrrolizine, azaspiro[3.3]heptane,optionally substituted with one or more groups independently selected from the group consisting of halogen, -CN, oxo, -OH, -OD, -C(O)-L10-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, and - N(Ra)C(O)Ra. In some embodiments, R2Ais 1,3-diazaspiro[4.5]decane optionally substituted with one to three oxo. In some embodiments, R2Ais unsubstituted 5 to 10-membered heterocyclyl (e.g., unsubstituted hexahydropyrrolizine or azaspiro[3.3]heptane). In some embodiments,. some embodiments, R2Ais C6-C12 aryl (e.g., phenyl) optionally substituted with one or more groups independently selected from the group consisting of halogen, -CN, -C(O)-N(Ra)2, and -N(Ra)C(O)Ra. In some embodiments, R2Ais 5- to 10-membered heteroaryl (e.g. imidazole or thiazole). In some embodiments, R2Ais imidazole. In some embodiments, R2Ais thiazole. In some embodiments, R2Ais C5-C10 l lk l ( l t l l h l) ti ll b tit t d ithindependently selected -ORa(e.g., -OH or -OD). In some embodiments, R2Ais cyclopentyl optionally substituted with one to three -OH.

[0110] In some embodiments of Formula (I), R2is -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, or - N(Rx9)-M2-L4-R2f. In some embodiments, R2is -N(Rx9)-M2-R2f, wherein M2is C3-C14cycloalkylene or 3- to 14-membered heterocyclylene, each of which is optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl, for example, one or more C1-C6 alkyl. In some embodiments, M2 is C5-C10 cycloalkylene (e.g., cyclopentylene, cyclohexylene). In some embodiments, M2is cyclohexylene. In some embodiments, M2is 3- to 12-membered heterocyclylene comprising at least one annular N (e.g., azabicyclo[3.3.1]nonanylene, piperidinylene, dihydropyridinylene, pyrrolidinylene, azetidinylene, or azabicyclo[4.3.1]decenylene), each of which is optionally substituted with one or more halogen (e.g., F) or C1-C6 alkyl (e.g., methyl, ethyl, propyl, or butyl). In some embodiments, M2is azabicyclo[3.3.1]nonanylene, piperidinylene, dihydropyridinylene, pyrrolidinylene, azetidinylene, or azabicyclo[4.3.1]decenylene, each of which is optionally substituted with one or more F or methyl. The compound of any one of claims 2-4, 16, or 17, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, wherein R2fis 3- to 14-membered heterocyclyl optionally substituted with one or more R21, and wherein R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), - C(O)ORa, -C(O)-L8-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6 alkyl optionally substituted with one or more R21a, C3-C6cycloalkyl optionally substituted with one or more R21a, 5- to 14-membered heteroaryl optionally substituted with one or more Ra, C6- C12 aryl optionally substituted with one or more independently selected –(C1-C6 alkyene)- OH, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or. In some embodiments, R2is -N(Rx9)-M2-R2f, and R2fis C6- C12 aryl (e.g. phenyl) optionally substituted with one or more independently selected R22(e.g., methyl or -NH2). In some embodiments, R2is -N(Rx9)-M2-R2f, and R2fis 5- to 14- membered heteroaryl (e.g., imidazolyl, pyridyl, or quinolinyl). In some embodiments, R2fis imidazolyl. In some embodiments, R2fis pyridyl. In some embodiments, R2fis quinolinyl. In some embodiments, R2is -N(Rx9)-M2-R2f, and R2fis C3-C10cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl). In some embodiments, R2fis cyclopropyl. In some embodiments, R2fis cyclohexyl. In some embodiments, R2is -N(Rx9)-M2-R2f, wherein R2fis 3 14 b d h l l b i d i ll i h R21d h iR21, at each occurrence, is independently selected from the group consisting of H, D, oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-L8-N(Ra)2, -C(O)- N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6 alkyl optionally substituted one or more independently selected R21a, C3-C6cycloalkyl optionally substituted with one or more R21a, 5- to 12 membered heteroaryl substituted with one or more independently selected Ra, C6-C12aryl, 3- to 14-membered heterocyclyl optionally substituted with one or more independently. In some embodiments, R2is -N(Rx9)-M2- R2f, wherein R2fis 3- to 14-membered heterocyclyl containing one, two or three annular atoms selected from N, O, and S (e.g., piperidinyl, tetrahydropyridine, 1,3- diazaspiro[4.5]decane, hexahydropyrrolizine, azaspiro[3.3]heptane,, tetrahydropyrane, dihydropyridine, pyrrolidine, oxetane, 2-oxa-6-azaspiro[3.3]heptane, 2,6- diazaspiro[3.3]heptane, morpholine, 2-oxa-7-azaspiro[3.5]heptane, 1-oxa-6- azaspiro[3.4]octane, 2,6-diazaspiro[3.4]octane, tetrahydro-5-furo[3,4-c]pyrrole, tetrahydrofurane, 3,6-diazabicyclo[3.1.1]heptane, 6-oxa-3-azabicyclo[3.1.1]heptane, isoindoline, 5-oxa-2-azaspiro[3.5]nonane, 3-azabicyclo[4.1.0]heptane, 6-oxa-3- azabicyclo[3.2.2]nonane, 7-oxa-4-azaspiro[2.5]octane, 6-azaspiro[2.5]octane, 6-oxa-2- azaspiro[3.4]octane, hexahydro-3H-2,5-pyrrolo[3,4-c]pyridine, 1,4-oxazepane, 2,6-dihydro- 4H-5-pyrrolo[3,4-c]pyrazole, 2,5-diazabicyclo[2.2.1]heptane, hexahydro-6-[1,4]dioxino[2,3- c]pyrrole, hexahydro-5H-cyclopenta[b][1,4]dioxine, 1,4-piperazine, hexahydro-4H-5- furo[3,2-c]pyridine, thiomorpholine, 1,6-diazaspiro[3.3]heptane, or 5-oxa-2- azaspiro[3.5]nonane) optionally substituted with one or more independently selected R21, and wherein R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2- (C6-C12 aryl), -C(O)ORa, -C(O)-L8-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted one or more independently selected R21a, C3-C6cycloalkyl optionally substituted with one or more R21a, or 5- to 12 membered heteroaryl substituted with one or more independently selected Ra. In some embodiments, R2is -N(Rx9)-M2-R2f, wherein R2fis unsubstituted 3- to 13-membered heterocyclyl. In some embodiments, R2fis, wherein any hydrogen of the foregoing groups can be replaced by a covalent bond connected to the parent structure, wherein the any of the foregoing groups can be optionally substituted with one or more independently selected R21, and wherein the one or more R21can be at any annular position(s) of the foregoing groups, as valency permits. In some embodiments, R2is -N(Rx9)-L4-R2f, wherein L4is C1-C8alkylene (e.g., methylene, ethylene, or propylene). In some embodiments, R2is -N(Rx9)-L4-R2f, and R2fis unsubstituted 3- to 13-membered heterocyclyl (e.g., unsubstituted hexahydro-pyrrolizinyl). In some b di t R2i N(Rx9) L R2fd R2fi 3 t 13 b d h t l l ti llsubstituted with one or more substituents independently selected from the group consisting of -OH, -OD, -C(O)-N(Ra)2, C1-C6 alkyl, and C3-C6 cycloalkyl. In some embodiments of the foregoing, R2fis 3- to 13-membered heterocyclyl containing at least one annular N atom, such as pyrrolidine, 7-azabicyclo[2.2.1]heptane, or piperidine, each of which is optionally substituted one or more -OH, -OD, -C(O)-N(Ra)2, or methyl. In some embodiments, R2is - N(Rx9)-L4-R2f, and R2fis C6-C12 aryl (e.g., phenyl) optionally substituted with one or more - NH2. In some embodiments, R2is -N(Rx9)-M2-L4-R2f. In some embodiments of the foregoing, M2is C3-C10cycloalkylene or 3- to 10-membered heterocyclylene optionally substituted with one or more C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments, M2 is C3-C10 cycloalkylene or 3- to 10-membered heterocyclylene optionally substituted with one or more independently selected from the group consisting of oxo, -CN, halogen, -OH, C1-C6alkyl, C3- C6 cycloalkyl, and -C(O)-N(Ra)2. In some embodiments of the foregoing, L4 is C1-C6 alkylene, C1-C4 alkylene, ethylene, or methylene. In some embodiments, L4 is C1-C6 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen. In some embodiments, M2is 3- to 14-membered heterocyclylene (e.g., 9- azabicyclo[3.3.1]nonanylene or 8-azabicyclo[3.2.1]octanylene), and wherein L4 is C1-C6 alkylene (e.g., methylene, ethylene, or propylene). In some embodiments, R2is -N(Rx9)-M2- L4-R2f, wherein M2is C5-C10cycloalkylene (e.g., cyclopentylene, cyclohexylene), and wherein L4 is C1-C6 alkylene (e.g., methylene, ethylene, or propylene). In some embodiments, M2is cyclohexylene. In some embodiments, R2is -N(Rx9)-M2-L4-R2f, and R2fis C6-C12aryl (e.g., phenyl) optionally substituted with one or more independently selected R22. In some embodiments, R2fis azetidinyl optionally substituted with one to three methyl.

[0111] In some embodiments of Formula (I), R2is -N(Rx10)-M3-N(Rx11)-R2jor -N(Rx10)-L5- N(Rx11)-R2j. In some embodiments, R2is -N(Rx10)-M3-N(Rx11)-R2j, and wherein M3is 3- to 14-membered heterocyclylene or C3-C14 cycloalkylene, each of which is optionally substituted by one or more groups independently selected from oxo, C1-C6 alkyl, and C3-C6 cycloalkyl. In some embodiments, M3is C5-C10cycloalkylene (e.g., cyclopentylene or cyclohexylene). In some embodiments, M3 is cyclohexylene. In some embodiments, R2is - N(Rx10)-M3-N(Rx11)-R2j, and wherein R2jis C6-C12 aryl (e.g. phenyl or 2,3-dihydro-indene) optionally substituted with one or more independently selected R22(e.g., -OH, -OD, oxo, or SO2CH3). In some embodiments, R2is -N(Rx10)-M3-N(Rx11)-R2j, and wherein R2jis 3- to 14- membered heterocyclyl optionally substituted with one or more independently selected R21wherein R21, at each occurrence, is independently selected from the group consisting of oxo,R2j, and wherein R2jis 3- to 13-membered heterocyclyl (e.g., piperidine, dihydropyridine, tetrahydrofurane, or 1,2,3,4-tetrahydroquinoline) optionally substituted with one to three independently selected R21(e.g., oxo, methyl, or -NMe-C(O)-Me). In some embodiments, R2is -N(Rx10)-M3-N(Rx11)-R2j, and wherein R2jis 5- to 14-membered heteroaryl optionally substituted with one or more independently selected R23, wherein R23, at each occurrence, is independently selected C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments, R2is - N(Rx10)-M3-N(Rx11)-R2j, and wherein R2jis 5- to 12-membered heteroaryl (e.g., indazole or pyrazole) optionally substituted with one to three independently selected R23(e.g., methyl). In some embodiments, R2is -N(Rx10)-M3-N(Rx11)-R2j, and wherein R2jis C3-C14 cycloalkyl optionally substituted with one or more independently selected R24, and wherein R24, at each occurrence, is independently oxo, halogen, -ORa, -C(O)-(L8)n-N(Ra)2, or -N(Ra)C(O)Ra. In some embodiments, R2is -N(Rx10)-M3-N(Rx11)-R2j, and wherein R2jis C3-C10 cycloalkyl (e.g., cyclopropyl, bicyclo[2.1.1]hexanyl, cyclopentyl, or cyclohexyl) optionally substituted with one to three independently selected R23(e.g., -OH, -OD, -NMe-C(O)-Me, or - C(O)NHMe). In some embodiments, R2is -N(Rx10)-L5-N(Rx11)-R2j, and wherein L5is C1-C8alkylene (e.g., methylene, ethylene, propylene, or butylene). In some embodiments, R2is - N(Rx10)-L5-N(Rx11)-R2j, and wherein R2jis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected R21or 5- to 14-membered heteroaryl optionally substituted with one or more independently selected R23, wherein R21, at each occurrence, is independently selected from the group consisting of oxo, halogen, -CN, -ORa, - N(Ra)C(O)Ra, C1-C6alkyl, and C3-C6cycloalkyl, and wherein R23, at each occurrence, is independently selected C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments, R2jis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, halogen, -CN, -ORa, -S(O)2Ra, C1-C6alkyl, or C3-C6cycloalkyl. In some embodiments, R2jis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, halogen, -CN, -ORa, -S(O)2Ra, or C1-C6 alkyl. In some embodiments, R2jis unsubstituted 3- to 14-membered heterocyclyl. In some embodiments, R2jis 5- to 14- membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments, R2jis 5- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl. In some embodiments, R2jis C3-C10cycloalkyl (e.g., cyclopentyl or cyclohexyl) optionally substituted with one to three independently selected R23(e.g., -OH or -OD).

[0112] In some embodiments of Formula (I), R2is -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L7-N(Rx14)-R2y, and wherein M5is C3-C20cycloalkylene optionally substituted by one or more C1-C6 alkyl. In some embodiments, M5 is C5-C10 cycloalkylene (e.g., cyclobutylene, cyclopentylene, cyclohexylene, or bicyclo[2.2.2]octanylene). In some embodiments, M5 is cyclohexylene. In some embodiments, M5is cyclopentylene. In some embodiments, M5is cyclobutylene. In some embodiments, M5is bicyclo[2.2.2]octanylene. In some embodiments, M5 is optionally substituted with one or more C1-C3 alkyl (e.g., methyl), C3-C6 cycloalkyl, or -OH. In some embodiments, M5 is cyclobutylene, cyclopentylene, cyclohexylene, or bicyclo[2.2.2]octanylene optionally substituted with one to three methyl or -OH. In some embodiments, R2is -N(Rx13)-L7-N(Rx14)-R2y, and wherein L7 is C1-C8 alkylene (e.g., methylene, ethylene, propylene, butylene, or pentylene). In some embodiments, R2is - N(Rx13)-M5-L7-N(Rx14)-R2y, wherein M5is C3-C14cycloalkylene (e.g., cyclopentylene or cyclohexylene), and wherein L7 is C1-C8 alkylene (e.g., methylene, ethylene, or propylene). In some embodiments, R2yis C1-C6 alkyl optionally substituted with one or more R26, and R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)-N(Ra)2; -N(Ra)C(O)- Ra; -N(Ra)C(O)-(C6-C12aryl); -N(Ra)C(O)-(C1-C6alkylene)-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6 alkyl, or C3-C6cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; C6-C12aryl optionally substituted with one or more independently selected CN or C1-C6 alkoxy; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD. In some embodiments of the foregoing, R2yis C1-C6alkyl optionally substituted with one or more independently selected R26, and R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)- N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(C6-C12 aryl); -N(Ra)C(O)-(C1-C6 alkylene)-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14cycloalkyl optionally substituted with one or more independently selected - OH or -OD. In some embodiments, R2yis C1-C6 alkyl (e.g., methyl or ethyl) substituted with one or more independently selected R26, and R26, at each occurrence, is independently -ORa; - N(Ra)2; -C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(C6-C12aryl); -N(Ra)C(O)-(C1-C6alkylene)-(C6-C12aryl); 3- to 10-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6 alkyl or C3-C6 cycloalkyl; or 3 to 10-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-embodiments, at least one of R26is -C(O)-N(Ra)2. In some embodiments, at least one of R26is -N(Ra)C(O)-Ra. In some embodiments, R2yis C1-C4 alkyl (e.g., methyl or ethyl) substituted with one or more independently selected R26, and R26, at each occurrence, is independently -OH, -OD, -OCH3, -O-phenyl, -N(CH3)2, -C(O)-N(Ra)2(e.g., -C(O)-NH2or - C(O)-N(CH3)2), -N(Ra)C(O)-Ra(e.g., -NMeC(O)-Me), -N(Ra)C(O)-(C6-C12aryl) (e.g., - NMe-C(O)-phenyl), -N(Ra)C(O)-(C1-C6 alkylene)-(C6-C12 aryl)), 3- to 10-membered heterocyclyl (e.g., tetrahydrofuran, oxetane, or pyrrolidine) optionally substituted with one or more oxo or methyl, or 3 to 6-membered heteroaryl (e.g., pyrazole, 1,2,4-oxadiazole) optionally substituted with one or more independently selected C1-C3 alkyl (e.g., methyl), or cyclopropyl optionally substituted with one or more -OH.

[0113] In some embodiments of Formula (I), R2is -N(Rx12)-R2xor -N(Rx12)-M4-R2x. In some embodiments, R2is -N(Rx12)-R2x. In some embodiments, R2is -N(Rx12)-M4-R2x, and wherein M4 is C3-C20 cycloalkylene, 3- to 14-membered heterocyclylene, C6-C12 arylene, or 3- to 6-membered heteroarylene, each of which is optionally substituted by one or more groups independently selected from oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, and -C(O)-N(Ra)2. In some embodiments, M4 is C3-C14 cycloalkylene or 3- to 14- membered heterocyclylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2. In some embodiments, M4 is C5-C10 cycloalkylene (e.g., cyclopentylene or cyclohexylene). In some embodiments, M4is cyclohexylene. In some embodiments, M4is cyclopentylene. In some embodiments, M4is C6-C12arylene. In some embodiments, M4is phenylene optionally substituted with one or more -C(O)-NH2. In some embodiments, M4 is 3- to 6-membered heteroarylene, such as pyrazolylene. In some embodiments, M4 is 3- to 14- membered heterocyclylene containing at least one annular N atom (e.g., piperidinylene, 8- azabicyclo[3.2.1]octanylene, 2-azaspiro[4.4]nonanylene, 2-azaspiro[3.3]heptanylene, 6- azaspiro[3.4]octanylene, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinylene, 5,6,7,8-tetrahydro- 1,6-naphthyridinylene, isoindolinylene, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinylene, octahydro-isoindolylene, 1,2,3,4-tetrahydroisoquinolinylene, 5,6,7,8-tetrahydro-1,7- naphthyridinylene, 2-azaspiro[4.5]decenylene, octahydrocyclopenta[c]pyrrolylene, 5- azaspiro[3.5]nonanylene, 2-azaspiro[3.4]octanylene, 9-azabicyclo[3.3.1]nonanylene, 3- azabicyclo[3.2.0]heptanylene, 5-azaspiro[3.4]octanylene, or 5-oxa-2- azaspiro[3.4]octanylene) optionally substituted with one or more halogen, -CN, methyl, ethyl,wherein any hydrogen of the foregoing groups can be replaced by a covalent bond connected to the parent structure, wherein the any of the foregoing groups can be optionally substituted with one or more independently selected halogen, -CN, methyl, ethyl, -C(O)NH2, or - C(O)NHCH3, and wherein the one or more substituents can be at any annular position(s) of the foregoing groups, as valency permits. In some embodiments of the foregoing, R2xis C1- C6 alkyl substituted optionally with one or more independently selected R25, and wherein R25, at each occurrence, is independently halogen, -OH, -OCH3, or -N(CH3)2. In some embodiments, R2xis methyl or ethyl, each optionally substituted with one or more independently selected F, -OH, -OD, -OCH3, or -N(CH3)2.

[0114] In some embodiments of Formula (I), R2is -C(O)ORx3, -C(O)R2i, -L6-R2h, 3- to 14- membered heterocyclyl optionally substituted with one or more independently selected R21, C6-C12aryl optionally substituted with one or more R22, or C3-C20cycloalkyl optionally substituted with one or more R24. In some embodiments, R2is -C(O)ORx3, and wherein Rx3is H, D, or C1-C3 alkyl (e.g., methyl), or C3-C6 cycloalkyl. In some embodiments, R2is - C(O)R2i. In some embodiments, R2iis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments, R2iis 3- to 10-membered heterocyclyl (e.g., cyclohexyl) optionally substituted with one to three methyl. In some embodiments, R2is -L6-R2h. In some embodiments, L6is C1-C8 alkylene (e.g.,C1-C6 alkylene, C1-C3 alkylene, ethylene, or methylene) optionallysubstituted with one or more independently selected -OH, -OD, or Br. In some embodiments, R2his 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3 alkyl or C3-C6 cycloalkyl, each of which is optionally substituted with one or more -OH, -OD, halogen, or -N(Ra)2. In some embodiments, R2his 3- to 10-membered heterocyclyl (e.g., piperazinyl) or C3-C10cycloalkyl (e.g., cyclohexyl), each of which is optionally substituted with one to three independently selected methyl or -CH2OH. In some embodiments, R2is -L6-R2h, wherein L6 is C1-C8 alkylene (e.g., methylene, ethylene, or propylene), and wherein R2his 3- to 10-membered heterocyclyl optionally substituted with one to three methyl. In some embodiments, R2is 5- to 13-membered heterocyclyl (e.g., 2- azaspiro[3.5]nonane) optionally substituted with one or more -CH2OH. In some embodiments, R2is 5- to 13-membered heteroaryl (e.g., thiazolyl or thiophenyl) optionally substituted with one or more -NH2.

[0115] In some embodiments of Formula (I), R1is taken together with R2, and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b. In some embodiments, R1is taken together with R2, and the atoms to which they are attached to form a 5- to 10-membered heteroaryl (e.g., furan, thiophene, or pyrrole), each of which is optionally substituted with one or more independently selected R1b. In some embodiments, R1b, at each occurrence, is independently 3- to 14-membered heterocyclyl or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14-membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more methyl or C3-C6cycloalkyl. In some embodiments, R1bis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl (e.g., methyl) or C3-C6 cycloalkyl. In some embodiments, R1bis 3- to 14- membered heterocyclyl optionally substituted with one or more independently selected C1-C6alkyl (e.g., methyl). In some embodiments, R1bis -N(Ra)-(3- to 14-membered heterocyclyl), wherein the 3- to 14-memebred heterocyclyl is optionally substituted with one or more independently selected C1-C6alkyl (e.g., methyl) or C3-C6cycloalkyl. In some embodiments, R1bis -N(Ra)-(3- to 14-membered heterocyclyl), wherein the 3- to 14-memebred heterocyclyl is optionally substituted with one or more independently selected C1-C6 alkyl (e.g., methyl).

[0116] In some embodiments of Formula (I), R4is H or D. In some embodiments, R4is - NH2or -NO2. In some embodiments, R4is -N(Ra)2or -NO2, wherein each Rais independently H or D. In some embodiments, R4is unsubstituted C3-C14 cycloalkyl. In some embodiments, R4is unsubstituted C3-C10cycloalkyl. In some embodiments, R4is unsubstituted cyclopropyl.

[0117] In some embodiments of Formula (I), R4is -C(O)ORz1, -C(O)-R4b, -C(O)N(Rz3)- R4c, -C(O)-N(Rz4)-L12-M6-R4d, -C(O)-N(Rz4)-M6-R4d, -C(O)-N(Rz4)-L12-R4d, or - C(O)NRz5Rz6. In some embodiments, R4is -COOH or -COOMe. In some embodiments, R4is -C(O)-R4b, and R4bis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected R41. In some embodiments of the foregoing, R41is H; D; C1-C6alkyl optionally substituted one or more -OH or -OD; or C3-C6 cycloalkyl optionally substituted one or more -OH or -OD. In some embodiments, R4is -C(O)-R4b, and R4bis pyrrolidinyl or 1,3-oxazinanyl, optionally substituted with one or more -CH2CH2OH. In some embodiments, R4is -C(O)N(Rz3)-R4c, wherein R4cis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected halogen, or C6-C12 aryl optionally substituted with one or more -S(O)2NH2. In some embodiments, R4is -C(O)N(Rz3)-R4c, wherein R4cis 2- azabicyclo[2.2.1]heptane optionally substituted with one to three independently groups independently selected from the group consisting of F and phenyl optionally substituted with one -S(O)2NH2.

[0118] In some embodiments of Formula (I), R4is -C(O)-N(Rz4)-L12-M6-R4d, -C(O)- N(Rz4)-M6-R4d, or -C(O)-N(Rz4)-L12-R4d. In some embodiments, M6 is 3- to 10-membered heterocyclylene (e.g., pyran) or C6-C12arylene (e.g., phenylene), optionally unsubstituted. In some embodiments, L12is C1-C6alkylene, C1-C4alkylene, propylene, ethylene, or methylene. In some embodiments, L12 is C1-C6 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen. In some embodiments, R4dis 3- to 14- membered heterocyclyl optionally substituted with one or more R41, C6-C12aryl optionally substituted with one or more R42, 5- to 14-membered heteroaryl optionally substituted with one or more R43, or C3-C14 cycloalkyl optionally substituted with one or more R44. In some embodiments, R4dis 3- to 14-membered heterocyclyl (e.g., tetrahydrofuran, oxetane, or 6,7- dihydro-pyrrolo[2,1-c][1,2,4]triazole), optionally unsubstituted. In some embodiments, R4dis C6-C12 aryl (e.g., phenyl or naphthalenyl) optionally unsubstituted. In some embodiments, R4dis 5- to 6-membered heteroaryl (e.g., pyridine or imidazole), optionally unsubstituted. In some embodiments, R4dis C3-C14 cycloalkyl (e.g., cyclopentyl or cyclphexyl) optionally substituted with one or more -OH, -OD, or methyl.

[0119] In some embodiments of Formula (I), R4is -C(O)NRz5Rz6. In some embodiments of Formula (I), R4is -N(Rz2)-L11-R4aor -N(Rz2)-R4a. In some embodiments, R4ais 3- to 14 membered heterocycle optionally substituted with one or more C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments, R4ais piperidine optionally substituted with one or moremethyl. In some embodiments, R4ais C6-C12aryl optionally substituted with one or more R42. In some embodiments, R4ais phenyl. In some embodiments, L11 is methylene.

[0120] In some embodiments of Formula (I), R5is H. In some embodiments of Formula (I), R5is D. In some embodiments, R5is -L13-NR5AR5Bor -NR5AR5B, wherein L13is C1-C6alkylene (e.g., methylene), and R5Aand R5Bare independently C2-C6alkynyl (e.g., prop-1- ynyl) or C6-C12 aryl (e.g., phenyl). In some embodiments, R5is C2-C6 alkenyl (e.g., - CH=CH2, -CH=CH(CH3), -CH=CH2CH3, - CH2CH=CH2, -CH=C=CH2) optionally substituted with one or more R5C. In some embodiments, R5C, at each occurrence, is independently -OH, -OD, -OCH3, -O-(C6-C12 aryl), -NH-(C6-C12 aryl), -ND-(C6-C12 aryl), C3-C12 cycloalkyl, or C6-C12 aryl. In some embodiments, R5C, at each occurrence, is independently -OH, -OD, -OCH3, -O-phenyl, -NH-phenyl, C3-C12cycloalkyl (e.g., cyclopentyl), or C6-C12 aryl (e.g., phenyl). In some embodiments, R5is C2-C6 alkynyl (e.g., C2-C4 alkynyl) optionally substituted with one or more R5D. In some embodiments, R5D, at each occurrence, is independently C6-C12aryl (e.g., phenyl), -NH-(C6-C12aryl) (e.g., -NH-

[0121] In some embodiments of Formula (I), R5is -C(O)-N(Ru1)-L14-R5eor -C(O)-N(Ru1)- R5e. In some embodiments, L14 is C1-C8 alkylene (e.g., methylene, ethylene, or propylene) optionally substituted with -CN. In some embodiments, R5eis 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12aryl optionally substituted with one or more R52, 5- to 14-membered heteroaryl optionally substituted with one or more R53, or C3-C12cycloalkyl optionally substituted with one or more R54. In some embodiments, R5eis 3- to 14-membered heterocyclyl (e.g., azetidine), optionally unsubstituted 3- to 14- membered heterocyclyl. In some embodiments, R5eis C6-C12 aryl (e.g., phenyl or naphthalenyl), optionally substituted with one or more independently selected halogen, -CN, - C(O)Rz8, -S(O)2CH3, -C(O)-NHCH3, 5- to 6-membered heteroaryl (e.g., pyrazole or pyridine), C1-C6 alkyl optionally substituted one or more independently selected halogen (e.g., CF3), or C3-C6alkyl optionally substituted one or more independently selected halogen (e.g., CF3). In some embodiments, R5eis 5- to 14-membered heteroaryl (e.g., imidazole, pyrazole, indole, pyrimidine, or pyridine) optionally substituted with one or more methyl, - C(O)-NHCH3, phenyl, or -CN. In some embodiments, R5eis C3-C12 cycloalkyl (e.g., l l l b l d l) i ll b i d i h h

[0122] In some embodiments of Formula (I), R5is-C(O)-N(Ru2)-R5x. In some embodiments, R5xis C1-C6 alkyl (e.g., ethyl) optionally substituted with one or more -O-(C1- C6 haloalkyl) such as -O-CF3.

[0123] In some embodiments of Formula (I), R1is H, deuterium, halogen, or C1-C6alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; R2is SR2b, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, -N(Rx8)- R2A, -N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, - N(Rx10)-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -(L6)n-R2h, -N(Rx13)-M5- L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7-N(Rx14)-R2y, R4is H, C3-C14cycloalkyl, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-(L12)n-(M6)m-R4d, or - C(O)NRz5Rz6; R4is H, D, C3-C14 cycloalkyl, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-(L12)n-(M6)m-R4d, or - C(O)NRz5Rz6; and R5is H, D, C2-C6alkenyl optionally substituted with one or more R5C, C2-C6alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or -C(O)-N(Ru2)-R5x, wherein each other variable is as defined for Formula (I).

[0124] In some embodiments, Rw1, Rx1, Rx2, Rx3, Rx4, Rx5, Rx6, Rx7, Rx8, Rx9, Rx10, Rx11, Rx12, Rx13, Rx14, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Ru1, Ru2, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen. In some embodiments of Formula (I), Rw1, Rx1, Rx2, Rx3, Rx4,, at each occurrence, are independently H, or C1-C6alkyl (e.g., methyl) optionally substituted with one or more independently selected halogen (e.g., F).

[0125] In some embodiments of Formula (Ia) or (I), at least one of R1, R2, and R4is not H or halo. In some embodiments, at least one of R1, R2, and R4is not H. In some embodiments, the compound of Formula (Ia) or (I) is not the compound No. 1 in Table 1.

[0126] In some embodiments, provided herein are compounds and pharmaceutically acceptable salts thereof described in Table 1. In some embodiments, provided herein are compounds and pharmaceutically acceptable salts thereof described in Table 1A. In some embodiments, the compound is selected from Compound No. 1 to Compound No. 972 in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the compoundacceptable salt thereof. In some embodiments, the compound is selected from Compound No. 3, 4, 5, 6, and 9-972 in Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is selected from compound No. 978 to Compound No. 1034 in Table 1A or a pharmaceutically acceptable salt thereof. Table 1Cmp Structure d No. 372 373 374 375 376 377 378 379 380 381 382 383 384Cmp Structure d No. 450 451 452 453 454 455 456 457 458 459 460 461Table 1ACompounds of Formula (II)

[0127] In one aspect, provided herein is a compound of Formula (II)or a pharmaceutically acceptable salt thereof, wherein: R1is H, deuterium, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, -N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, C1-C6alkyl optionally substituted with one or more independently selected halogen, C3-C6cycloalkyl optionally substituted with one or more independently selected halogen, or C2-C6 alkynyl optionally substituted with one or more independently selected -N(Rw9)R1f, R3is H, deuterium, -N(Ry3)-R3a, -C(O)ORy4, -N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, or - S(O)2NRy8Ry9; R4is H, deuterium, halogen, -N(Rz1)Rz2, -N(Rz3)-(L4)n-R4a, -N(Rz4)-C(O)-(L5)n-R4b, - C(O)ORz5, -C(O)N(Rz6)R4c, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more independently selected -NRz7R4d, R5is H, deuterium, Br, I, -ORu1, -O-(C2-C6 alkynyl), -C(O)NRu2Ru3, -C(O)-M1-N(Ry1)-R5a, - C(O)-N(Ry1)-L6-R5a, -C(O)-M1-N(Ry1)-L6-R5a, -N(Ru6)-(L7)n-R5b, C1-C6alkyl optionally substituted with one or more -OR5A, C3-C6cycloalkyl optionally substituted with one or more -OR5A, C2-C6 alkenyl optionally substituted with one or more R5B, C2-C6 alkynyl optionallysubstituted with one or more -NRu7R5c, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5C, R5A, at each occurrence, is independently selected from the group consisting of H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl, and C3-C6cycloalkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; R5B, at each occurrence, is independently -ORa, -N(Ra)2, or C6-C12 aryl; and R5C, at each occurrence, is independently C1-C6alkyl or C3-C14 cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R3a, R3b, R4a, R4b, R4c, R4d, R5a, R5b, and R5c, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl optionally substituted with one or more independently selected -ORa, C(O)N(Ra)2, or -S(O)2N(Ra)2; or C3-C14 cycloalkyl; M1is C6-C12arylene, C3-C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14- membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or - C(O)-N(Ra)2; L1, L2, L3, L4, L5, L6, and L7, at each occurrence, are independently C1-C8 alkylene; n, at each occurrence, is independently 0 or 1;, Rz2, Rz3, Rz4, Rz5, Rz6, Rz7, Ru1, Ru2, Ru3, Ru6, Ru7, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen; provided that, when R5is unsubstituted C1-C6alkyl or -ORu1, or when R4is Br, R3is not H; and at least one of R1, R3, R4, and R5is not H.

[0128] In some embodiments of Formula (II), R1is -OR1c. In some embodiments of the foregoing, R1cis C6-C12aryl (e.g., phenyl). In some embodiments of Formula (II), R1is H, D, -N(Rw1)-(L1)n-R1a, -N(Rw4)-C(O)-(L2)n-R1b, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, C1-C6alkyl optionally substituted with one or more independently selected halogen, C3-C6alkynyl optionally substituted with one or more independently selected N(Rw9)R1f. In some embodiments of Formula (II), R1is H. In some embodiments of Formula (II), R1is -N(Rw1)- (L1)n-R1a, In some embodiments, R1is -N(Rw1)-L1-R1a. In some embodiments of the foregoing, L1is C1-C6alkylene (e.g., methylene, ethylene, or propylene). In some embodiments of the foregoing, R1ais 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more independently selected C1-C6 alkyl (e.g., methyl) or C3-C6 cycloalkyl. In some embodiments of the foregoing, R1ais piperdinyl substituted with one to three methyl. In some embodiments, R1is -N(Rw2)C(O)Rw, optionally -NH-C(O)CH3. In some embodiments, R1is -N(Rw4)-C(O)-R1bor -N(Rw4)-C(O)-L2-R1b. In some embodiments of the foregoing, L2 is C1-C6 alkylene, C1-C4 alkylene, ethylene, or methylene. In some embodiments of the foregoing, R1bis 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments of the foregoing, R1is -NH-C(O)-R1bor -NH-C(O)-CH2-R1b, and R1bis piperdinyl substituted with one to three methyl. In some embodiments, R1is - N(Rw6)C(O)N(Rw7)R1d, optionally -NHC(O)NHR1d. In some embodiments of the foregoing, R1dis 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more C1-C3alkyl or C3-C6cycloalkyl. In some embodiments of the foregoing, R1is - NHC(O)NHR1d, and R1dis piperdinyl substituted with one to three methyl. In some embodiments, R1is -C(O)N(Rw8)-(L3)n-R1e, optionally -C(O)NH-R1e. In some embodiments of the foregoing, R1eis 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more C1-C3alkyl or C3-C6cycloalkyl. In some embodiments of the foregoing, R1is -C(O)NH-R1e, and R1eis piperdinyl substituted with one to three methyl. In some embodiments, R1is C1-C6 alkyl (e,g., methyl) optionally substituted with one or more independently selected halogen (e.g. F) . In some embodiments, R1is C2-C6alkynyl optionally substituted with one or more independently selected N(Rw9)R1f. In some embodiments, R1is C2-C6 alkynyl (e.g., ethynyl or prop-1-ynyl) optionally substituted with.

[0129] In some embodiments of Formula (II), R3is H or D. In some embodiments of Formula (II), R3is -S(O)2NRy8Ry9, optionally -S(O)2NHCH3. In some embodiments, R3is - N(Ry3)-R3a, -C(O)ORy4, or -N(Ry7)C(O)R3b, wherein R3aand R3bare each independently 3- to b d h l l i ll b i d i h i d d l l dC1-C6alkyl or C3-C6cycloalkyl. In some embodiments of Formula (II), R3is -N(Ry3)-R3a, - C(O)ORy4, or -N(Ry7)C(O)R3b. In some embodiments of the foregoing, R3aand R3bare each independently selected 3- to 10-membered heterocyclyl (e.g., piperidinyl or 8- azabicyclo[3.2.1]octanyl) optionally substituted with one or more independently selected C1- C6alkyl. In some embodiments of the foregoing, R3aand R3bare each independently piperdinyl or 8-azabicyclo[3.2.1]octanyl optionally substituted with one to three methyl. In some embodiments of Formula (II), R3is -C(O)ORy4, optionally -COOH or -COOD.

[0130] In some embodiments of Formula (II), R4is halogen. In some embodiments of Formula (II), R4is F, Cl, Br, or I. In some embodiments of Formula (II), R4is -N(Rz1)Rz2, - N(Rz3)-(L4)n-R4a, -N(Rz4)-C(O)-(L5)n-R4b, -C(O)ORz5, -C(O)N(Rz6)R4c, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6alkynyl optionally substituted with one or more independently selected NRz7R4d. In some embodiments of Formula (II), R4is -N(Rz1)Rz2, optionally -NH2. In some embodiments of Formula (II), R4is -N(Rz3)-R4aor -N(Rz3)-L4-R4a. In some embodiment of the foregoing, R4ais 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more C1-C3alkyl or C3-C6cycloalkyl. In some embodiments of the foregoing, R4ais piperdinyl optionally substituted with one to three methyl. In some embodiment of the foregoing, L4is C1-C6alkylene, C1-C4alkylene, ethylene, or methylene. In some embodiments of Formula (II), R4is -N(Rz4)-C(O)-R4bor -N(Rz4)-C(O)-L5-R4b. In some embodiment of the foregoing, L5 is C1-C6 alkylene, C1-C4 alkylene, ethylene, or methylene. In some embodiment of the foregoing, R4bis 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more C1-C3alkyl or C3-C6cycloalkyl. In some embodiments of the foregoing, R4bis piperdinyl optionally substituted with one to three methyl. In some embodiments of Formula (II), R4is -C(O)ORz5, optionally -COOCH3. In some embodiments of Formula (II), R4is -C(O)N(Rz6)R4c, wherein R4cis 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more C1-C3 alkyl. In some embodiments of the foregoing, R4cis piperdinyl optionally substituted with one to three methyl. In some embodiments of Formula (II), R4is C1-C6alkyl, optionally ethyl or methyl. In some embodiments of Formula (II), R4is C2-C6 alkenyl (e.g., ethylenyl), or C2-C6 alkynyl (e.g., ethynyl or prop-1-ynyl) optionally substituted.

[0131] In some embodiments of Formula (II), R5is H, D, or Br. In some embodiments of l ( )5i1i ll b di f l(II), R5is -O-(C2-C6alkynyl), -C(O)NRu2Ru3, -C(O)-(M1)m-N(Ry1)-(L6)n-R5a, -N(Ru6)-(L7)n- R5b, C1-C6 alkyl optionally substituted with one or more independently selected -OR5A, C3-C6 cycloalkyl optionally substituted with one or more independently selected -OR5A, C2-C6 alkenyl optionally substituted with one or more R5B, C2-C6alkynyl optionally substituted with one or more independently selected -NRu7R5c, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5C. In some embodiments of Formula (II), R5is C1-C6 alkyl (e.g, methyl or ethyl) optionally substituted with one or more independently selected -OR5A, wherein R5A, at each occurrence, is independently selected from the group consisting of H and C1-C6 alkyl optionally substituted with one or more independently selected -ORa(e.g., -OCH3) or C6-C12 aryl (e.g., phenyl). In some embodiments, R5A, at each occurrence, is independently –(CH2)-phenyl or -CH2CH2OCH3). In some embodiments of Formula (II), R5is -O-(C1-C6 haloalkyl), -C(O)NRu2Ru3, -C(O)-M1- N(Ry1)-R5a, -C(O)-N(Ry1)-L6-R5a, -C(O)-M1-N(Ry1)-L6-R5a, C2-C6 alkenyl optionally substituted with one or more R5B, or C2-C6alkynyl optionally substituted with one or more independently selected -NRu7R5c, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5C. In some embodiments of Formula (II), R5is -C(O)NRu2Ru3, -C(O)-N(Ry1)-L6-R5a, C2-C6alkenyl optionally substituted with one or more independently selected R5B, or C2-C6alkynyl optionally substituted with one or more groups independentlysome embodiments of Formula (II), R5is -O-(C1-C6 haloalkyl) (e.g., -OCHF2) or -C(O)NRu2Ru3(e.g., - C(O)NHCH3). In some embodiments of Formula (II), R5is -C(O)-M1-N(Ry1)-R5a, -C(O)- N(Ry1)-L6-R5a, or -C(O)-M1-N(Ry1)-L6-R5a. In some embodiments of Formula (II), M1is 3- to 12-membered heterocyclylene comprising at least one annular N (e.g., azetidinylene). In some embodiments, L6is C1-C6alkylene, C1-C4alkylene, ethylene, or methylene. In some embodiments, M1is azetidinylene and L6is methylene. In some embodiments, R5ais C6-C12aryl (e.g., phenyl), optionally unsubstituted.

[0132] In some embodiments of Formula (II), R5is C2-C6alkenyl optionally substituted with one or more R5B. In some embodiments, R5B, at each occurrence, is independently -ORa, -NH2, or C6-C12 aryl. In some embodiments, R5is ethylenyl, propylenyl, or butylenyl, each of which is optionally substituted with one or more -OH, -OD, -NH2, -OCH3, or phenyl. Insome embodiments of Formula (II), R5is C2-C6alkynyl (e.g., ethynyl or prop-1-ynyl) optionally substituted

[0133] In some embodiments of Formula (II), M1 is 3- to 14-membered heterocyclylene.

[0134] In some embodiments, provided herein are compounds described in Table 2 and pharmaceutically acceptable salts thereof. In some embodiments, provided herein are compounds selected from Compounds 2-1 to 2-88 in Table 2, and pharmaceutically acceptable salts thereof Table 2Compounds of Formula (III)

[0135] In one aspect, provided herein is a compound of Formula (III)or a pharmaceutically acceptable salt thereof, wherein: R2is halogen, -N(Rx1)Rx2, -N(Rx3)R2a, -C(O)N(Rx4)R2b, -N(Rx5)C(O)Rx6, -N(Rx7)C(O)R2c, or -N(Rx8)C(O)N(Rx9)R2d, R3is H, deuterium, halogen, or -CN; R4is H or deuterium; R5is H, deuterium, halogen, -OH, -OD, -NRu1Ru2, -N(Ru3)C(O)ORu4, -N(Ru5)-C(O)-(L1)n- R5a, -N(Ru6)C(O)NRu7Ru8, -N(Ru9)-C(O)-N(Ru10)-(L2)n-R5b, -(L3)n-COORu11, -(L4)n- C(O)NRu12Ru13, or C2-C6 alkynyl optionally substituted with one or more -NRu14R5c, R2a, R2b, R2c, R2d, R5a, R5b, and R5c, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl, C3- C6 cycloalkyl, or -C(O)ORa; or C6-C12 aryl optionally substituted with one or more independently selected -ORaor -S(O)2N(Ra)2; n, at each occurrence, is independently 0 or 1; L1, L2, L3, L4, at each occurrence, are independently C1-C8 alkylene;, Ru10, Ru11, Ru12, Ru13, Ru14, and Ra, at each occurrence, are independently H, deuterium, C1- C6 alkyl, or C3-C6 cycloalkyl. .

[0136] In some embodiments of Formula (III), R2is Cl or Br. In some embodiments ofN(Rx5)C(O)Rx6, or -N(Rx8)C(O)N(Rx9)R2d. In some embodiments, R2is -N(Rx1)Rx2, - N(Rx3)R2a, -N(Rx7)C(O)R2c, -N(Rx5)C(O)Rx6, or -N(Rx8)C(O)N(Rx9)R2d. In some embodiments, R2is -N(Rx3)R2a, -C(O)N(Rx4)R2b, -N(Rx7)C(O)R2c, or -N(Rx8)C(O)N(Rx9)R2d. In some embodiments of Formula (III), R2is -C(O)N(Rx4)R2b, wherein R2bis 3 to 14- membered heterocyclyl (e.g., 3- to 10-membered heterocyclyl such as e.g., piperidinyl) optionally substituted with one or more independently selected C1-C3 alkyl (e.g., methyl) or C3-C6 cycloalkyl. In some embodiments of the foregoing, R2is -C(O)NHR2b, and R2bis piperdinyl substituted with one to three methyl. In some embodiments of Formula (III), R2is -N(Rx3)R2aor -N(Rx8)C(O)N(Rx9)R2d, and wherein R2aand R2dare each independently selected 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6alkyl, C3-C6cycloalkyl or -C(O)ORa. In some embodiments, R2is -NHR2aor -NHC(O)NHR2d, wherein R2aand R2dare each independently selected 3- to 14- membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl, C3-C6cycloalkyl, or -C(O)OC(CH3)3. In some embodiments of Formula (III), R2is - N(Rx3)R2a, optionally -NHR2a. In some embodiments, R2ais 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more methyl or -COOC(CH3)3. In some embodiments of Formula (III), R2is -N(Rx8)C(O)N(Rx9)R2d, optionally -NHC(O)NHR2d, and R2dis 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with methyl.

[0137] In some embodiments of Formula (III), R3is H, D, or F. In some embodiments of Formula (III), R3is -CN.

[0138] In some embodiments of Formula (III), R5is H, halogen, -OH, -OH, -NH2, -NHD, - ND2, -NHC(O)OC(CH3)3, -NH-C(O)-(L1)n-R5a, -NHC(O)NHCH3, -NH-C(O)-NH-(L2)n-R5b, -(L3)n-COORu11, -(L4)n-C(O)NRu12Ru13, or C2-C6 alkynyl optionally substituted with one or more independently selected -NRu14R5c. In some embodiments, R5is -NH-C(O)-NH-L2-R5b. In some embodiments, L2 is methylene. In some embodiments, R5bis 3- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments, R5bis piperdinyl substituted with one to three methyl. In some embodiments of Formula (III), R5is H, -NH2, -N(R O)-L1-R5a, or C2-C6 alkynyl optionally substituted with one or more. n some embodiments of Formula (III), R5is H. In some embodiments of Formula (III), R5is -NH2. In b di f l ( )5i (5) ( )5b di fFormula (III), R5is -N(Ru5)-C(O)-L1-R5a, wherein L1is methylene. In some embodiments, R5ais phenyl. In some embodiments of Formula (III), R5is C2-C6 alkynyl (e.g., prop-1-ynyl) optionally substituted with one or more.

[0139] In some embodiments, provided herein are compounds described in Table 3and pharmaceutically acceptable salts thereof. In some embodiments, provided herein are compounds selected from compounds 3-1 to 3-25 in Table 3. Table 3Compounds of Formula (IV)

[0140] In some embodiments, provided herein is a compound of Formula (IV)or a pharmaceutically acceptable salt thereof, wherein: R1is H, deuterium, or halogen; R2is -N(Rx1)-R2a, -OR2b, or -SR2c; R3is H, deuterium, -C(O)NRy1Ry2, or -C(O)N(Ry3)-L1-R2d; R2a, R2b, R2c, and R2dare each independently 3- to 14-membered heterocyclyl, C6-C12 aryl, 5- to 14-membered heteroaryl, or C3-C14 cycloalkyl, each of which is independently substituted with one or more Ra; L1 is C1-C6 alkylene; Rx1, Ry1, Ry2, Ry3, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl, or C3-C6cycloalkyl. .

[0141] In some embodiments of Formula (IV), R1is H or D. In some embodiments of Formula (IV), R1is Br. In some embodiments, R2is -N(Rx1)-R2a, and R2ais 3- to 14- membered heterocyclyl optionally substituted with one or more independently selected Ra. In some embodiments, R2ais 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl. In some embodiments, R2ais 5- to 10-membered heterocyclyl (e.g., piperidinyl) optionally substituted with one or more methyl. In some embodiments, R3is H or D. In some embodiments, R3is -C(O)NRy1Ry2. In some embodiments, R3is -C(O)-NH-(C1-C3 alkyl). In some embodiments, R3is -C(O)N(Ry3)- L1-R2d, wherein L1is methylene and R2dis phenyl.

[0142] In some embodiments, provided herein are compounds described in Table 4 and pharmaceutically acceptable salts thereof. In some embodiments, provided herein are compounds selected from compounds 4-1 to 4-4 in Table 4.Table 4

[0143] In some embodiments, provided herein are compounds described in Table 5 and pharmaceutically acceptable salts thereof. Table 5

[0144] In some embodiments, provided herein are compounds described in Table 6 and pharmaceutically acceptable salts thereof. Table 6

[0145] In some embodiments, provided herein are compounds described in Table 7 and pharmaceutically acceptable salts thereof. Table 7

[0146] In some embodiments, provided herein are compounds described in Table 8 and pharmaceutically acceptable salts thereof. Table 8

[0147] All the compounds described herein or a pharmaceutically acceptable salt thereof, can be used in the methods provided herein. The methods can be in vitro methods, such as in vitro methods of administering a compound to cells for screening purposes and / or for conducting quality control assays. The methods can also be in vivo methods, such as in vivo methods of administering a compound to a subject in need thereof for treating certain disorders. III. Method of Use

[0148] Certain bicyclic compounds containing a nitrile have been found to be effective in binding to p53 proteins having a Y220C mutation, and these compounds may be useful in stabilizing the protein and in treating conditions associated with this mutation.

[0149] In one aspect, provided herein are methods comprising contacting a mutant p53 protein with an effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0150] In some embodiments of Formula (Y), J and K are both C. In some embodiments, r and s are each 1 and q is 2. In some embodiments, one of r and s is 1 and the other is 2. In some embodiments, r is 1, s is 2, and q is 1. In some embodiments, r is 1, s is 2, and q is 2. In some embodiments, r is 2, s is 1, and q is 2. In some embodiments, r is 2, s is 1, and q is 2. In some embodiments of Formula (Y), J and K are both C. In some embodiments of Formula (Y), r and s are each 1 and q is 2. In some embodiments of Formula (Y), one of r and s is 1 and the other is 2. In some embodiments of Formula (Y), q is 1. In some embodiments of Formula (Y), q is 2. In some embodiments, the compound of Formula (Y) is a compound of Formula (Za), (Aa), (Ba), (Oa), (Ia), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the foregoing Formulae are as defined herein or any variation thereof. In some embodiments, the compound of Formula (Y) is a compound of Formula (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 2, Table 3, Table 4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the foregoing Formulae are as defined herein or any variation thereof.

[0151] In some embodiments, the methods provided herein comprise contacting a mutant p53 protein with an effective amount of a compound of Formula (Z) provided herein, or a pharmaceutically acceptable salt thereof, or any variation thereof described herein. In some embodiments, the mutant p53 protein comprises a Y220C mutation.

[0152] In some aspects, provided herein is a method of restoring wild-type function of a mutant p53 protein, comprising contacting the mutant p53 protein with an effective amount of a compound of Formula (Y):(Y) or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0153] In some embodiments of the foregoing, the mutant p53 protein comprises a Y220C mutation.

[0154] In some embodiments of Formula (Y), J and K are both C. In some embodiments of Formula (Y), r and s are each 1 and q is 2. In some embodiments of Formula (Y), one of r and s is 1 and the other is 2. In some embodiments of Formula (Y), q is 1. In some embodiments of Formula (Y), q is 2. In some embodiments, the compound of Formula (Y) is a compound of Formula (Za), (Aa), (Ba), (Oa), (Ia), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the foregoing Formulae are as defined herein or any variation thereof. In some embodiments, the compound of Formula (Y) is a compound of Formula (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 2, Table 3, Table 4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the foregoing Formulae are as defined herein or any variation thereof.p53 Protein

[0155] The p53 protein, a tumor suppressor, is an amino acid transcription factor that can regulate cell growth in response to cellular stresses including, for example, UV radiation, hypoxia, oncogene activation, and DNA damage. P53 protein has various mechanisms for inhibiting the progression of cancer including, for example, initiation of apoptosis, maintenance of genomic stability, cell cycle arrest, induction of senescence, and inhibition of angiogenesis. Due to the critical role of p53 protein in tumor suppression, p53 protein is inactivated in almost all cancers either by direct mutation or through perturbation of associated signaling pathways involved in tumor suppression. The presence of certain p53 protein mutations in several types of human cancer can correlate with less favorable patient prognosis.

[0156] In an unstressed cell, p53 protein levels are maintained at low levels via the interaction of p53 protein with Mdm2, an E3 ubiquitin ligase, and Mdm2 can target p53 protein for degradation by the proteasome. Under stress conditions, the interaction between Mdm2 and p53 protein is disrupted, and p53 protein accumulates. The critical event leading to the activation of p53 protein is phosphorylation of the N-terminal domain of p53 by protein kinases, thereby transducing upstream stress signals. The phosphorylation of p53 results in a conformational change, which can promote DNA binding by p53 and allow transcription of downstream effectors. The activation of p53 can induce, for example, the intrinsic apoptotic pathway, the extrinsic apoptotic pathway, cell cycle arrest, senescence, and DNA repair. P53 protein can activate proteins involved in the above pathways including, for example, Fas / Apo, KILLER / DRS, Bax, Puma, Noxa, Bid, caspase-3, caspase-6, caspase-7, caspase-8, caspase-9, and p21 (WAFl). Additionally, p53 can repress the transcription of a variety of genes including, for example, c-MYC, Cyclin B, VEGF, RAD51, and hTERT.

[0157] Each chain of the p53 protein tetramer is composed of several functional domains including the transactivation domain (amino acids 1-100), the DNA-binding domain (amino acids 101-306), and the tetramerization domain (amino acids 307-355), which are highly mobile and largely unstructured. Most p53 protein mutations related to proliferative disorders are located in the DNA-binding core domain of the protein, which contains a central β- sandwich of anti-parallel β-sheets that serves as a basic scaffold for the DNA-binding surface. The DNA-binding surface is composed of two β-turn loops, L2 and L3, which are stabilized by a zinc ion, for example, at Arg175 and Arg248, and a loop-sheet-helix motif. Altogether,these structural elements form an extended DNA-binding surface that is rich in positively- charged amino acids, and makes specific contact with various p53 protein response elements.

[0158] Due to the prevalence of p53 protein mutations in many types of cancer, the reactivation of wild type p53 protein function in a cancerous cell can be an effective therapy. Mutations in p53 located in the DNA-binding domain of the protein or periphery of the DNA-binding surface result in aberrant protein folding required for DNA recognition and binding. Mutations in p53 can occur, for example, at amino acids Val143, His168, Arg175, Tyr220, Gly245, Arg248, Arg249, Phe270, Arg273, and Arg282. P53 mutations that can abrogate the activity of p53 include, for example, Rl75H, Y220C, G245S, R248Q, R248W, R273H, and R282H. These p53 protein mutations can either distort the structure of the DNA- binding site or thermodynamically destabilize the folded protein at body temperature. Without being bound by theory, wild-type function of p53 mutants can be recovered by binding of the p53 protein mutant to a compound that can shift the folding-unfolding equilibrium towards the folded state, thereby reducing the rate of unfolding and destabilization. With the wild-type function of p53 protein recovered, downstream targets involved in tumor suppression can be further activated. Restore wild-type function of p53 mutants

[0159] In one aspect, provided herein is a method of modulating the conformation of a mutant p53 protein. In some embodiments, provided herein is a method of restoring wild-type activity of a mutant p53 protein including, for example, DNA binding function and activation of downstream targets involved in tumor suppression, wherein the method comprises selectively binding a compound described herein to the p53 mutant. In some embodiments, before contacted with the compounds described herein (e.g., a compound of Formula (Za), Formula (Aa), Formula (Ba), Formula (Oa), Formula (Ia), Formula (O), Formula (I), Formula (II), Formula (III), Formula (IV), Formula (Y), Formula (Z), Formula (A), and Formula (B), Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8), the p53 mutant has a conformation that is not pro-apoptotic, and the compound described herein can bind to the binding site on the p53 mutant and modulate the conformation of the p53 mutant to a form that is pro-apoptotic. In some embodiments, the modulation of the conformation of the p53 mutant comprises forming a covalent bond between the compounds provided herein (e.g., a compound of Formula (Za), Formula (Aa), Formula (Ba), Formula (Oa), Formula (Ia), l ( ) l ( ) l ( ) l ( ) l ( ) l ( ) l(Z), Formula (A), and Formula (B), Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8) and the p53 mutant. In some embodiments, the p53 mutant is Y220C. In some embodiments, the method of modulating the conformation of a mutant p53 protein comprises contacting the mutant p53 protein with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each the Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), and (IV) is as defined herein. In some embodiments, the method of restoring wild-type function of a mutant p53 protein comprises contacting the mutant p53 protein with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each the Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), and (IV) is as defined herein.

[0160] In some embodiments, provided herein is a method of binding a compound described herein to a p53 protein containing a Y220C mutation. In some embodiments, the compound described herein selectively binds to (e.g., has a higher binding affinity for) a p53 protein containing a Y220C mutation over a p53 protein that lacks the Y220C mutation. In some embodiments, the compound described herein has higher binding affinity for the Y220C residue on a p53 protein over other residues on the protein. In some embodiments, the compound described herein has higher binding affinity for the cysteine at position 220 in a p53 Y220C mutant protein compared to other cysteine residues in the protein. In some embodiments, provided herein is a method of stabilizing the Y220C mutant, optionally to reduce the likelihood of denaturation of the protein at body temperature with a compound provided herein. The Y220C mutant is a temperature sensitive mutant, which binds to DNA at lower temperature and is denatured at body temperature. Located in the periphery of the p53 β-sandwich connecting β-strands S7 and S8, the aromatic ring of Y220 is an integral part of the hydrophobic core of the β-sandwich. The Y220C mutation can be highly destabilizing, due to the formation of an internal surface cavity. In some embodiments, the compounds described herein can bind to and occupy this surface crevice to stabilize the sandwich, thereby restoring wild-type p53 DNA-binding activity.

[0161] In some embodiments, the method comprises determining the ability of a compound described herein to bind and stabilize mutant p53. In some embodiments, assays can be employed to detect, for example, a conformational change in the p53 mutant or activation of wild-type p53 targets. Conformational changes in p53 can be measured by, for example, differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC), nuclear magnetic resonance spectrometry (NMR), or X-ray crystallography. Additionally, antibodies specific for the wild type of mutant conformation of p53 can be used to detect a conformational change via, for example, immunoprecipitation (IP), immunofluorescence (IF), or immunoblotting.

[0162] In some embodiments, provided herein is a method of reactivating the transcriptional activity of p53. In some embodiments, the method is to activate downstream targets in the p53 signaling cascade. In some embodiments, the method is to activate p53 effector proteins. In some embodiments, the potency and efficacy of the compounds described herein in reactivating the transcriptional activity of p53 can be measured by, for example, immunohistochemistry (IHC-P), reverse transcription polymerase chain reaction (RT-PCR), and immununoblotting. The activation of p53 can also be measured by the induction of apoptosis via the caspase cascade and using methods including, for example, Annexin V staining, TUNEL assays, pro-caspase and caspase levels, and cytochrome c levels. Another consequence of p53 activation is senescence, which can be measured using methods such as galactosidase staining.

[0163] In some embodiments, the method provided herein is in vitro, wherein the method comprises contacting the mutant p53 protein with an effective amount of a compound or a salt thereof descried herein. In some embodiments, the method is in vivo, wherein the method comprises contacting the mutant p53 protein in a subject in need thereof with an effective amount or a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof described herein.

[0164] In some embodiments, the method provided herein increases the ability of a p53 mutant to bind to DNA by at least about 0.1%, such as at least about any of 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%,92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200%, 225%, or 250%, as compared to the ability of the p53 mutant to bind to DNA in the absence of the method. In some embodiments, the method provided herein increases the ability of a p53 mutant to bind to DNA by up to about 0.1%, such as up to about any of 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200%, 225%, or 250%, as compared to the ability of the p53 mutant to bind to DNA in the absence of the method. In some embodiments, the p53 mutant comprises a Y220C mutation, with or without other mutations.

[0165] In some embodiments, the method provided herein increases the DNA-binding activity of the Y220C mutant by at least about 2-fold, such as by at least about any of 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, at least or up to about 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, at least or up to about 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, 100-fold, 110-fold, 120-fold, 130-fold, 140-fold, 150-fold, 160-fold, 170-fold, 180-fold, 190-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450- fold, 500-fold, 550-fold, 600-fold, 650-fold, 700-fold, 750-fold, 800-fold, 850-fold, 900-fold, 950-fold, 1,000-fold, 1,500-fold, 2.000-fold, 3,000-fold, 4,000-fold, 5,000-fold, 6,000-fold, 7,000-fold, 8,000-fold, 9,000-fold, or 10,000-fold compared to the ability of Y220C to bind DNA in the absence of the method. In some embodiments, the method provided herein increases the DNA-binding activity of the Y220C mutant by up to about 2-fold, such as by up to about any of 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, at least or up to about 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, at least or up to about 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, 100-fold, 110-fold, 120-fold, 130- fold, 140-fold, 150-fold, 160-fold, 170-fold, 180-fold, 190-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450-fold, 500-fold, 550-fold, 600-fold, 650-fold, 700-fold, 750-fold, 800- fold, 850-fold, 900-fold, 950-fold, 1,000-fold, 1,500-fold, 2.000-fold, 3,000-fold, 4,000-fold,5,000-fold, 6,000-fold, 7,000-fold, 8,000-fold, 9,000-fold, or 10,000-fold compared to the ability of Y220C to bind DNA in the absence of the method.

[0166] In some embodiments, the method provided herein increases the stability of a p53 mutant by at least about 0.1%, such as at least about any of 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200%, 225%, or 250%, as compared to the stability of the p53 mutant in the absence of the method. In some embodiments, the method provided herein increases the stability of a p53 mutant by up to about 0.1%, such as up to about any of 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 125%, 150%, 175%, 200%, 225%, or 250%, as compared to the stability of the p53 mutant in the absence of the method. In some embodiments, the p53 mutant comprises a Y220C mutation, with or without other mutations.

[0167] In some embodiments, the method provided herein restores the wild-type function of a p53 mutant by at least about 5%, such as at least about any of 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or 100%. In some embodiments, the method provided herein restores the wild-type function of a p53 mutant by up to about 5%, such as up to about any of 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or 100%. In some embodiments, the p53 mutant comprises a Y220C mutation, with or without other mutations. Treating proliferative disorders

[0168] In some embodiments, provided herein is a method of inducing apoptosis, cell cycle arrest, and / or senescence in a cell. In some embodiments, the cell is a cancer cell. In some embodiments, the cell carries a mutation in p53. In some embodiments, the method is in vitro. In some embodiments, the method is in vivo.

[0169] In some embodiments, provided herein is a method of treating a proliferative disorder comprising administering an effective amount or a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

[0170] In some aspects, provided herein is a method of treating a proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0171] In some embodiments of Formula (Y), J and K are both C. In some embodiments ofs is 1 and the other is 2. In some embodiments of Formula (Y), q is 1. In some embodiments of Formula (Y), q is 2. In some embodiments, the compound of Formula (Y) is a compound of Formula (Za), (Aa), (Ba), (Oa), (Ia), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the forgoing Formulae are as defined herein or any variation thereof. In some embodiments, the compound of Formula (Y) is a compound of Formula (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 2, Table 3, Table 4, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the forgoing Formulae are as defined herein or any variation thereof.

[0172] In some embodiments, the proliferative disorder is associated with a mutant p53 protein. In some embodiments, also provided herein is a method of preventing a proliferative disorder. In some embodiments, the mutant p53 protein comprises a Y220C mutation, with or without other mutations. In some embodiments, the proliferative disorder is a cancer.

[0173] In some embodiments, provided herein is a method of treating cancer.

[0174] In some embodiments, provided herein is a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (Y):(Y) or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

[0175] In some embodiments of Formula (Y), J and K are both C. In some embodiments of Formula (Y), r and s are each 1 and q is 2. In some embodiments of Formula (Y), one of r and s is 1 and the other is 2 In some embodiments of Formula (Y) q is 1 In some embodimentsof Formula (Y), q is 2. In some embodiments, the compound of Formula (Y) is a compound of Formula (Za), (Aa), (Ba), (Oa), (Ia), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the forgoing Formulae are as defined herein or any variation thereof. In some embodiments, the compound of Formula (Y) is a compound of Formula (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein each of the forgoing Formulae are as defined herein or any variation thereof.

[0176] In some embodiments, the method is to slow the proliferation of cancer cell lines, or kill cancer cells. In some embodiments, also provided herein is a method of preventing cancer. In some embodiments, the cancer is associated with a p53 protein comprising a Y220C mutation, with or without other mutations.

[0177] In some embodiments, the method of treating a proliferative disorder comprises comprising administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein each the Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), and (IV) is as defined herein. In some embodiments, the method of treating cancer comprises comprising administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), (IV), a compound of Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein each the Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (A), (B), (O), (I), (II), (III), and (IV) is as defined herein.

[0178] In some embodiments, the method provided herein slows the progression of cancer in a subject in need thereof by at least about 0.5%, such as at least about any of 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%,80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9%, when compared to not using the method. In some embodiments, the method provided herein slows the progression of cancer in a subject in need thereof by up to about 0.5%, such as up to about any of 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9%, when compared to not using the method.

[0179] In some embodiments, the method provided herein reduces the likelihood of development of a proliferative disorder or any symptom thereof in a subject in need thereof by at least about 0.5%, such as at least about any of 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9%, when compared to not using the method. In some embodiments, the method provided herein reduces the likelihood of development of a proliferative disorder or any symptom thereof in a subject in need thereof by up to about 0.5%, such as up to about any of 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9%, when compared to not using the method.

[0180] In some embodiments, the method provided herein delays the development of a proliferative disorder or any symptom thereof in a subject in need thereof by at least about 0.5%, such as at least about any of 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%,24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9%, when compared to not using the method. In some embodiments, the method provided herein delays the development of a proliferative disorder or any symptom thereof in a subject in need thereof by up to about 0.5%, such as up to about any of 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9%, when compared to not using the method. IV. Composition

[0181] In some aspects, provided herein is a composition comprising a mutant p53 protein and a p53 stabilizer having a covalent bond to the mutant p53 protein, wherein the mutant p53 protein comprises a Y220C mutation, and the covalent bond is formed between a -CN group of the p53 stabilizer and the cysteine at position 220 in the mutant p53 protein. In some embodiments, the mutant p53 protein has greater wild-type function compared to a composition comprising the mutant p53 protein without the p53 stabilizer having a covalent bond to the mutant p53 protein. In some embodiments, the mutant p53 protein has a greater wild-type conformation compared to a composition comprising the mutant p53 protein without the p53 stabilizer having a covalent bond to the mutant p53 protein. In some embodiments, the stabilizer selectively binds to the cysteine at position 220 in the mutant p53 protein compared to other positions within the protein (e.g., compared to other cysteines in the protein). In some embodiments, the p53 stabilizer is a compound of Formula (Za), (Oa), (Aa), (Ba), (Ia), (Y), (Z), (O), (A), (B), (I), (II), (III), or (IV), or a compound selected from Table 1, Table 1A, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8, or a pharmaceutically acceptable salt thereof.V. Formulation

[0182] In some embodiments, the compounds provided herein can be formulated in a formulation, such as a pharmaceutical formulation. In some embodiments, the formulation further comprises one or more additional medicinal agents, pharmaceutical agents, adjuvants, carriers, excipients, and the like. Suitable medicinal and pharmaceutical agents include those described herein. In some embodiments, the pharmaceutical formulation includes a pharmaceutically acceptable excipient or adjuvant and at least one chemical entity as described herein. Examples of pharmaceutically acceptable excipients include, but are not limited to, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, and magnesium carbonate. In some embodiments, provided are formulations, such as pharmaceutical formulations that contain one or more compounds described herein, or a pharmaceutically acceptable salt thereof.

[0183] In some embodiments, the formulation may be sterile or contains components that are sterile. Sterilization can be achieved by methods known in the art. In some embodiments, the formulation comprises one or more compounds that are substantially pure (e.g., with a purity of at least about any of 85%, 90%, 95%, 98%, 99%,99.5%, 99.9%, or 99.99%). In some embodiments, especially wherein a formulation is administered by inhalation, injection, or other parenteral administration including the routes listed herein, or wherein a formulation is used for oral, gastric, gastrointestinal, or enteric administration, the formulations and preparations used in the methods disclosed herein are sterile. Methods for preparing sterile, pharmaceutically acceptable compositions include steam sterilization, dry-heat sterilization, gas sterilization, ionizing radiation, or sterile filtration. Sterile pharmaceutical formulations are compounded or manufactured according to pharmaceutical-grade sterilization standards (United States Pharmacopeia Chapters 797, 1072, and 1211; California Business & Professions Code 4127.7; 16 California Code of Regulations 1751, 21 Code of Federal Regulations 211) known to those of skill in the art. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in propylene glycol. Among the acceptable vehicles and solvents that may be employed are water, i ’ l i d i i di hl id l i ddi i il fi d ilconventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0184] Also provided are packaged pharmaceutical formulations, comprising a pharmaceutical formulation as described herein and instructions for using the formulation to treat a patient suffering from a disease or condition described herein. VI. Dose and method of administration

[0185] The compounds and compositions described herein are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease state. While human dosage levels have yet to be optimized for the chemical entities described herein, generally, a daily dose ranges from about 0.01 to 100 mg / kg of body weight; in some embodiments, from about 0.05 to 10.0 mg / kg of body weight, and in some embodiments, from about 0.10 to 1.4 mg / kg of body weight. Thus, for administration to a 70 kg person, in some embodiments, the dosage range would be about from 0.7 to 7000 mg per day; in some embodiments, about from 3.5 to 700.0 mg per day, and in some embodiments, about from 7 to 100.0 mg per day. The amount of the chemical entity administered will be dependent, for example, on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. For example, an exemplary dosage range for oral administration is from about 5 mg to about 500 mg per day, and an exemplary intravenous administration dosage is from about 5 mg to about 500 mg per day, each depending upon the compound pharmacokinetics.

[0186] Administration of the compounds and compositions described herein can be via any accepted mode of administration for therapeutic agents including, but not limited to, oral, sublingual, subcutaneous, parenteral, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, or intraocular administration. In some embodiments, the compound or composition is administered orally or intravenously. In some embodiments, the compound or composition disclosed and / or described herein is administered orally.

[0187] Pharmaceutically acceptable compositions include solid, semi-solid, liquid and aerosol dosage forms, such as tablet, capsule, powder, liquid, suspension, suppository, and aerosol forms. The compounds disclosed and / or described herein can also be administered in i d ll d l d f ( ll d / i d l ill dinjection, osmotic pump, or transdermal (including electrotransport) patch forms) for prolonged timed, and / or pulsed administration at a predetermined rate. In some embodiments, the compositions are provided in unit dosage forms suitable for single administration of a precise dose.

[0188] The compounds disclosed and / or described herein can be administered either alone or in combination with one or more conventional pharmaceutical carriers or excipients (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate). If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate). Generally, depending on the intended mode of administration, the pharmaceutical composition will contain about 0.005% to 95%, or about 0.5% to 50%, by weight of a compound disclosed and / or described herein. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington’s Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.

[0189] In some embodiments, the compositions will take the form of a pill or tablet and thus the composition may contain, along with a compounds disclosed and / or described herein, one or more of a diluent (e.g., lactose, sucrose, dicalcium phosphate), a lubricant (e.g., magnesium stearate), and / or a binder (e.g., starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives). Other solid dosage forms include a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils or triglycerides) encapsulated in a gelatin capsule.

[0190] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing or suspending etc. a compound disclosed and / or described herein and optional pharmaceutical additives in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to injection. The percentage of the compound contained in such parenteral compositions depends, for example, on the physical nature of the compound, the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable, andconcentration. In some embodiments, the composition will comprise from about 0.2 to 2% of a compound disclosed and / or described herein in solution.

[0191] Pharmaceutical compositions of the compounds disclosed and / or described herein may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the pharmaceutical composition may have diameters of less than 50 microns, or in some embodiments, less than 10 microns.

[0192] In addition, pharmaceutical compositions can include a compound disclosed and / or described herein and one or more additional medicinal agents, pharmaceutical agents, adjuvants, and the like. Suitable medicinal and pharmaceutical agents include those described herein. VII. Kits

[0193] Also provided herein are kits for carrying out the methods described herein, which comprises one or more compounds described herein, or a pharmaceutically acceptable salt thereof, or a pharmacological composition comprising a compound described herein. The kits may employ any of the compounds disclosed herein. In one variation, the kit employs a compound described herein or a pharmaceutically acceptable salt thereof. The kits may be used for any one or more of the uses described herein, and, accordingly, may contain instructions for use in the treatment of any of the diseases described herein.

[0194] Kits generally comprise suitable packaging. The kits may comprise one or more containers comprising any compound described herein. Each component (if there is more than one component) can be packaged in separate containers or some components can be combined in one container where cross-reactivity and shelf life permit. One or more components of a kit may be sterile and / or may be contained within sterile packaging.

[0195] The kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub-unit doses. For example, kits may be provided that contain sufficient dosages of a compound as disclosed herein (e.g., a therapeutically effective amount) and / or a second pharmaceutically active compound useful for a disease detailed herein (e.g., cancer) to provide effective treatment of an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kits may also include multiple unit doses of the compounds andinstructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).

[0196] The kits may optionally include a set of instructions, generally written instructions, although electronic storage media (e.g., magnetic diskette or optical disk) containing instructions are also acceptable, relating to the use of component(s) of the methods described herein. The instructions included with the kit generally include information as to the components and their administration to an individual. GENERAL SYNTHETIC EXAMPLES

[0197] The chemical reactions in the Synthetic Examples described can be readily adapted to prepare a number of other compounds of the invention, and alternative methods for preparing the compounds of this invention are deemed to be within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention can be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the invention.

[0198] Compounds provided herein may be prepared according to Schemes, as exemplified herein. Minor variations in temperatures, concentrations, reaction times, and other parameters can be made when following the Examples and Methods, which do not substantially affect the results of the procedures. Method 1 (M1)

[0199] Int-1 is coupled with amine M1-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide carboxamide M1-2, which is converted to title nitrile using dehydrating reagents such as trifluoracetic anhydride or ethyl phosphodichloridite in the presence of organic base.Method 2 (M2)

[0200] Int-1 is coupled with mono Boc-protected diamine M2-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide carboxamide M2-2. Boc removed under acidic conditions to provide free amine M2-3 which is alkylated via reductive amination of carbonyl compound M2-4 or directly by treatment with alkyl halide M2-6. Carboxamides M2-5 and M2-7 are converted into final nitrile using dehydrating reagents such as trifluoracetic anhydride or ethyl phosphodichloridite in the presence of organic base. Method 3 (M3)

[0201] Int-2 is coupled with carboxamide M3-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide final nitrile. Method 4 (M4)

[0202] Int-7 is coupled with amine M4-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide final nitrile. Method 5 (M5)

[0203] Int-7 is coupled with mono Boc-protected diamine M5-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide intermediate M5-2. Boc is removed under acidic conditions to provide free amine M5-3 which is alkylated via reductive amination of carbonyl compound M5-4 or acetylated by treatment with chloroanhydride M5-5 yielding final product. Method 6 (M6)

[0204] Int-7 is coupled with amine M6-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide intermediate M6-2, which is brominated upon treatment with NBS yielding final nitrile. Method 7 (M7)

[0205] Int-7 is coupled with mono Boc-protected diamine M7-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide intermediate M7-2, which is brominated upon treatment with NBS yielding nitrile M7-3. Boc removed under acidic conditions to provide free amine M7-4 which is alkylated via reductive amination of carbonyl compound M7-5 or directly by treatment with alkyl halide M7-6 to provide final nitrile. Method 8 (M8)

[0206] Int-7 is coupled with amino-1,2- or 1,3-diols protected as 5- or 6-membered cyclic acetal M8-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide intermediate M8-2, which is brominated upon treatment with NBS yielding nitrile M8-3. Acetal protection is removed under acidic conditions to provide final nitrile. Method 9 (M9)

[0207] Int-5 is coupled with amine M9-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide intermediate to provide final nitrile.Method 10 (M10)

[0208] Int-8 is converted into final nitrile via reductive alkylation of amine M10-1 (obtained commercially or synthesized according to methods known in the art) in the presence of reducing agents such as sodium triacetoxyborohydride or sodium cyanoborohydride. Method 11 (M11)

[0209] Int-4 is acylated by acid chloride M11-1 (obtained commercially or synthesized according to methods known in the art) to provide final nitrile. In other embodiments Int-4 is treated with carbonyl compound M11-2 (obtained commercially or synthesized according to methods known in the art) under reductive amination conditions yielding final nitrile. Method 12 (M12)

[0210] Int-9 or 10 is converted into amides M12-2 using Pd-catalyzed carbonylation chemistry and range of secondary and primary amines M12-1 (obtained commercially or synthesized according to methods known in the art). Then primary amide M12-3 is obtained by treating intermediate M12-2 with ammonia in methanol. M12-3 is converted to finalnitrile using dehydrating reagents such as trifluoracetic anhydride or ethyl phosphodichloridite in the presence of organic base. Method 13 (M13)

[0211] Int-9 or 10 is coupled with boronic acid or ester M13-1 (obtained commercially or synthesized according to methods known in the art) under Suzuki coupling conditions to provide intermediate M13-3. In some embodiments intermediate M13-3 is obtained via Heck coupling of int-9 with alkenes M13-2. Treatment of M13-3 with with ammonia in methanol may result in primary amide M13-4 which is further converted to final nitrile using dehydrating reagents such as trifluoracetic anhydride or ethyl phosphodichloridite in the presence of organic base. Method 14 (M14)

[0212] Int-9 is coupled with alkyne M14-1 (obtained commercially or synthesized according to methods known in the art) under Sonogashira coupling conditions to provide intermediate M14-2. Treatment of M14-2 with with ammonia in methanol may result inprimary amide M14-3 which is further converted to final nitrile using dehydrating reagents such as trifluoracetic anhydride in the presence of organic base. Method 15 (M15)

[0213] Int-8 is converted into Int-17-2 via reductive alkylation of amine M17-1 (obtained commercially or synthesized according to methods known in the art) in the presence of reducing agents such as sodium triacetoxyborohydride or sodium cyanoborohydride. The b li i i d ih i ( b i d illsynthesized according to methods known in the art) under amide coupling conditions. Final compounds may be purified by prep-HPLC; cis and trans isomers of cyclohexyl diamine may be isolated separately, and relative stereochemistry of centers on cyclohexyl ring may be assigned based on1H NMR. EXAMPLE Synthetic Examples Abbreviations: DIAD - Diisopropyl azodicarboxylate MeCN – acetonitrile TFAA – trifluoroacetic anhydride TFA – trifluoroacetic acid BINAP - Bis(diphenylphosphino)-1,1'-binaphthyl DBU - 1,8-Diazabicyclo[5.4.0]undec-7-ene DCM – dichloromethane NBS - N-Bromosuccinimide THF – tetrahydrofuran DPPF - 1,1′-Bis(diphenylphosphino)ferrocene DMSO – dimethyl sulfoxide HATU - Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium DMF – dimethylformamide DIEA - N,N-diisopropylethylamine TCFH - Chloro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate NMI - N-methylimidazole TEA – triethylamine MOMBr – bromomethylmethylether LDA - Lithium diisopropylamide MTBE, MtBE - tert-Butyl methyl ether PE– petroleum ether EA - ethyl acetate NIS N I d i i idFA – formic acid STAB – sodium triacetoxyborohydride DCE - dichloroethane DAST - Diethylaminosulfur trifluoride NMP - N-Methyl-2-pyrrolidone DMAP - N N-dimethyl-4-pyridylamine DMA - N,N-Dimethylacetamide BBBPY - 4,4燵-Di-tert-butyl-2,2燵-dipyridyl TBAF - Tetrabutylammonium fluoride Synthetic Example 1. Preparation of key synthetic intermediates IStep 1: 5-chlorofuro[2,3-c]pyridine-2-carboxamide – Int-1

[0214] A solution of 6-chloro-4-iodopyridin-3-ol (20.4 g, 79.862 mmol, 1 equiv) ,propiolamide (8.27 g, 119.793 mmol, 1.5 equiv) ,Pd(PPh3)2Cl2 (2.80 g, 3.993 mmol, 0.05 equiv) ,CuI (0.76 g, 3.993 mmol, 0.05 equiv), TEA (48.49 g, 479.172 mmol, 6 equiv) in DMF (160 mL) was stirred for 2h at 50°C under nitrogen atmosphere. After complete, the resulting mixture was diluted with EtOAc (2000mL). The resulting mixture was filtered, the filter cake was washed with EtOAc. The filtrate was washed with 3x200 mL of brine. The organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by trituration withm / z): 196.95[M+H]+.1H NMR (300 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.46 (s, 1H), 8.03 (s, 1H), 7.72 (s, 1H), 7.62(s, 1H). Step 2: 5-chlorofuro[2,3-c]pyridine-2-carbonitrile – Int-2

[0215] A solution of 5-chlorofuro[2,3-c]pyridine-2-carboxamide (4.14 g, 21.059 mmol, 1 equiv) in THF (42 mL) was treated with TEA (4.26 g, 42.118 mmol, 2 equiv) for 5 min at 0°C , followed by the addition of TFAA (8.85 g, 42.118 mmol, 2 equiv) dropwise at 0°C. The resulting mixture was stirred for 0.5 hour at 0 °C. The resulting mixture was concentrated under reduced pressure. The crude product was purified by trituration with acetonitrile to afford title compound (3 g, 79.77%) as a white solid. LC-MS: (ESI, m / z): 178.95[M+H]+.1H NMR (300 MHz, DMSO-d6) δ 9.01 (s, 1H), 8.16 (s, 1H), 8.04 (s, 1H). Step 3: tert-butyl (2-cyanofuro[2,3-c]pyridin-5-yl)carbamate and 5-aminofuro[2,3- c]pyridine-2-carbonitrile

[0216] A solution of 5-chlorofuro[2,3-c]pyridine-2-carbonitrile (257 mg, 1.439 mmol, 1 equiv), tert-butyl carbamate (318 mg, 2.715 mmol, 1.89 equiv) , K3PO4(0.73 g, 3.425 mmol, 2.38 equiv), XantPhos (81 mg, 0.140 mmol, 0.10 equiv) and Xantphos Pd 2G (60 mg, 0.068 mmol, 0.05 equiv) in 1,4-dioxane (10 mL) was stirred for overnight at 120 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. After filtration, the filtrate was concentrated under reduced pressure and the crude product was purified by reverse flash chromatography with the following conditions: column, C18 silica gel; mobile phase, CH3CN / H2O (0.1% of NH4HCO3), 40% to 50% gradient in 10 min; detector, UV 254 nm) to afford 300 mg of tert-butyl (2-cyanofuro[2,3-c]pyridin-5- yl)carbamate(A) with only 50% purity) as yellow solid and 40 mg of 5-aminofuro[2,3- c]pyridine-2-carbonitrile(B) with 90% purity as yellow solid. Step 4: 5-aminofuro[2,3-c]pyridine-2-carbonitrile – Int-3

[0217] A solution of tert-butyl N-{2-cyanofuro[2,3-c]pyridin-5-yl}carbamate (300 mg, 0.694 mmol, 1 equiv, 50% purity) in TFA (6.00 mL) was stirred for 1 hour at 25 °C. stirred The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse flash chromatography with the following conditions: column, C18 silica gel; mobile phase, CH3CN / H2O (0.1% of NH4HCO3), 40% to 50% gradient in 10 min; detector, UV 254 nm) to afford 40 mg of title compound as a yellow solid. LC-MS: (ESI, m / z): 160.00[M+H]+.1H NMR (300 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.00 (s, 1H), 7.00 (s, 1H), 5.88(br, 2H).

[0218] A solution of 5-aminofuro[2,3-c]pyridine-2-carbonitrile (130 mg, 0.817 mmol, 1 equiv) and NBS (87.23 mg, 0.490 mmol, 0.6 equiv) in MeCN (5 mL) was stirred for overnight at room temperature. The reaction was quenched with saturated Na2SO3 aqueous at 0°C. The aqueous layer was extracted with EtOAc (3x10 mL). The combined was washed with brine (3x10 mL) and dried over anhydrous Na2SO3. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (92:8) to afford title compound (40 mg, 16.46%) as a brown yellow solid. LC-MS: (ESI, m / z): 237.95, 239.95[M+H]+.1H NMR (300 MHz, DMSO-d6) δ 8.57 (s, 1H), 7.95 (s, 1H), 6.20(br, 2H). Step 6: 4-bromo-5-iodofuro[2,3-c]pyridine-2-carbonitrile – Int-5

[0219] A solution of 5-amino-4-bromofuro[2,3-c]pyridine-2-carbonitrile (12 g, 35.288 mmol, 1 equiv, 70%), CuI (10 g, 52.507 mmol, 1.49 equiv), I2 (9.4 g, 37.036 mmol, 1.05 equiv) in DMF (90 mL) was treated with tert-butyl nitrite (18.1 g, 175.522 mmol, 4.97 equiv) for 2.5 hours at 50°C under nitrogen atmosphere. The reaction was quenched by the addition of sat. Na2S2O3 (aq.) (25 mL) at 0°C. The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with NH3.H2O (3x18 mL) and brine (3x15 mL), dried over anhydrous Na2SO4and the organic layers were concentrated under reduced pressure. The crude product was purified by reverse phase column eluting with H2O (NH4HCO3) / CH3CN (2 / 3) to afford title compound (4.8 g, 37.42%) as a brown solid. LC- MS: (ES, m / z): 349.10,351.10 [M+H]+.1H NMR (300 MHz, DMSO-d6) δ 9.03 (s, 1H), 8.25 (s, 1H). Intermediates 6, 7, 8Step 1: 2-bromo-5-(methoxymethoxy)pyridine

[0220] To a stirred solution of NaH (14.00 g, 350.006 mmol, 1.4 equiv, 60%) in DMF (4001 equiv) and bromo(methoxy)methane (46.86 g, 375.006 mmol, 1.5 equiv) in DMF (200 mL) at -10°C. The resulting mixture was stirred for 2 hours at room temperature. The mixture was acidified to pH =8 with HCl aqueous (3M). The resulting mixture was extracted with EtOAc (3 x 300mL). The combined organic layers were washed with water, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (10:1) to afford title compound (45 g, 82.55%) as a colorless oil. LC-MS: (ES, m / z): 217.00, 219.00 [M+H]+. Step 2: 2-bromo-4-iodo-5-(methoxymethoxy)pyridine

[0221] Under nitrogen atmosphere, to a stirred solution of 2-bromo-5- (methoxymethoxy)pyridine (30 g, 140 mmol,1 eq) in THF (600 ml) was added LDA in THF (82.5ml , 1.2 eq, 2M) at -70oC. The resulting solution was stirred for 30 min at -70oC. Then the mixture was dropwise added into the solution of iodine (38.4 g, 151.2mmol,1.1 eq) in THF (150 mL) at-70oC and the solution stirred for another 30 min at room temperature. After completion, the reaction was quenched by saturated Na2SO3aqueous and extracted with ethyl acetate (600 mL x 3). The organic layers were combined and washed with brine (4x200 mL) and concentrated under vacuum. The residue was purified by trituration with MTBE (50mL). The precipitated solids were collected by filtration and washed with MTBE (2x50 mL) to afford title compound (36 g, 76.11% yield) as a white solid. LC-MS: (ES, m / z): 343.90, 345.90 [M+H]+. Step 3: 6-bromo-4-iodopyridin-3-ol

[0222] A solution of 2-bromo-4-iodo-5-(methoxymethoxy)pyridine (36 g, 104.668 mmol, 1 equiv), TFA(200 mL) in DCM (150 mL) was stirred at room temperature for 9 hours. After completion, the resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 5 with saturated Na2CO3aqueous. The precipitated solids were collected by filtration and washed with water (2x30 mL). The residue was purified by trituration with MTBE (30mL), The precipitated solids were collected by filtration and washed with MTBE (30 mL) to afford title compound (30 g, 95.57%) as off-white solid. LC- MS: (ES, m / z): 299.90, 301.90 [M+H]+. Step 4: 5-bromofuro[2,3-c]pyridine-2-carboxamide – Int-6

[0223] Under nitrogen atmosphere, a solution of 6-bromo-4-iodopyridin-3-ol (25 g, 83.363 mmol, 1 equiv), propiolamide (7.48 g, 108.372 mmol, 1.3 equiv), Pd(PPh3)2Cl2 (2.93 g, 4.168 mmol, 0.05 equiv), CuI (0.79 g, 4.168 mmol, 0.05 equiv), TEA (50.61 g, 500.178 mmol, 6 equiv) in DMF (350 mL) was stirred for 2 hours at 50 °C. The resulting mixture wasEtOAc(1L). The filtrate was washed with water(500mL*2), The organic layers were washed by brine, NH3.H2O, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by trituration with MTBE to afford title compound (14 g, 69.67%) as a light yellow solid. LC-MS: (ES, m / z): 241.00, 243.00 [M+H]+.1H NMR: (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 8.40 (s, 1H), 8.09 (s, 1H), 7.97 (s, 1H), 7.57 (s, 1H). Step 5: 5-bromofuro[2,3-c]pyridine-2-carbonitrile – Int-7

[0224] A solution of 5-bromofuro[2,3-c]pyridine-2-carboxamide (12.4 g, 51.443 mmol, 1 equiv) in THF was treated with TEA (10.41 g, 102.886 mmol, 2 equiv) for 20 min at 0°C under nitrogen atmosphere followed by the addition of TFAA (21.61 g, 102.886 mmol, 2 equiv) dropwiseat 0 °C. The resulting mixture was concentrated under reduced pressure. The precipitated solids were collected by filtration and washed with acetonitrile. This resulted in title compound (9.5 g, 82.80%) as a white solid. LC-MS: (ES, m / z): 222.95, 224.95 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 1H), 8.18 (s, 1H), 8.15 (s, 1H). Step 6: 5-((1,4-dioxaspiro[4.5]decan-8-yl)amino)furo[2,3-c]pyridine-2-carbonitrile

[0225] A solution of 5-bromofuro[2,3-c]pyridine-2-carbonitrile (15.61 g, 69.991 mmol, 1 equiv), 1,4-dioxaspiro[4.5]decan-8-amine (13.20 g, 83.989 mmol, 1.2 equiv) , Pd-PEPPSi- IPentCl 2-methylpyridine (o-picoline (3.83 g, 4.549 mmol, 0.065 equiv) and Cs2CO3 (45.61 g, 139.982 mmol, 2 equiv) in dioxane (350 mL) was stirred for 9h at 100°C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was filtered; the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was purified by trituration with MTBE. This resulted in title compound (17 g, 81.14%) as a light yellow solid. LC-MS: (ES, m / z):300.15 [M+H]+. Step 7: 5-((1,4-dioxaspiro[4.5]decan-8-yl)amino)-4-bromofuro[2,3-c]pyridine-2- carbonitrile

[0226] A solution of 5-{1,4-dioxaspiro[4.5]decan-8-ylamino}furo[2,3-c]pyridine-2- carbonitrile (36.2 g, 120.937 mmol, 1 equiv) in MeCN (800 mL) was stirred for 20 min at °C . followed by the addition of NBS (19.37 g, 108.843 mmol, 0.9 equiv) in portions at 0°C. the mixture was stirred for 1 hour at room temperature. The reaction was quenched by the addition of sat. Na2SO3 (aq.). The precipitated solids were collected by filtration and washed with water. This resulted in title compound (41 g, 89.63%) as a light yellow solid. LC-MS: (ES, m / z):378.05, 380.05 [M+H]+. Step 8: 4-bromo-5-((4-oxocyclohexyl)amino)furo[2,3-c]pyridine-2-carbonitrile – Int-8

[0227] A solution of 4-bromo-5-{1,4-dioxaspiro[4.5]decan--8-ylamino}furo[2,3- c]pyridine-2-carbonitrile (21.3 g, 56.316 mmol, 1 equiv) in TFA (81 mL) was stirred for 3 hours at 45 °C .The resulting mixture was diluted with DCM . The mixture was basified to pH 8 with saturated NaHCO3 (aq.). The resulting mixture was extracted with CH2Cl2. The combined organic layers were washed with saturated NaCl (aq.), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by trituration with MTBE. This resulted in title compound (15 g, 79.71%) as a light yellow solid. LC-MS: (ES, m / z):334.05, 336.05 [M+H]+.1H NMR (300 MHz, DMSO- d6) δ 8.70 (s, 1H), 7.95 (s, 1H), 5.88(d, J=7.5Hz,1H), 4.53-4.24(m, 1H), 3.65-3.30(m,2H), 2.30-2.12(m, 4H), 1.93-1.78(m, 2H). Intermediates 9, 10Step 1: ethyl 5-bromo-3-hydroxyfuro[2,3-c]pyridine-2-carboxylate

[0228] A solution of NaH (3.48 g, 86.991 mmol, 2.9 equiv, 60%) in THF (30 mL) was stirred for 5 minutes at 0°C. To the above mixture was added ethyl 2-hydroxyacetate (7.81 g, 74.993 mmol, 2.5 equiv) dropwise at 0°C. The resulting mixture was stirred for additional 10 minutes at 0°C. Then a solution of methyl 2-bromo-5-fluoropyridine-4-carboxylate (7.02 g, 29.997 mmol, 1 equiv) in THF (30 mL) was added dropwise at 0°C. The resulting mixture was stirred for additional 2 hours at 75°C. After complete the reaction, the mixture was acidified neutralized to pH 7 with HCl (aq.). The precipitated solids were collected by filtration and washed with water. This resulted in title compound (7.9 g, 92.06%) as a white solid. LC-MS: (ES, m / z): 286.00, 288.00 [M+H]+. Step 2: ethyl 3-hydroxy-5-({8-methyl-8-azabicyclo[3.2.1]octan-3-yl}amino)furo[2,3- c]pyridine-2-carboxylate

[0229] A solution of ethyl 5-bromo-3-hydroxyfuro[2,3-c]pyridine-2-carboxylate (5 g, 17.478 mmol, 1 equiv) ,t-BuONa (4.20 g, 43.695 mmol, 2.5 equiv) ,t-BuXPhos (0.74 g, 1.748 mmol, 0.1 equiv), t-BuXPhos G3 (1.39 g, 1.748 mmol, 0.1 equiv) and 8-methyl-8- azabicyclo[3.2.1]octan-3-amine (3.68 g, 26.217 mmol, 1.5 equiv) in THF (55 mL) was treated with for 4 hours at 60°C under nitrogen. The solution was filtered and the cake was washed with THF (3x20 mL). The filtrate was diluted with EtOAc (50 mL). The mixture was washed with H2O (3x30 mL). The organic layers were concentrated and the residue was purified by silica gel column chromatography, eluted with PE / EA (78%) to afford title compound (1.4 g, 16.23%) as a yellow solid. LC-MS: (ES, m / z): 346.20 [M+H]+. Step 3: ethyl 5-({8-methyl-8-azabicyclo[3.2.1]octan-3-yl}amino)-3- (trifluoromethanesulfonyloxy)furo[2,3-c]pyridine-2-carboxylate – Int-9

[0230] A solution of ethyl 3-hydroxy-5-({8-methyl-8-azabicyclo[3.2.1]octan-3- yl}amino)furo[2,3-c]pyridine-2-carboxylate (1.5 g, 4.343 mmol, 1 equiv), DIEA (0.84 g, 6.514 mmol, 1.5 equiv) and 1,1,1-trifluoro-N-phenyl-N- trifluoromethanesulfonylmethanesulfonamide (2.33 g, 6.514 mmol, 1.5 equiv) in THF (16 mL) was stirred for 1.5hours at room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was used in the next step directly without further purification. This resulted in title compound (3.8 g, 91.63%) as a yellow solid. LC-MS: (ES, m / z): 478.10 [M+H]+. Step 4: ethyl 5-((8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino)-3- (((perfluorobutyl)sulfonyl)oxy)furo[2,3-c]pyridine-2-carboxylate – Int-10

[0231] A solution of ethyl 3-hydroxy-5-({8-methyl-8-azabicyclo[3.2.1]octan-3- yl}amino)furo[2,3-c]pyridine-2-carboxylate (6.8 g, 19.687 mmol, 1 equiv) ,TEA (13.2 g, 130.444 mmol, 6.63 equiv) in DCM (80 mL) was treated with 1,1,2,2,3,3,4,4,4- nonafluorobutane-1-sulfonic anhydride (31.5 g, 54.108 mmol, 2.75 equiv) for 1.5 hours at room temperature under nitrogen. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (25%) to afford title compound (10 g, 44.52%) as a brown solid. LC-MS: (ES, m / z): 628.10 [M+H]+.Intermediate 11Step 1: methyl 6-bromo-3-hydroxy-4-iodopyridine-2-carboxylate

[0232] A solution of methyl 6-bromo-3-hydroxypyridine-2-carboxylate (5 g, 21.55 mmol, 1 equiv) and NBS (6.52 g, 36.63 mmol, 1.7 equiv) in DMF (60 mL) was stirred for 2 hours at 50°C.The mixture was allowed to cool down to room temperature. The residue was purified by trituration with water (3L). The precipitated solids were collected by filtration and washed with water (2x50 mL) to afford title compound (5.2 g, 67.42%) as a light yellow solid.LC- MS: (ES, m / z): 357.60 [M+H]+. Step 2: methyl 5-bromo-2-carbamoylfuro[2,3-c]pyridine-7-carboxylate

[0233] A solution of methyl 6-bromo-3-hydroxy-4-iodopyridine-2-carboxylate (1 g, 2.79 mmol, 1 equiv), propiolamide (0.39 g, 5.59 mmol, 2 equiv), Pd(PPh3)2Cl2 (0.20 g, 0.28 mmol, 0.1 equiv), CuI (0.11 g, 0.56 mmol, 0.2 equiv) and TEA (0.85 g, 8.382 mmol, 3 equiv) in THF (10 mL) was stirred for 2.5 hours at 80°C under nitrogen. The resulting mixture was diluted with EtOAc (50mL). The combined organic layers were washed with aq. NaCl (3x10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (4:1) to afford title compound (150 mg, 17.95%) as a yellow solid. LC-MS: (ES, m / z): 299.05 [M+H]+. Step 3: 5-bromo-2-carbamoylfuro[2,3-c]pyridine-7-carboxylic acid – Int-11

[0234] A solution of methyl 5-bromo-2-carbamoylfuro[2,3-c]pyridine-7-carboxylate (5 g, 16.72 mmol, 1 equiv) and NaOH (1.34 g, 33.43 mmol, 2 equiv) in MeOH (40 mL) and H2O (20 mL) was stirred for 1.5 hours at room temperature. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (10:1) to afford title compound (3 g, 62.95%) as a light yellow solid.LC-MS: (ES, m / z): 284.80[M+H]+.Intermediate 12Step 1: 5-bromo-2-cyanofuro[2,3-c]pyridine-7-carboxylate

[0235] A solution of methyl 5-bromo-2-carbamoylfuro[2,3-c]pyridine-7-carboxylate (6 g, 20.062 mmol, 1 equiv) and TEA (8.12 g, 80.243 mmol, 4.00 equiv) in DCM (75 mL) was stirred for 5 minutes at 0°C under nitrogen atmosphere followed by the addition of TFAA (8.5 g, 40.470 mmol, 2.02 equiv) dropwise at 0°C. The resulting mixture was stirred for 35 minutes at room temperature under nitrogen atmosphere. The precipitated solids were collected by filtration and washed with DCM (3x10 mL). The resulting solid was dried under infrared light. This resulted in title compound (4 g, 67.39%) as a white solid. LC-MS: (ES, m / z): 281.10; 283.10 [M+H]+. Step 2: 2-cyano-5-[(1-methylpiperidin-4-yl)amino]furo[2,3-c]pyridine-7-carboxylate

[0236] A solution of methyl 5-bromo-2-cyanofuro[2,3-c]pyridine-7-carboxylate (2 g, 7.116 mmol, 1 equiv), 1-methylpiperidin-4-amine (0.9 g, 7.881 mmol, 1.11 equiv), Pd-PEpPSI- IPentCl o-picoline (0.6 g, 0.714 mmol, 0.10 equiv) and Cs2CO3 (4.8 g, 14.732 mmol, 2.07 equiv) in 1,4-dioxane (140 mL) was stirred for 10 h at 90°C under nitrogen atmosphere. The resulting mixture was diluted with EtOAc (180 mL). The resulting mixture was filtered, the filter cake was washed with EtOAc (3x20 mL). The filtrate was washed with water (45 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was used in the next step directly without further purification. This resulted in title compound (490 mg, 20.81%) as a yellow solid. LC-MS: (ES, m / z): 315.20 [M+H]+. Step 3: 4-bromo-2-cyano-5-[(1-methylpiperidin-4-yl)amino]furo[2,3-c]pyridine-7- carboxylate

[0237] A solution of methyl 2-cyano-5-[(1-methylpiperidin-4-yl)amino]furo[2,3- c]pyridine-7-carboxylate (12.5 g, 39.765 mmol, 1 equiv) and NBS (6.23 g, 34.993 mmol, 0.88 equiv) in DCM (175 mL) was stirred for 20 minutes at room temperature under nitrogenThe resulting mixture was extracted with CH2Cl2(3 x 150 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in title compound (9.1 g, 44.23%) as a yellow green solid. LC-MS: (ES, m / z): 393.10; 395.10 [M+H]+. Step 4: 4-bromo-2-carbamoyl-5-[(1-methylpiperidin-4-yl)amino]furo[2,3-c]pyridine-7- carboxylic acid

[0238] A solution of methyl 4-bromo-2-cyano-5-[(1-methylpiperidin-4-yl)amino]furo[2,3- c]pyridine-7-carboxylate (3.8 g, 9.663 mmol, 1 equiv) and LiOH (0.23 g, 9.603 mmol, 0.99 equiv) in THF (32 mL) and H2O (8 mL) was stirred for 2.5 hours at room temperature (note ˖keep the PH of the reaction solution below 9). The mixture was neutralized to pH 7 with HCl (aq.). The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase column eluting with H2O(FA) / CH3CN(FA) (3 / 1) to afford title compound (700 mg, 15.50%) as a yellow solid. LC-MS: (ES, m / z): 397.10; 399.10 [M+H]+. Step 5: 4-bromo-2-cyano-5-[(1-methylpiperidin-4-yl)amino]furo[2,3-c]pyridine-7- carboxylic acid – Int-12

[0239] A solution of 4-bromo-2-carbamoyl-5-[(1-methylpiperidin-4-yl)amino]furo[2,3- c]pyridine-7-carboxylic acid (1 g, 2.517 mmol, 1 equiv), TEA (1.55 g, 15.354 mmol, 6.1 equiv) in DCM (120 mL) was stirred for 5 minutes at 0°C under nitrogen atmosphere. To the above mixture was added TFAA (1.59 g, 7.551 mmol, 3 equiv) dropwise over 5min at 0°C. The resulting mixture was stirred for additional 40 min at room temperature. The reaction was quenched by the addition of sat. NaHCO3 (aq.) (6 mL) at 0°C. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase column eluting with H2O(FA) / CH3CN(FA) (2 / 1) to afford title compound (380 mg, 36.62%) as a yellow solid. LC-MS: (ES, m / z): 379.00; 381.00 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ 7.97 (s, 1H), 5.85 (d, J = 7.6 Hz, 1H), 4.10-3.99(m, 1H), 3.20-3.06 (m, 3H), 2.60-2.51 (m, 2H), 2.47 (s, 3H), 2.02-1.91 (m, 2H), 1.80 - 1.67 (m, 2H). Synthetic Example 2. General methods for preparation of furo[2,3-c]pyridine-2- carbonitriles with amino substitution in position 5. Method 1 (M1)

[0240] Int-1 coupled with amine M1-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide carboxamide M1-2, which was converted to title nitrile using dehydrating reagents such as trifluoracetic anhydride or ethyl phosphodichloridite in the presence of organic base. Examples:Method 2 (M2)

[0241] Int-1 coupled with mono Boc-protected diamine M2-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide carboxamide M2-2. Boc removed under acidic conditions to provide free amine M2-3 which was alkylated via reductive amination of carbonyl compound M2-4 or directly by treatment with alkyl halide M2-6. Carboxamides M2-5 and M2-7 converted into final nitrile using dehydrating reagents such as trifluoracetic anhydride or ethyl phosphodichloridite in the presence of organic base. Examples:Method 3 (M3)

[0242] Int-2 coupled with carboxamide M3-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide final nitrile. Examples:Method 4 (M4)

[0243] Int-7 coupled with amine M4-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide final nitrile. Examples:Method 5 (M5)

[0244] Int-7 coupled with mono Boc-protected diamine M5-1 (obtained commercially or synthesized according to methods known in the art) under Pd-catalyzed conditions to provide intermediate M5-2. Boc removed under acidic conditions to provide free amine M5-3 which was alkylated via reductive amination of carbonyl compound M5-4 or acetylated by treatment with chloroanhydride M5-5 yielding final product. Examples:Synthetic Example 3. Additional furo[2,3-c]pyridine-2-carbonitriles with differentiated preparation methods: Compound 40Step 1: 5-((1-methylpiperidin-4-yl)oxy)furo[2,3-c]pyridine-2-carbonitrile

[0245] To a solution of Int-7 (20 mg, 89.68 umol, 1 eq) and 1-methylpiperidin-4-ol (51.64 mg, 448.38 umol, 52.43 uL, 5 eq) in dioxane (4 mL) were added Cs2CO3(43.83 mg, 134.51 umol, 1.5 eq), Pd2(dba)3 (8.21 mg, 8.97 umol, 0.1 eq) and DPPF (17.40 mg, 31.39 umol, 0.35 eq), and the reaction mixture was stirred at 105°C under N2 for 2h. The reaction mixture was150*40mm*10um, Mobile Phase A: Water (NH4HCO3), Mobile Phase B: MeCN, 25% B to 55% B in 8min, flow 60 mL / min) to afford title compound (2.30 mg, 8.53 umol, 95.46% purity) as white amorphous solid. LCMS: (ES, m / z): 258.10[M+H]+.1H NMR (400 MHz, CD3CN) δ ppm 1.70 - 1.78 (m, 2 H) 2.01 (br s, 2 H) 2.19 (br s, 2 H) 2.21 (s, 3 H) 2.62 - 2.71, (m, 2 H) 4.87 - 5.04 (m, 1 H) 7.01 (s, 1 H) 7.61 (s, 1 H) 8.53 (s, 1 H). Compound 755Step 1: tert-butyl 4-((2-cyanofuro[2,3-c]pyridin-5-yl)thio)piperidine-1-carboxylate

[0246] A solution of Int-7 (1.25 g, 5.605 mmol, 1 equiv), tert-butyl 4-sulfanylpiperidine-1- carboxylate (1.83 g, 8.408 mmol, 1.5 equiv), XantPhos (486 mg, 0.840 mmol, 0.15 equiv), Cs2CO3 (3.65 g, 11.210 mmol, 2 equiv) and Pd2(dba)3.CHCl3 (580 mg, 0.560 mmol, 0.10 equiv) in dioxane (10 mL) was stirred for 2 hours at 80°C under nitrogen atmosphere. The reaction was quenched with saturated NaHCO3 aqueous at room temperature. The resulting mixture was extracted with CH2Cl2 (3 x 10mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash with the following conditions (H2O(0.1%FA) / MeCN(8:2)) to afford title compound (1.5 g, 90.08%) as a light yellow solid. LCMS: (ES, m / z): 360.44[ M+H]+. Step 2: 5-(piperidin-4-ylthio)furo[2,3-c]pyridine-2-carbonitrile

[0247] A solution of tert-butyl 4-({2-cyanofuro[2,3-c]pyridin-5-yl}sulfanyl)piperidine-1- carboxylate (500 mg, 1.391 mmol, 1 equiv) and TFA (1 mL) in DCM (5 mL) was stirred for 3 hours at room temperature under nitrogen atmosphere. The resulting mixture was concentrated under vacuum to afford crude title compound (300 mg) as a white solid. The crude product was used in the next step directly without further purification. LCMS: (ES, m / z): 260.08 [ M+H]+. Step 3: 5-((1-methylpiperidin-4-yl)thio)furo[2,3-c]pyridine-2-carbonitrile; formic acid

[0248] A solution of 5-(piperidin-4-ylsulfanyl)furo[2,3-c]pyridine-2-carbonitrile (100 mg, 0.386 mmol, 1 equiv), STAB (200 mg, 0.944 mmol, 2.45 equiv) and formaldehyde solution (30 mg, 0.999 mmol, 2.59 equiv,40%) in DCM (3 mL) was stirred for 3 hours at room temperature under nitrogen atmosphere. The reaction was quenched with saturated NaHCO3aqueous at room temperature. The resulting mixture was extracted with CH2Cl2(3 x 5mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product (50mg) was purified by Prep- HPLC with the following conditions (Xselect CSH OBD Column, 30*150mm, 5um; Mobile Phase A: Water(0.1% FA), Mobile Phase B: MeCN; 5% B to 11% B in 10 min, flow 60 mL / min mL / min) to afford title compound (11.4 mg, 10.73%) as an off-white solid. LCMS: (ES, m / z):274.05[ M+H]+.1H NMR (300 MHz, DMSO-d6) δ 9.05 (d, J = 1.1 Hz, 1H), 8.06 (d, J = 0.9 Hz, 1H), 7.79 (d, J = 1.1 Hz, 1H), 3.81-3.61 (m, 1H), 2.81-2.70 (m, 2H), 2.20 (s, 3H), 2.13 – 2.02 (m, 2H), 2.00-1.89 (m, 2H), 1.78-1.56 (m, 2H). Compound 753Step 1: Synthesis of 5-bromo-2-{[(tert-butyldimethylsilyl)oxy]methyl}furo[2,3- c]pyridine.

[0249] To a stirred solution of 6-bromo-4-iodopyridin-3-ol (5 g, 16.673 mmol, 1 equiv) in DMF (50 mL) was added Pd(PPh3)2Cl2(2.34 g, 3.335 mmol, 0.2 equiv) CuI (1.59 g, 8.336 mmol, 0.5 equiv), TEA (8.44 g, 83.365 mmol, 5 equiv) and tert-butyldimethyl(prop-2-yn-1- yloxy)silane (4.26 g, 25.009 mmol, 1.5 equiv) in portions at room temperature under nitrogen atmosphere. The resulting mixture was quenched with water and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (3x100 mL) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (3:7) to afford title compound (4.6 g, 80.60%) as a brown oil. LCMS: (ES, m / z): 342[ M+H]+. Step 2:4-(2-{[(tert-butyldimethylsilyl)oxy]methyl}furo[2,3-c]pyridine-5-carbonyl)-1- methylpiperidine.

[0250] A solution of 5-bromo-2-{[(tert-butyldimethylsilyl)oxy]methyl}furo[2,3-c]pyridine (4.4 g, 12.854 mmol, 1 equiv) in DCM (50 mL) was treated with n-BuLi (1.65 g, 25.708 mmol, 2 equiv) for 1 h at -78°C under nitrogen atmosphere. Then N-methoxy-N,1- dimethylpiperidine-4-carboxamide (3.09 g, 16.582 mmol, 1.29 equiv) was added inportions at -78°C and stirred for another 1 hour. The reaction was quenched with sat. NH4Cl (aq.) at -78°C. The resulting mixture was extracted with CH2Cl2 (3 x100 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse phase flash with the following conditions (column, C18 silica gel; mobile phase, MeOH in Water (10mmol / L NH4HCO3), 99% to 1% in 10 min; detector, UV 254 nm.) to afford title compound (1.1348 g, 21.30%) as a brown solid. LCMS: (ES, m / z): 389[ M+H]+. Step 3: [5-(1-methylpiperidine-4-carbonyl)furo[2,3-c]pyridin-2-yl]methanol

[0251] A solution of 4-(2-{[(tert-butyldimethylsilyl)oxy]methyl}furo[2,3-c]pyridine-5- carbonyl)-1-methylpiperidine (1.44 g, 3.706 mmol, 1 equiv) and CsF (2.25 g, 14.812 mmol, 4.00 equiv) in THF (20 mL) was stirred for 1 hour at 60°C under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The crude product was purified by reverse phase flash with the following conditions (column, C18 silica gel; mobile phase, MeCN in Water (10mmol / L NH4HCO3), 25% to 75% in 10 min; detector, UV 254 nm) to afford title compound (260 mg, 24.48%) as a brown solid. LCMS: (ES, m / z): 275[ M+H]+. Step 4: 5-(1-methylpiperidine-4-carbonyl)furo[2,3-c]pyridine-2-ca...

Claims

CLAIMS 1. A compound of Formula (Oa):or a salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; and wherein at least one of R1, R2, R3, and R4is RA; wherein RA, at each occurrence, is independently -ORAa, -O-(L1)n-NRw2Rw3, -SRAl, -N(Rw4)-M1-C(O)- L2-RAb, -N(Rw4)-M1-C(O)-RAb, -N(Rw4)-C(O)-L2-RAb, -N(Rw5)-C(O)-RAc, -N(Rw7)-(L3)n- C(O)-N(Rw8)-RAd, -N(Rw5)-M1-M2-C(O)-RAd, -N(Rw9)-RAe, -N(Rw5)-M1-M2-C(O)-N(Rw7)- (L3)n-RAe, -N(Rw10)-M2-L4-RAf, -N(Rw10)-M2-RAf, -N(Rw10)-L4-RAf,-N(Rw11)-(M3)m-Rx, - N(Rw12)-M4-M5-C(O)-N(Rw13)-Rx, -N(Rw12)-M4-L5-N(Rw13)RAg, -N(Rw12)-M4-N(Rw13)RAg, - N(Rw12)-L5-N(Rw13)RAg, -S(O)2NRw24Rw25, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5- N(Rw15)-Ry, or -N(Rw14)-L6-N(Rw15)-Ry; R1, R2, R3, and R4, when present, are each independently RA, H, deuterium, halogen, -CN, -C(O)NRw22Rw23, -Rz, C2-C6alkenyl, or C2-C6alkynyl optionally substituted with one or more -NRw26RAm, or any two vicinal R1, R2, R3, and R4are taken together with the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-memberedmembered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl, or C3-C6cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; RAa, RAb, RAc, RAd, RAe, RAf, RAg, RAh, RAi, RAj, RAk, RAl, RAm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3- C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12optionally substituted with one or more independently selected –(C1-C6alkyene)-OH, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more oxo, independently selected C1- C6 alkyl, or independently selected C3-C6 cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl; C6-C12aryl optionally substituted with one or more independently selected CN or C1-C6 alkoxy; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12 arylene, C3- C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw17, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6,independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen.

2. The compound of claim 1, or a salt thereof, wherein the compound is a compound of Formula (O):or a salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; and wherein at least one of R1, R2, R3, and R4is RA; wherein RA, at each occurrence, is independently -ORAa, -O-(L1)n-NRw2Rw3, -SRAl, -N(Rw4)-M1-C(O)- L2-RAb, -N(Rw4)-M1-C(O)-RAb, -N(Rw4)-C(O)-L2-RAb, -N(Rw5)-C(O)-RAc, -N(Rw7)-(L3)n- C(O)-N(Rw8)-RAd, -N(Rw9)-RAe, -N(Rw10)-M2-L4-RAf, -N(Rw10)-M2-RAf, -N(Rw10)-L4-RAf,- N(Rw11)-(M3)m-Rx, -N(Rw12)-M4-L5-N(Rw13)RAg, -N(Rw12)-M4-N(Rw13)RAg, -N(Rw12)-L5- N(Rw13)RAg, -S(O)2NRw24Rw25, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, or - N(Rw14)-L6-N(Rw15)-Ry; R1, R2, R3, and R4, when present, are each independently RA, H, deuterium, halogen, -CN, -C(O)NRw22Rw23, -Rz, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26RAm, or any two vicinal R1, R2, R3, and R4are taken together with the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered h l l ( ) ( b d h l l) h imembered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl, or C3-C6cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; RAa, RAb, RAc, RAd, RAe, RAf, RAg, RAh, RAi, RAj, RAk, RAl, RAm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3- C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more oxo, independently selected C1- C6 alkyl, or independently selected C3-C6 cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl; or C3-C14cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw17, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or moreindependently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

3. A compound of Formula (Ia)or a salt thereof, wherein: R1is H; deuterium; halogen; -NO2; C(O)Rw1; C1-C6 alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; C3-C14cycloalkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; or C2-C6alkynyl, R2is -OR2a, -O-(L1)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, - N(Rx5)-M1-M2-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n- C(O)-N(Rx7)-R2e, -N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2e, -N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, - N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, - N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -N(Rx12)-M4-M5-C(O)-N(Rx13)-R2x, -(L6)n-R2h, - C(O)R2i, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7-N(Rx14)-R2y, or R1is taken together with R2and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R2a, R2b, R2c, R2d, R2e, R2f, R2h, R2i, and R2j, at each occurrence, are independently 3- to 14- membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24;R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, - S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L8)n-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6 alkyl optionally substituted with one or more R21a, C3-C6 cycloalkyl optionally substituted with one or more R21a, 5- to 12-membered heteroaryl optionally substituted with one or more Ra, C6-C12aryl optionally substituted with one or more independently selected –(C1-C6 alkyene)-OH, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or; R21a, at each occurrence, is independently halogen, -ORa, - N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, 3- to 14-membered heterocyclyl, C6-C12 aryl, or 5- to 12-membered heteroaryl, R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6 cycloalkyl; R22, at each occurrence, is independently C1-C6 alkyl, C3-C6 cycloalkyl, -OH, - OD, -S(O)2Ra, -C(O)N(Ra)2, or -N(Ra)2; R23, at each occurrence, is independently -N(Ra)2, C1-C6 alkyl, or C3-C6 cycloalkyl; R24, at each occurrence, is independently -OH, -OD, oxo, -(C1-C6alkylene)- C(O)N(Ra)2, -C(O)N(Ra)2, or -N(Ra)C(O)Ra; R2xis C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen, -ORa, -N(Ra)2, -C(O)- N(Ra)2, or -N(Ra)C(O)-Ra; R2yis C1-C6 alkyl optionally substituted with one or more R26; R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)- N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L9)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl optionally substituted with one or more independently selected CN or C1-C6alkoxy; or C3-C14cycloalkyl optionallyR2Ais 3- to 14-membered heterocyclyl, C6-C12 aryl, 5- to 14-membered heteroaryl, or C3-C14 cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, -N(Ra)2, oxo, -OH, -OD, -C(O)-(L10)n-N(Ra)2, - C(O)Ra, or -N(Ra)C(O)Ra; R4is H, deuterium, -N(Ra)2, -NO2, C3-C14cycloalkyl, -C(O)ORz1, -N(Rz2)-(L11)n-R4a, -C(O)- R4b, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-L12-M6-R4d, -C(O)N(Rz4)-L12-R4d, -C(O)N(Rz4)-M6-R4d, or -C(O)NRz5Rz6, R4a, R4b, R4c, and R4d, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R41, C6-C12 aryl optionally substituted with one or more R42, 5- to 14-membered heteroaryl optionally substituted with one or more R43, or C3-C14cycloalkyl optionally substituted with one or more R44; R41, R42, R43, and R44, at each occurrence, are independently halogen, - S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more -ORa, or C3-C6cycloalkyl optionally substituted one or more -ORa; R5is H, deuterium, halogen, -(L13)n-NR5AR5B, C1-C6alkyl optionally substituted with one or more halogen, C3-C6 cycloalkyl optionally substituted with one or more halogen, C2-C6 alkenyl optionally substituted with one or more R5C, C2-C6 alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or -C(O)-N(Ru2)-R5x; R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5a; R5C, at each occurrence, is independently -OR5C1, -N(Ra)R5C2, or R5c; R5C1and R5C2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6 cycloalkyl, or C6-C12 aryl; R5D, at each occurrence, is independently -N(Ra)R5D1or R5d; R5D1, at each occurrence, is independently C6-C12aryl optionally substituted with one or more independently selected -ORa, -C(O)N(Ra)2, or -S(O)2N(Ra)2; R5a, R5c, R5d, and R5e, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12aryl optionallysubstituted with one or more R53, or C3-C12cycloalkyl optionally substituted with one or more R54; R51, R52, R53, and R54, at each occurrence, are independently halogen, oxo, - CN, -C(O)Rz8, -S(O)2Ra, -C(O)-N(Ra)2, 3- to 14-membered heteroaryl, C1-C6alkyl optionally substituted one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted one or more independently selected halogen; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O- (C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, and L14, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, and M6, at each occurrence, are independently C6-C12arylene, C3-C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1; Rw1, Rx1, Rx2, Rx3, Rx4, Rx5, Rx6, Rx7, Rx8, Rx9, Rx10, Rx11, Rx12, Rx13, Rx14, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Ru1, Ru2, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen.

4. The compound of claim 3, wherein the compound is a compound of Formula (I)or a salt thereof, wherein:R1is H; deuterium; halogen; -NO2; C(O)Rw1; C1-C6alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; or C2-C6 alkynyl, R2is -OR2a, -O-(L1)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, - N(Rx5)-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n-C(O)-N(Rx7)-R2e, -N(Rx8)-R2A, - N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3- N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -(L6)n-R2h, -C(O)R2i, -N(Rx13)-M5- L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7-N(Rx14)-R2y, or R1is taken together with R2and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R2a, R2b, R2c, R2d, R2e, R2f, R2h, R2i, and R2j, at each occurrence, are independently 3- to 14- membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, - S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L8)n-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6 alkyl optionally substituted with one or more R21a, C3-C6 cycloalkyl optionally substituted with one or more R21a, 5- to 12-membered heteroaryl optionally substituted with one or more Ra, C6-C12aryl, 3- to 14- membered heterocyclyl optionally substituted with one or more R21b, orR21a, at each occurrence, is independently halogen, -ORa, - N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, 3- to 14-membered heterocyclyl,R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6 cycloalkyl; R22, at each occurrence, is independently C1-C6 alkyl, C3-C6 cycloalkyl, -OH, - OD, -S(O)2Ra, -C(O)N(Ra)2, or -N(Ra)2; R23, at each occurrence, is independently -N(Ra)2, C1-C6alkyl, or C3-C6cycloalkyl; R24, at each occurrence, is independently -OH, -OD, oxo, -C(O)N(Ra)2, or - N(Ra)C(O)Ra; R2xis C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen, -ORa, -N(Ra)2, -C(O)- N(Ra)2, or -N(Ra)C(O)-Ra; R2yis C1-C6 alkyl optionally substituted with one or more R26; R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)- N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L9)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or -OD; R2Ais 3- to 14-membered heterocyclyl, C6-C12 aryl, 5- to 14-membered heteroaryl, or C3-C14 cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, oxo, -OH, -OD, -C(O)-(L10)n-N(Ra)2, -C(O)Ra, or -N(Ra)C(O)Ra; R4is H, deuterium, -N(Ra)2, -NO2, C3-C14 cycloalkyl, -C(O)ORz1, -N(Rz2)-(L11)n-R4a, -C(O)- )N(Rz4)-L12-M6-R4d, -C(O)N(Rz4)-L12-R4d, -C(O)N(Rz4)-M6-R4d,d, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R41, C6-C12 aryl optionally substituted with one or more R42, 5- to 14-membered heteroaryl optionally substitutedwith one or more R43, or C3-C14cycloalkyl optionally substituted with one or more R44; R41, R42, R43, and R44, at each occurrence, are independently halogen, - S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more -ORa, or C3-C6cycloalkyl optionally substituted one or more -ORa; R5is H, deuterium, halogen, -(L13)n-NR5AR5B, C1-C6alkyl optionally substituted with one or more halogen, C3-C6 cycloalkyl optionally substituted with one or more halogen, C2-C6 alkenyl optionally substituted with one or more R5C, C2-C6 alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or -C(O)-N(Ru2)-R5x; R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5a; R5C, at each occurrence, is independently -OR5C1, -N(Ra)R5C2, or R5c; R5C1and R5C2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6cycloalkyl, or C6-C12aryl; R5D, at each occurrence, is independently -N(Ra)R5D1or R5d; R5D1, at each occurrence, is independently C6-C12aryl optionally substituted with one or more independently selected -ORa, -C(O)N(Ra)2, or -S(O)2N(Ra)2; R5a, R5c, R5d, and R5e, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12aryl optionally substituted with one or more R52, 5- to 14-membered heteroaryl optionally substituted with one or more R53, or C3-C12 cycloalkyl optionally substituted with one or more R54; R51, R52, R53, and R54, at each occurrence, are independently halogen, oxo, - CN, -C(O)Rz8, -S(O)2Ra, -C(O)-N(Ra)2, 3- to 14-membered heteroaryl, C1-C6 alkyl optionally substituted one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted one or more independently selected halogen; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O- (C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, and L14, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selectedM1, M2, M3, M4, M5, and M6, at each occurrence, are independently C6-C12arylene, C3-C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6alkyl, C3-C6cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1; Rw1, Rx1, Rx2, Rx3, Rx4, Rx5, Rx6, Rx7, Rx8, Rx9, Rx10, Rx11, Rx12, Rx13, Rx14, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Ru1, Ru2, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen.

5. The compound of claim 3 or 4, or a salt thereof, wherein R1is H, deuterium, or Br.

6. The compound of claim 3, or a salt thereof, wherein R2is -OR2a, -O-(L1)n-NRx1Rx2, - SR2b, -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-M1-M2-C(O)-R2d, -N(Rx5)- C(O)-L2-R2d, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n-C(O)-N(Rx7)-R2e, -N(Rx5)-M1- M2-C(O)-N(Rx7)-(L3)n-R2e, -N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)- L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, - N(Rx12)-M4-M5-C(O)-N(Rx13)-R2x, -N(Rx12)-(M4)m-R2x, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L7-N(Rx14)-R2y, 5- to 14-membered heterocycle optionally substituted with one or more R21, or 5- to 14-membered heteroaryl optionally substituted with one or more R23.

7. The compound of claim 6, or a salt thereof, wherein R2is -N(Rx5)-M1-M2-C(O)-R2d, - N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2e, or -N(Rx12)-M4-M5-C(O)-N(Rx13)-R2x.

8. The compound of claim 7, or a salt thereof, wherein R2is -N(Rx5)-M1-M2-C(O)-R2d.

9. The compound of claim 8, or a salt thereof, wherein R2is -N(Rx5)-M1-M2-C(O)-R2dand M1 is cyclohexylene.

10. The compound of claim 8 or 9, or a salt thereof, wherein R2is -N(Rx5)-M1-M2-C(O)- R2dand M2is 5- to 8-membered heterocyclylene.

11. The compound of any one of claims 8-10, or a salt thereof, wherein R2is -N(Rx5)-M1- M2-C(O)-R2dand R2dis 4- to 6-membered heterocycle, optionally substituted with one or more R21.

12. The compound of claim 7, or a salt thereof, wherein R2is -N(Rx5)-M1-M2-C(O)- N(Rx7)-(L3)n-R2e.

13. The compound of claim 7 or 12, or a salt thereof, wherein R2is -N(Rx5)-M1-M2-C(O)- N(Rx7)-(L3)n-R2eand M1is cyclohexylene.

14. The compound of any one of claims 7, 12, or 13, or a salt thereof, wherein R2is - N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2eand M2 is 5- to 8-membered heterocyclylene.

15. The compound of any one of claims 7 and 12-14, or a salt thereof, wherein R2is - N(Rx5)-M1-M2-C(O)-N(Rx7)-L3-R2eand R2eis 5- to 6-membered heteroaryl optionally substituted with one or more R23, C3-C6 cycloalkyl optionally substituted with one or more R24, or 3- to 10-membered heterocyclyl optionally substituted with one or more R21.

16. The compound of any one of claims 7 and 12-14, or a salt thereof, wherein R2is N(Rx5)-M1-M2-C(O)-N(Rx7)-R2eand R2eis 5- to 10-membered heterocyclyl optionally substituted with one or more R21.

17. The compound of claim 7, or a salt thereof, wherein R2is -N(Rx12)-M4-M5-C(O)- N(Rx13)-R2x.

18. The compound of claim 7 or 17, or a salt thereof, wherein R2is -N(Rx12)-M4-M5- C(O)-N(Rx13)-R2xand M4is cyclohexylene.

19. The compound of any one of claims 7, 17, or 18, or a salt thereof, wherein R2is - N(Rx12)-M4-M5-C(O)-N(Rx13)-R2xand M5is 5- to 8-membered heterocyclylene.

20. The compound of any one of claims 7 and 12-14, or a salt thereof, wherein R2is - N(Rx12)-M4-M5-C(O)-N(Rx13)-R2xand R2xis C1-C6 alkyl optionally substituted with one or more halogen or -ORa.

21. The compound of claim 4 or 5, or a salt thereof, wherein R2is -OR2a, -O-(L1)n- NRx1Rx2, -SR2b, -N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, - N(Rx5)-M1-C(O)-L2-R2d, -N(Rx6)-(L3)n-C(O)-N(Rx7)-R2e, -N(Rx8)-R2A, -N(Rx9)-M2- L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, -N(Rx10)-M3- N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L7-N(Rx14)-R2y, 5- to 14-membered heterocycle optionally substituted with one or more R21, or 5- to 14-membered heteroaryl 2322. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is -OR2a, -O-L1-NRx1Rx2, or -SR2b.

23. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is 5- to 14-membered heteroaryl optionally substituted with one or more R23.

24. The compound of claim 23, or a salt thereof, wherein R2is unsubstituted 5- to 10- membered heteroaryl.

25. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is - N(Rx4)-C(O)-R2c, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, or -N(Rx5)-M1-C(O)- L2-R2d.

26. The compound of claim 25, or a salt thereof, wherein R2is -N(Rx4)-C(O)-R2c, and wherein R2cis 3- to 14-membered heterocyclyl optionally substituted with one or more R21.

27. The compound of claim 25, or a salt thereof, wherein R2is -N(Rx5)-M1-C(O)-R2d, - N(Rx5)-C(O)-L2-R2d, or -N(Rx5)-M1-C(O)-L2-R2d, wherein M1is 3- to 12-membered heterocyclylene, L2 is C1-C8 alkylene, and R2dis 3- to 14-membered heterocyclyl optionally substituted with one or more R21.

28. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is - N(Rx6)-C(O)-N(Rx7)-R2eor -N(Rx6)-L3-C(O)-N(Rx7)-R2e.

29. The compound of any one of claims 4, 5, 21, or 28, or a salt thereof, wherein R2is N(Rx6)-L3-C(O)-N(Rx7)-R2e, and L3is C1-C8alkylene.

30. The compound of claim 28 or 29, or a salt thereof, wherein R2eis 3- to 14-membered heterocyclyl optionally substituted with one or more R21or C3-C14 cycloalkyl optionally substituted with one or more R24.

31. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is - N(Rx8)-R2A.

32. The compound of claim 31, or a salt thereof, wherein R2Ais C6-C12 aryl or C3-C14 cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, -N(Ra)2, oxo, -OH, -OD, -C(O)-L10-N(Ra)2, -C(O)-N(Ra)2, - C(O)Ra, or -N(Ra)C(O)Ra.

33. The compound of claim 31, or a salt thereof, wherein R2Ais C6-C12aryl or C3-C14cycloalkyl, each of which is optionally substituted with one or more independently selected halogen, -CN, oxo, -OH, -OD, -C(O)-L10-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, or - N(Ra)C(O)Ra.

34. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is - N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, or -N(Rx9)-M2-L4-R2f.

35. The compound of any one of claims 4, 5, 21, or 34, or a salt thereof, wherein R2is - N(Rx9)-M2-R2f, wherein M2is C3-C14cycloalkylene or 3- to 14-membered heterocyclylene optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl.

36. The compound of any one of claims 4, 5, 21, 34, or 35, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, and R2fis C6-C12 aryl.

37. The compound of any one of claims 4, 5, 21, 34, or 35, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, and R2fis 5- to 14-membered heteroaryl.

38. The compound of any one of claims 4, 5, 21, 34, or 35, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, and R2fis C3-C14 cycloalkyl.

39. The compound of any one of claims 4, 5, 21, 34, or 35, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, wherein R2fis 3- to 14-membered heterocyclyl optionally substituted with one or more R21, and wherein R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-L8-N(Ra)2, - C(O)-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted with one or more R21a, C3-C6 cycloalkyl optionally substituted with one or more R21a, 5- to 14-membered heteroaryl optionally substituted with one or more Ra, C6-C12 aryl optionally substituted with one or more independently selected –(C1-C6alkyene)-OH, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or.

40. The compound of any one of claims 4, 5, 21, 34, or 35, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, wherein R2fis 3- to 14-membered heterocyclyl optionally substituted with one or more R21, and wherein R21, at each occurrence, is independently oxo,C(O)-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6alkyl optionally substituted with one or more R21a, C3-C6 cycloalkyl optionally substituted with one or more R21a, 5- to 14-membered heteroaryl optionally substituted with one or more Ra, C6-C12 aryl, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or.

41. The compound of any one of claims 4, 5, 21, or 34-36, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, wherein R2fis 3- to 14-membered heterocyclyl substituted with one or more R21, and wherein R21, at each occurrence, is independently oxo, halogen, - CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-L8-N(Ra)2, -C(O)-N(Ra)2, -C(O)Ra, -N(Ra)C(O)Ra, -N(Ra)2, C1-C6 alkyl optionally substituted with one or more R21a, C3-C6 cycloalkyl optionally substituted with one or more R21a, or 5- to 12 membered heteroaryl substituted with one or more Ra.

42. The compound of any one of claims 4, 5, 21, or 34-36, or a salt thereof, wherein R2is -N(Rx9)-M2-R2f, wherein R2fis unsubstituted 3- to 14-membered heterocyclyl.

43. The compound of any one of claims 4, 5, 21, or 34, or a salt thereof, wherein R2is - N(Rx9)-L4-R2f, and wherein L4 is C1-C8 alkylene.

44. The compound of any one of claims 4, 5, 21, 34, or 43, or a salt thereof, wherein R2is -N(Rx9)-L4-R2f, and R2fis unsubstituted 3- to 14-membered heterocyclyl.

45. The compound of any one of claims 4, 5, 21, 34, or 43, or a salt thereof, wherein R2is -N(Rx9)-L4-R2f, and R2fis 3- to 14-membered heterocyclyl substituted with one or more independently selected -OH, -C(O)-N(Ra)2, C1-C6 alkyl, or C3-C6 cycloalkyl.

46. The compound of any one of claims 4, 5, 21, or 34, or a salt thereof, wherein R2is - N(Rx9)-M2-L4-R2f.

47. The compound of any one of claims 4, 5, 21, 34, or 46, or a salt thereof, wherein R2is -N(Rx9)-M2-L4-R2f, wherein M2is 3- to 14-membered heterocyclylene, and wherein L4 is C1-C6 alkylene.

48. The compound of any one of claims 4, 5, 21, 34, 46, or 47, or a salt thereof, wherein R2is -N(Rx9)-M2-L4-R2f, and R2fis C6-C12aryl optionally substituted with one or more R22.

49. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is - N(Rx10)-M3-N(Rx11)-R2jor -N(Rx10)-L5-N(Rx11)-R2j.

50. The compound of any one of claims 4, 5, 21, or 49, or a salt thereof, wherein R2is - N(Rx10)-M3-N(Rx11)-R2j, and wherein M3is 3- to 14-membered heterocyclylene or C3- C14cycloalkylene, each of which is optionally substituted with one or more independently selected oxo, C1-C6 alkyl, or C3-C6 cycloalkyl.

51. The compound of any one of claims 4, 5, 21, or 49, or a salt thereof, wherein R2is - N(Rx10)-L5-N(Rx11)-R2j, and wherein L5is C1-C8alkylene.

52. The compound of any one of claims 49-51, or a salt thereof, wherein R2jis 3- to 14- membered heterocyclyl optionally substituted with one or more R21, 5- to 14- membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; wherein R21, at each occurrence, is independently oxo, halogen, -CN, -ORa, -N(Ra)C(O)Ra, C1-C6 alkyl, or C3-C6cycloalkyl, wherein R23, at each occurrence, is independentlyC1-C6alkyl or C3- C6 cycloalkyl; and wherein R24, at each occurrence, is independently oxo, halogen, - ORa, -C(O)-(L8)n-N(Ra)2, or -N(Ra)C(O)Ra.

53. The compound of any one of claims 4, 5, 21, or a salt thereof, wherein R2is -N(Rx13)- M5-N(Rx14)-R2y, -N(Rx13)-L7-N(Rx14)-R2y, or -N(Rx13)-M5-L7-N(Rx14)-R2y.

54. The compound of any one of claims 4, 5, 21, or 53, or a salt thereof, wherein R2is - N(Rx13)-M5-N(Rx14)-R2y, and wherein M5is C3-C14cycloalkylene optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl.

55. The compound of any one of claims 4, 5, 21, or 53, or a salt thereof, wherein R2is - N(Rx13)-L7-N(Rx14)-R2y, and wherein L7 is C1-C8 alkylene.

56. The compound of any one of claims 4, 5, 21, or 53, or a salt thereof, wherein R2is - N(Rx13)-M5-L7-N(Rx14)-R2y, wherein M5 is C3-C14 cycloalkylene, and wherein L7 is C1-C8 alkylene.

57. The compound of any one of claims 53-56, or a salt thereof, wherein R2yis C1-C6alkyl optionally substituted with one or more R26, and R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)- (C6-C12aryl); -N(Ra)C(O)-(C1-C6alkylene)-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo C1-C6alkyl, or C3-C6cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl optionally substituted with one or more independently selected CN or C1-C6 alkoxy; or C3-C14cycloalkyl optionally substituted with one or more independently selected - OH or -OD.

58. The compound of any one of claims 53-56, or a salt thereof, wherein R2yis C1-C6 alkyl optionally substituted with one or more R26, and R26, at each occurrence, is independently halogen; -ORa; -N(Ra)2; -C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)- (C6-C12 aryl); -N(Ra)C(O)-(C1-C6 alkylene)-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6alkyl, or C3-C6cycloalkyl; 3 to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected - OH or -OD.

59. The compound of claim 58, or a salt thereof, wherein R2yis C1-C6 alkyl optionally substituted with one or more R26, and R26, at each occurrence, is independently -ORa; -N(Ra)2; -C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(C6-C12aryl); -N(Ra)C(O)-(C1-C6alkylene)-(C6-C12aryl); 3- to 10-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-C6 alkyl or C3-C6 cycloalkyl; or 3 to 10- membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl.

60. The compound of any one of claims 4, 5, or 21, or a salt thereof, wherein R2is - N(Rx12)-R2xor -N(Rx12)-M4-R2x.

61. The compound of any one of claims 4, 5, 21, or 60, or a salt thereof, wherein R2is - N(Rx12)-R2x.

62. The compound of any one of claims 4, 5, 21, or 60, or a salt thereof, wherein R2is - N(Rx12)-M4-R2x, and wherein M4is C3-C14cycloalkylene or 3- to 14-membered heterocyclylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2.

63. The compound of any one of claims 4, 5, 21, or 60, or a salt thereof, wherein R2is -heterocyclylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2.

64. The compound of any one of claims 60-63, or a salt thereof, wherein R2xis C1-C6alkyl optionally substituted with one or more R25, and wherein R25, at each occurrence, is independently halogen, -OH, -OD, -OCH3, or -N(CH3)2.

65. The compound of claims 4 or 5, or a salt thereof, wherein R2is -C(O)ORx3, -C(O)R2i, -L6-R2h, 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, or C3-C14 cycloalkyl optionally substituted with one or more R24.

66. The compound of any one of claims 4, 5, or 65, or a salt thereof, wherein R2is - C(O)ORx3, and wherein Rx3is H, D, C1-C3 alkyl, or C3-C6 cycloalkyl.

67. The compound of any one of claims 4, 5, or 65, or a salt thereof, wherein R2is - C(O)R2i, and wherein R2iis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3 alkyl or C3-C6 cycloalkyl.

68. The compound of any one of claims 4, 5, or 65, or a salt thereof, wherein R2is -L6- R2h, wherein L6is C1-C8alkylene, and wherein R2his 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3alkyl or C3-C6cycloalkyl, each of which is optionally substituted with one or more independently selected -OH, -OD, halogen, or -N(Ra)2.

69. The compound of any one of claims 4, 5, or 65, or a salt thereof, wherein R2is 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C3 alkyl or C3-C6 cycloalkyl, each of which is optionally substituted with one or more independently selected -OH, -OD, halogen, or -N(Ra)2.

70. The compound of any one of claims 4, 5, or a salt thereof, wherein R1is taken together with R2and the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b.

71. The compound of claim 70, or a salt thereof, wherein R1b, at each occurrence, is independently 3- to 14-membered heterocyclyl or -N(Ra)-(3- to 14-membered heterocyclyl) wherein any 3- to 14-membered heterocyclyl of R1bat eachoccurrence, is independently and optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl.

72. The compound of any one of claims 4-71, or a salt thereof, wherein R4is H or deuterium.

73. The compound of any one of claims 4-71, or a salt thereof, wherein R4is -N(Ra)2or - NO2, wherein each Rais independently H or D.

74. The compound of any one of claims 4-71, or a salt thereof, wherein R4is unsubstituted C3-C14cycloalkyl.

75. The compound of any one of claims 4-71, or a salt thereof, wherein R4is -C(O)ORz1, -C(O)-R4b, -C(O)N(Rz3)-R4c, -C(O)-N(Rz4)-L12-M6-R4d, -C(O)-N(Rz4)-M6-R4d, -C(O)- N(Rz4)-L12-R4d, or -C(O)NRz5Rz6.

76. The compound of any one of claims 4-71, or 75, or a salt thereof, wherein R4is - C(O)N(Rz3)-R4c, and wherein R4cis 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected halogen, or C6-C12aryl optionally substituted with one or more -S(O)2N(Ra)2, wherein each Rais independently H or D.

77. The compound of any one of claims 4-71, or 75, or a salt thereof, wherein R4is - C(O)-N(Rz4)-L12-M6-R4d, -C(O)-N(Rz4)-M6-R4d, or -C(O)-N(Rz4)-L12-R4d, wherein R4dis 3- to 14-membered heterocyclyl optionally substituted with one or more R41, C6-C12aryl optionally substituted with one or more R42, 5- to 14-membered heteroaryl optionally substituted with one or more R43, or C3-C14cycloalkyl optionally substituted with one or more R44.

78. The compound of any one of claims 4-71, or 75, or a salt thereof, wherein R4is - C(O)NRz5Rz6.

79. The compound of any one of claims 4-71, or a salt thereof, wherein R4is -N(Rz2)-L11- R4aor -N(Rz2)-R4a, and wherein R4ais C6-C12 aryl optionally substituted with one or more R42.

80. The compound of any one of claims 4-79, or a salt thereof, wherein R5is H or deuterium.

81. The compound of any one of claims 4-79, or a salt thereof, wherein R5is -L13-wherein R5Aand R5Bare independently C2-C6alkynyl or C6-82. The compound of any one of claims 4-79, or a salt thereof, wherein R5is C2-C6alkenyl optionally substituted with one or more R5C, and wherein R5C, at each occurrence, is independently -OH, -OD, -OCH3, -O-(C6-C12 aryl), -NH-(C6-C12 aryl), -ND-(C6-C12aryl), C3-C12cycloalkyl, or C6-C12aryl.

83. The compound of any one of claims 4-79, or a salt thereof, wherein R5is C2-C6alkynyl optionally substituted with one or more R5D, and wherein R5D, at each occurrence, is independently C6-C12 aryl, -NH-(C6-C12 aryl),84. The compound of any one of claims 4-79, or a salt thereof, wherein R5is -C(O)- N(Ru1)-L14-R5eor -C(O)-N(Ru1)-R5e, wherein R5eis 3- to 14-membered heterocyclyl optionally substituted with one or more R51, C6-C12 aryl optionally substituted with one or more R52, 5- to 14-membered heteroaryl optionally substituted with one or more R53, or C3-C12 cycloalkyl optionally substituted with one or more R54.

85. The compound of any one of claims 4-79, or a salt thereof, wherein R5is-C(O)- N(Ru2)-R5x, and wherein R5xis C1-C6alkyl optionally substituted with one or more - OCF3.

86. The compound of claim 2, wherein: R1is H, deuterium, halogen, or C1-C6alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; R2is -SR2b, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, - N(Rx5)-M1-M2-C(O)-R2d, -N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2e, -N(Rx8)-R2A, - N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5-N(Rx11)R2j, - N(Rx10)-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, -N(Rx12)-M4-M5- C(O)-N(Rx13)-R2x, -(L6)n-R2h, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7-N(Rx14)-R2y, R4is H, D, C3-C14 cycloalkyl, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-(L12)n-(M6)m-R4d, or - C(O)NRz5Rz6; andR5is H, deuterium, C2-C6alkenyl optionally substituted with one or more R5C, C2-C6alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or - C(O)-N(Ru2)-R5x.

87. The compound of claim 4, wherein: R1is H, deuterium, halogen, or C1-C6alkyl optionally substituted with one or more independently selected -OH, -OD, or halogen; R2is -SR2b, -N(Rx5)-M1-C(O)-L2-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L2-R2d, - N(Rx8)-R2A, -N(Rx9)-M2-L4-R2f, -N(Rx9)-M2-R2f, -N(Rx9)-L4-R2f, -N(Rx10)-M3-L5- N(Rx11)R2j, -N(Rx10)-L5-N(Rx11)R2j, -N(Rx10)-M3-N(Rx11)R2j, -N(Rx12)-(M4)m-R2x, - (L6)n-R2h, -N(Rx13)-M5-L7-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, or -N(Rx13)-L7- N(Rx14)-R2y, R4is H, D, C3-C14 cycloalkyl, -C(O)N(Rz3)-R4c, -C(O)N(Rz4)-(L12)n-(M6)m-R4d, or - C(O)NRz5Rz6; and R5is H, deuterium, C2-C6alkenyl optionally substituted with one or more R5C, C2-C6alkynyl optionally substituted with one or more R5D, -C(O)-N(Ru1)-(L14)n-R5e, or - C(O)-N(Ru2)-R5x.

88. The compound of claim 4, selected from compounds in Table 1 or Table 1A, or a salt thereof.

89. A compound of Formula (II)or a salt thereof, wherein: R1is H, deuterium, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, -N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, C1-C6 alkyl optionally substituted with one or more independently selected halogen, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen, or C2-C6alkynyl optionally substituted with one or more independently selected -N(Rw9)R1f,R3is H, deuterium, -N(Ry3)-R3a, -C(O)ORy4, -N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, or - S(O)2NRy8Ry9; R4is H, deuterium, halogen, -N(Rz1)Rz2, -N(Rz3)-(L4)n-R4a, -N(Rz4)-C(O)-(L5)n-R4b, - C(O)ORz5, -C(O)N(Rz6)R4c, C1-C6alkyl, C3-C6cycloalkyl, C2-C6alkenyl, or C2-C6alkynyl optionally substituted with one or more independently selected -NRz7R4d, R5is H, deuterium, Br, I, -ORu1, -O-(C2-C6alkynyl), -C(O)NRu2Ru3, -C(O)-M1-N(Ry1)-R5a, - C(O)-N(Ry1)-L6-R5a, -C(O)-M1-N(Ry1)-L6-R5a, -N(Ru6)-(L7)n-R5b, C1-C6 alkyl optionally substituted with one or more -OR5A, C3-C6 cycloalkyl optionally substituted with one or more -OR5A, C2-C6alkenyl optionally substituted with one or more R5B, C2-C6alkynyl optionally substituted with one or more -NRu7R5c, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5C, R5A, at each occurrence, is independently selected from the group consisting of H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl, and C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl; R5B, at each occurrence, is independently -ORa, -N(Ra)2, or C6-C12aryl; and R5C, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R3a, R3b, R4a, R4b, R4c, R4d, R5a, R5b, and R5c, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl optionally substituted with one or more independently selected -ORa, C(O)N(Ra)2, or -S(O)2N(Ra)2; or C3-C14cycloalkyl; M1 is C6-C12 arylene, C3-C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14- membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or - C(O)-N(Ra)2; L1, L2, L3, L4, L5, L6, and L7, at each occurrence, are independently C1-C8alkylene; n, at each occurrence, is independently 0 or 1; Rw1, Rw2, Rw3, Rw4, Rw5, Rw6, Rw7, Rw8, Rw9, Ry1, Ry3, Ry4, Ry5, Ry6, Ry7, Ry8, Ry9, Rz1, Rz2, Rz3, Rz4, Rz5, Rz6, Rz7, Ru1, Ru2, Ru3, Ru6, Ru7, and Ra, at each occurrence, areindependently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen; provided that, when R5is unsubstituted C1-C6alkyl or -ORu1, or when R4is Br, R3is not H; and at least one of R1, R3, R4, and R5is not H.

90. The compound of claim 89, or a salt thereof, wherein R1is H, D, -N(Rw1)-(L1)n-R1a, - N(Rw4)-C(O)-(L2)n-R1b, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, C1-C6alkyl optionally substituted with one or more independently selected halogen, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen, or C2-C6alkynyl optionally substituted with one or more independently selected - N(Rw9)R1f.

91. The compound of claim 89 or 90, or a salt thereof, wherein R1is -N(Rw1)-L1-R1a, wherein L1is C1-C6alkylene, and wherein R1ais 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl.

92. The compound of any one of claims 89-91, or a salt thereof, wherein R3is H or D.

93. The compound of any one of claims 89-91, or a salt thereof, wherein R3is -N(Ry3)- R3a, -C(O)ORy4, or -N(Ry7)C(O)R3b, wherein R3aand R3bare each independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl.

94. The compound of any one of claims 89-93, or a salt thereof, wherein R4is halogen.

95. The compound of any one of claims 89-93, or a salt thereof, wherein R4is C2-C6 alkenyl or C2-C6alkynyl optionally substituted.

96. The compound of any one of claims 89-95, or a salt thereof, wherein R5is H, deuterium, or Br.

97. The compound of any one of claims 89-95, or a salt thereof, wherein R5is -O-(C1-C6haloalkyl), -C(O)NRu2Ru3, -C(O)-M1-N(Ry1)-R5a, -C(O)-N(Ry1)-L6-R5a, -C(O)-M1- N(Ry1)-L6-R5a, C2-C6 alkenyl optionally substituted with one or more R5B, or C2-C6alkynyl optionally substituted with one or more independently selected.

98. The compound of any one of claims 89-97, or a salt thereof, wherein M1is 3- to 14- membered heterocyclylene.

99. The compound of claim 89, or a salt thereof, selected from compounds in Table 2, or a salt thereof.

100. A compound of Formula (III)or a salt thereof, wherein: R2is halogen, -N(Rx1)Rx2, -N(Rx3)R2a, -C(O)N(Rx4)R2b, -N(Rx5)C(O)Rx6, -N(Rx7)C(O)R2c, or -N(Rx8)C(O)N(Rx9)R2d, R3is H, deuterium, halogen, or -CN; R4is H or deuterium; R5is H, deuterium, halogen, -OH, -OD, -NRu1Ru2, -N(Ru3)C(O)ORu4, -N(Ru5)-C(O)-(L1)n- R5a, -N(Ru6)C(O)NRu7Ru8, -N(Ru9)-C(O)-N(Ru10)-(L2)n-R5b, -(L3)n-COORu11, -(L4)n- C(O)NRu12Ru13, or C2-C6alkynyl optionally substituted with one or more -NRu14R5c, R2a, R2b, R2c, R2d, R5a, R5b, and R5c, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6alkyl, C3- C6cycloalkyl, or -C(O)ORa; or C6-C12aryl optionally substituted with one or more independently selected -ORaor -S(O)2N(Ra)2; n, at each occurrence, is independently 0 or 1; L1, L2, L3, L4, at each occurrence, are independently C1-C8alkylene;, Ru10, Ru11, Ru12, Ru13, Ru14, and Ra, at each occurrence, are independently H, deuterium, C1- C6alkyl, or C3-C6cycloalkyl.

101. The compound of claim 100, or a salt thereof, wherein R2is -N(Rx1)Rx2, -N(Rx3)R2a, - N(Rx7)C(O)R2c, -N(Rx5)C(O)Rx6, or -N(Rx8)C(O)N(Rx9)R2d.

102. The compound of claim 100 or 101, or a salt thereof, wherein R2is -N(Rx3)R2aor - N(Rx8)C(O)N(Rx9)R2d, and wherein R2aand R2dare each independently 3- to 14- membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)ORa.

103. The compound of any one of claims 100-102, or a salt thereof, wherein R3is H, deuterium, or F.

104. The compound of any one of claims 100-103, or a salt thereof, wherein R5is H, deuterium, -NH2, -NHD, -ND2, -N(Ru5)-C(O)-R alkynyl optionally substituted with one or more.

105. The compound of claim 100, or a salt thereof, selected from compounds in Table 3, or a salt thereof.

106. A compound of Formula (IV)or a salt thereof, wherein: R1is H, deuterium, or halogen; R2is -N(Rx1)-R2a, -OR2b, or -SR2c; R3is H, deuterium, -C(O)NRy1Ry2, or -C(O)N(Ry3)-L1-R2d; R2a, R2b, R2c, and R2dare each independently 3- to 14-membered heterocyclyl, C6-C12aryl, 5- to 14-membered heteroaryl, or C3-C14 cycloalkyl, each of which is independently substituted with one or more Ra; L1is C1-C6alkylene; Rx1, Ry1, Ry2, Ry3, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl, or C3-C6 cycloalkyl.

107. The compound of claim 106, or a salt thereof, wherein R1is Br.

108. The compound of claim 106 or 107, or a salt thereof, wherein R2is -N(Rx1)-R2a, and R2ais 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl.

109. The compound of claim 106, or a salt thereof, selected from compounds Table 4, or a salt thereof. 110.! A pharmaceutical formulation comprising a compound of any one of claims 1-109, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

111. A method of modulating the conformation of a mutant p53 protein, comprising contacting the mutant p53 protein with an effective amount of a compound of Formula (Y):or a salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

112. The method of claim 111, wherein the mutant p53 protein comprises a Y220C mutation.

113. A method of restoring wild-type function of a mutant p53 protein, comprising contacting the mutant p53 protein with an effective amount of a compound of Formula (Y):or a salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

114. The method of claim 113, wherein the mutant p53 protein comprises a Y220C mutation.

115. A method of treating a proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

116. The method of claim 115, wherein the proliferative disorder is associated with a mutant p53 protein.

117. The method of claim 116, wherein the mutant p53 protein comprises a Y220C mutation.

118. The method of any one of claims 115-117, wherein the proliferative disorder is cancer.

119. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (Y):or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently CH, N, NH, O, or S, wherein each CH or NH is independently optionally substituted; J and K are each independently C or N; q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Y) is aromatic.

120. The method of claim 119, wherein the cancer is associated with a p53 protein comprising a Y220C mutation.

121. The method of any one of claims 111-120, wherein J and K are both C.

122. The method of any one of claims 111-121, wherein r and s are each 1 and q is 2.

123. The method of any one of claims 111-122, wherein one of r and s is 1 and the other is 2.

124. The method of claim 123, wherein q is 1.

125. The method of claim 123, wherein q is 2.

126. The method of any one of claims 111-125, wherein the compound is of Formula (Za)or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently C(Rz), N, N(Rz), O, or S;q, r, and s are each independently 1 or 2; at least one of r and s is 1; and the sum of r, s and q is 4 or 5; each Rz, when present, is independently H, deuterium, halogen, -CN, -NO2, -ORza, -ORw1, - O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2-Rzb, - N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw5)-M1-M2-C(O)- Rzd, -N(Rw9)-Rze, -N(Rw5)-M1-M2-C(O)-N(Rw7)-(L3)n-Rze, -N(Rw10)-M2-L4-Rzf, -N(Rw10)-M2- Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw12)-M4-M5-C(O)-N(Rw13)-Rx, -N(Rw11)-Rx, - N(Rw12)-M4-L5-N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5- L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, - C(O)ORw18, -C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)- M6-Rzk, -C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26Rzmor two vicinal Rzgroups are taken together with the atoms to which they are attached to form a C6-C12 aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e;R5C, at each occurrence, is independently H, deuterium, or C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, C1-C6alkyl, C3-C6cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, C6-C12aryl optionally substituted with one or more independently selected –(C1-C6 alkyene)-OH, 3- to 14- membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rxand Ry, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1-with one or more independently selected C1-C6alkyl; C6-C12aryl optionally substituted with one or more independently selected CN or C1-C6 alkoxy; and C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected- OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12 arylene, C3- C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen; and wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Z) is aromatic.

127. The method of any one of claims 111-125, wherein the compound is of Formula (Z)or a pharmaceutically acceptable salt thereof, wherein: each A, B, D, G, and H is independently C(Rz), N, N(Rz), O, or S; J and K are each independently C or N; d h i d d tl 1 2at least one of r and s is 1; and the sum of r, s and q is 4 or 5; each Rz, when present, is independently H, deuterium, halogen, -CN, -NO2, -ORza, -ORw1, - O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2-Rzb, - N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw9)-Rze, -N(Rw10)- M2-L4-Rzf, -N(Rw10)-M2-Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw11)-Rx, -N(Rw12)-M4-L5- N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, -C(O)ORw18, - C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)-M6-Rzk, - C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6 alkenyl, or C2-C6alkynyl optionally substituted with one or more -NRw26Rzmor two vicinal Rzgroups are taken together with the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H, deuterium, or C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl;R5D1and R5D2, at each occurrence, are independently H, C1-C6alkyl, C3-C6cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; Rxand Ry, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl; and C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or - OD;R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8alkylene optionally substituted with one or more independently selected- OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12 arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen; and wherein the dot-dashed bonds indicate that the bicyclic ring structure of Formula (Z) is aromatic.

128. The method of any one of claims 111-126, wherein the compound is of Formula (Aa)or a pharmaceutically acceptable salt thereof, wherein: wherein exactly oneR1to R4, when present, are each independently H, deuterium, halogen, -CN, -NO2, -ORza, - ORw1, -O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2- Rzb, -N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw5)-M1-M2-N(Rw10)-M2-Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw11)-Rx, -N(Rw12)-M4-M5-C(O)- N(Rw13)-Rx, -N(Rw12)-M4-L5-N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5-L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, - NRw16Rw17, -C(O)ORw18, -C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, - C(O)N(Rw21)-M6-Rzk, -C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, - Rzm, C2-C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26Rzmor R1is taken together with R2, and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6cycloalkyl optionally substituted with one or more halogen or -OR5C, C2-C6 alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6 alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; or C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12aryl; or C3-C6cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g;Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24,occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6 alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, C6-C12aryl optionally substituted with one or more independently selected –(C1-C6 alkyene)-OH, 3- to 14- membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6alkyl, or C3-C6cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6 alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12 aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl optionally substituted with one or more independently selected CN or C1-C6 alkoxy; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl);L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12arylene, C3- C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

129. The method of any one of claims 111-126, wherein the compound is of Formula (A)or a pharmaceutically acceptable salt thereof, wherein: A1is N or C(R1); A2is N or C(R2); A3is N or C(R3); A4is N or C(R4); wherein exactly one of A1, A2, A3, and A4is N; R1to R4, when present, are each independently H, deuterium, halogen, -CN, -NO2, -ORza, - ORw1, -O-(L1)n-NRw2Rw3, -N(Rw4)-M1-C(O)-L2-Rzb, -N(Rw4)-M1-C(O)-Rzb, -N(Rw4)-C(O)-L2- Rzb, -N(Rw5)-C(O)-Rzc, -N(Rw6)C(O)Rw6, -N(Rw7)-(L3)n-C(O)-N(Rw8)-Rzd, -N(Rw9)-Rze, - N(Rw10)-M2-L4-Rzf, -N(Rw10)-M2-Rzf, -N(Rw10)-L4-Rzf, -N(Rw11)-M3-Rx, -N(Rw11)-Rx, - N(Rw12)-M4-L5-N(Rw13)Rzg, -N(Rw12)-M4-N(Rw13)Rzg, -N(Rw12)-L5-N(Rw13)Rzg, -N(Rw14)-M5- L6-N(Rw15)-Ry, -N(Rw14)-M5-N(Rw15)-Ry, -N(Rw14)-L6-N(Rw15)-Ry, -(L7)n-Rzh, -NRw16Rw17, - C(O)ORw18, -C(O)Rzi, -C(O)Rw19, -C(O)N(Rw20)-Rzj, -C(O)N(Rw21)-L8-Rzk, -C(O)N(Rw21)-M6-Rzk, -C(O)N(Rw21)-L8-M6-Rzk, -C(O)NRw22Rw23, -SRzl, -S(O)2NRw24Rw25, -Rzm, C2-C6alkenyl, or C2-C6 alkynyl optionally substituted with one or more -NRw26Rzmor R1is taken together with R2, and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R5is H, deuterium, halogen, -(L9)n-NR5AR5B, -(L10)n-COORu1, -(L11)n-C(O)NRu2Ru3, -ORu4, - O-(C2-C6alkynyl), -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L12-R5a, -C(O)-M7-N(Ru5)-L12-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)Ru11, -N(Ru12)-C(O)-(L13)n- R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L14)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6cycloalkyl optionally substituted with one or more halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6 alkynyl optionally substituted with one or more R5E, C6-C12aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; or C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12 aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5for R5g; R5F, at each occurrence, is independently C1-C6alkyl or C3-C14cycloalkyl; Rza, Rzb, Rzc, Rzd, Rze, Rzf, Rzg, Rzh, Rzi, Rzj, Rzk, Rzl, Rzm, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionallyto 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L15)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; Rx, Ry, and Rz, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L16)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more independently selected -OH or - OD; R5xis C1-C6 alkyl optionally substituted with one or more independently selected -O-(C1-C6 haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, and L16, at each occurrence, are independently C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently C6-C12 arylene, C3- C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN,m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;Rw18, Rw19, Rw20, Rw21, Rw22, Rw23, Rw24, Rw25, Rw26, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, are independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen, or C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen.

130. The method of claim 128, wherein the compound of Formula (Aa) is a compound of Formula (Ba)or a pharmaceutically acceptable salt thereof, wherein exactly oneR1, when present, is H, deuterium, halogen, -NO2, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, - N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, - C(O)Rw9, C3-C14cycloalkyl, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OH, C3-C6cycloalkyl optionally substituted with one or more groups independently selected from the group consisting of halogen and -OH, or C2-C6 alkynyl optionally substituted with one or more independently selected -NRw10R1f, R2, when present, is H, halogen, -OR2a, -O-(L4)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)- R2c, -N(Rx5)-M1-C(O)-L5-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L5-R2d, -N(Rx5)-M1-M2- C(O)-R2d, -N(Rx6)-(L6)n-C(O)-N(Rx7)-R2e, -N(Rx5)-M1-M2-C(O)-N(Rx7)-(L3)n-R2e, -N(Rx8)- M3-L7-N(Rx9)R2f, -N(Rx8)-M3-N(Rx9)R2f, -N(Rx8)-L7-N(Rx9)R2f, -N(Rx10)-R2g, -N(Rx11)-M2- L8-R2h, -N(Rx11)-M2-R2h, -N(Rx11)-L8-R2h, -N(Rx12)-(M4)m-R2x, -N(Rx12)-M4-M5-C(O)- N(Rx13)-R2x, -(L9)n-R2i, -C(O)R2j, -N(Rx13)-M5-L10-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, - N(Rx13)-L10-N(Rx14)-R2y, -R2z, -C(O)N(Rx15)-R2k, or -N(Rx16)C(O)Rx17,or R1is taken together with R2, and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; R3, when present, is H, deuterium, halogen, -CN, -N(Ry1)Ry2, -N(Ry3)-R3a, -C(O)ORy4, - N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, -C(O)NRy8Ry9, or -S(O)2NRy10Ry11; R4, when present, is H, deuterium, halogen, -N(Rz1)Rz2, -NO2, -C(O)ORz3, -N(Rz4)-(L11)n-R4a, -N(Rz5)-C(O)-(L12)n-R4b, -C(O)-R4c, -C(O)N(Rz3)-R4d, -C(O)N(Rz4)-L13-M6-R4e, - C(O)N(Rz4)-L13-R4e, -C(O)N(Rz4)-M6-R4e, -C(O)NRz5Rz6, C3-C14cycloalkyl, C1-C6alkyl, C2- C6alkenyl, or C2-C6alkynyl optionally substituted with one or more independently selected NRz7R4f, R5is H, deuterium, halogen, -(L14)n-NR5AR5B, -(L15)n-COORu1, -(L16)n-C(O)NRu2Ru3, -ORu4, -O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-L17-R5a, -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L17-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)ORu11, -N(Ru12)-C(O)- (L18)n-R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L19)n-R5d, C1-C6alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F, R5Aand R5B, at each occurrence, are independently Ra, C2-C6alkynyl, or R5e; R5C, at each occurrence, is independently H; deuterium; C1-C6 alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6R5E, at each occurrence, is independently -N(Ra)R5f, or R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2j, R2k, R3a, R3b, R4a, R4b, R4c, R4d, R4e, R4f, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14 cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12 aryl), -C(O)ORa, -C(O)-(L20)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, C6-C12 aryl optionally substituted with one or more independently selected –(C1-C6alkyene)-OH3- to 14- membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; R2x, R2y, and R2z, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L21)n-(C6-C12aryl); 3- to 14-membered heterocyclyl optionally substituted with one or more independently selected oxo, C1- C6 alkyl, or C3-C6 cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; C6-C12aryl optionally substituted with one or more independently selected CN or C1-C6 alkoxy; or C3-C14 cycloalkyl optionally substituted with one or more -OH or -OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, and L21at each occurrence, are independently selected C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently selected C6-C12arylene, C3-C14cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -N(Ra)2, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)- N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rx10, Rx11, Rx12, Rx13, Rx14, Rx15, Rx16, Rx17, Ry1, Ry2, Ry3, Ry4, Ry5, Ry6, Ry7, Ry8, Ry9, Ry10, Ry11, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, is independently H, deuterium, C1-C6 alkyl optionally substituted with one or more independently selected halogen; or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

131. The method of claim 128, wherein the compound of Formula (A) is a compound of Formula (B)or a pharmaceutically acceptable salt thereof, wherein exactly oneR1, when present, is H, deuterium, halogen, -NO2, -N(Rw1)-(L1)n-R1a, -N(Rw2)C(O)Rw3, - N(Rw4)-C(O)-(L2)n-R1b, -C(O)ORw5, -OR1c, -N(Rw6)C(O)N(Rw7)R1d, -C(O)N(Rw8)-(L3)n-R1e, - C(O)Rw9, C3-C14 cycloalkyl, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OH, C3-C6 cycloalkyl optionally substituted with one or more groups independently selected from the group consisting of halogen and -OH, or C2-C6alkynyl optionally substituted with one or more independently selected -NRw10R1f,R2, when present, is H, halogen, -OR2a, -O-(L4)n-NRx1Rx2, -C(O)ORx3, -SR2b, -N(Rx4)-C(O)- R2c, -N(Rx5)-M1-C(O)-L5-R2d, -N(Rx5)-M1-C(O)-R2d, -N(Rx5)-C(O)-L5-R2d, -N(Rx6)-(L6)n- C(O)-N(Rx7)-R2e, -N(Rx8)-M3-L7-N(Rx9)R2f, -N(Rx8)-M3-N(Rx9)R2f, -N(Rx8)-L7-N(Rx9)R2f, - N(Rx10)-R2g, -N(Rx11)-M2-L8-R2h, -N(Rx11)-M2-R2h, -N(Rx11)-L8-R2h, -N(Rx12)-(M4)m-R2x, - (L9)n-R2i, -C(O)R2j, -N(Rx13)-M5-L10-N(Rx14)-R2y, -N(Rx13)-M5-N(Rx14)-R2y, -N(Rx13)-L10- N(Rx14)-R2y, -R2z, -C(O)N(Rx15)-R2k, or -N(Rx16)C(O)Rx17, or R1is taken together with R2, and the atoms to which they are attached to form a C6-C12aryl or 5- to 14-membered heteroaryl, each of which is optionally substituted with one or more R1b; R1b, at each occurrence, is independently halogen, -CN, 3- to 14-membered heterocyclyl, or -N(Ra)-(3- to 14-membered heterocyclyl), wherein any 3- to 14- membered heterocyclyl of R1b, at each occurrence, is independently and optionally substituted with one or more independently selected C1-C6alkyl or C3-C6cycloalkyl; R3, when present, is H, deuterium, halogen, -CN, -N(Ry1)Ry2, -N(Ry3)-R3a, -C(O)ORy4, - N(Ry5)C(O)Ry6, -N(Ry7)C(O)R3b, -C(O)NRy8Ry9, or -S(O)2NRy10Ry11; R4, when present, is H, deuterium, halogen, -N(Rz1)Rz2, -NO2, -C(O)ORz3, -N(Rz4)-(L11)n-R4a, -N(Rz5)-C(O)-(L12)n-R4b, -C(O)-R4c, -C(O)N(Rz3)-R4d, -C(O)N(Rz4)-L13-M6-R4e, - C(O)N(Rz4)-L13-R4e, -C(O)N(Rz4)-M6-R4e, -C(O)NRz5Rz6, C3-C14cycloalkyl, C1-C6alkyl, C2- C6 alkenyl, or C2-C6 alkynyl optionally substituted with one or more independently selected NRz7R4f, R5is H, deuterium, halogen, -(L14)n-NR5AR5B, -(L15)n-COORu1, -(L16)n-C(O)NRu2Ru3, -ORu4, -O-(C2-C6 alkynyl), -C(O)-M7-N(Ru5)-L17-R5a, -C(O)-M7-N(Ru5)-R5a, -C(O)-N(Ru5)-L17-R5a, - C(O)-N(Ru6)-R5b, -C(O)-N(Ru7)-R5x, -C(O)NRu8Ru9, -N(Ru10)C(O)ORu11, -N(Ru12)-C(O)- (L18)n-R5c, -N(Ru13)-C(O)-NRu14Ru15, -N(Ru16)-C(O)-N(Ru17)-(L19)n-R5d, C1-C6 alkyl optionally substituted with one or more independently selected halogen or -OR5C, C3-C6 cycloalkyl optionally substituted with one or more independently selected halogen or -OR5C, C2-C6alkenyl optionally substituted with one or more R5D, C2-C6alkynyl optionally substituted with one or more R5E, C6-C12 aryl, or 5- to 14-membered heteroaryl optionally substituted with one or more R5F,R5C, at each occurrence, is independently H; deuterium; C1-C6alkyl optionally substituted with one or more independently selected -ORaor C6-C12 aryl; or C3-C6 cycloalkyl optionally substituted with one or more independently selected -ORaor C6- C12aryl; R5D, at each occurrence, is independently -OR5D1, -N(Ra)R5D2, or R5h; R5D1and R5D2, at each occurrence, are independently H, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, or R5i; R5E, at each occurrence, is independently -N(Ra)R5f, or R5g; R5F, at each occurrence, is independently C1-C6 alkyl or C3-C14 cycloalkyl; R1a, R1b, R1c, R1d, R1e, R1f, R2a, R2b, R2c, R2d, R2e, R2f, R2g, R2h, R2i, R2j, R2k, R3a, R3b, R4a, R4b, R4c, R4d, R4e, R4f, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5i, at each occurrence, are independently 3- to 14-membered heterocyclyl optionally substituted with one or more R21, C6-C12 aryl optionally substituted with one or more R22, 5- to 14-membered heteroaryl optionally substituted with one or more R23, or C3-C14cycloalkyl optionally substituted with one or more R24; R21, R22, R23, and R24, at each occurrence, are independently oxo, halogen, -CN, -ORa, -S(O)2Ra, -S(O)2-(C6-C12aryl), -C(O)ORa, -C(O)-(L20)n-N(Ra)2, -C(O)Ra, - C(O)N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)2, -S(O)2N(Ra)2, C1-C6alkyl optionally substituted one or more R21a, C3-C6 cycloalkyl optionally substituted one or more R21a, 5- to 12 membered heteroaryl substituted with one or more Ra, 3- to 14-membered heterocyclyl optionally substituted with one or more R21b, or, R21a, at each occurrence, is independently halogen, oxo, -ORa, -N(Ra)C(O)Ra, -C(O)-N(Ra)2, -N(Ra)2, C6-C12 aryl, 3- to 14-membered heterocyclyl, or 5- to 14-membered heteroaryl; R21b, at each occurrence, is independently -CN, oxo, C1-C6 alkyl, or C3-C6 cycloalkyl; R2x, R2y, and R2z, at each occurrence, are independently C1-C6alkyl optionally substituted with one or more R25; R25, at each occurrence, is independently halogen; -ORa; -O-(C6-C12 aryl); -N(Ra)2; - C(O)-N(Ra)2; -N(Ra)C(O)-Ra; -N(Ra)C(O)-(L21)n-(C6-C12aryl); 3- to 14-memberedC6alkyl, or C3-C6cycloalkyl; 3- to 14-membered heteroaryl optionally substituted with one or more independently selected C1-C6 alkyl or C3-C6 cycloalkyl; C6-C12 aryl; or C3-C14 cycloalkyl optionally substituted with one or more -OH or -OD; R5xis C1-C6alkyl optionally substituted with one or more independently selected -O-(C1-C6haloalkyl); L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, and L21 at each occurrence, are independently selected C1-C8 alkylene optionally substituted with one or more independently selected -OH, -OD, -CN, or halogen; M1, M2, M3, M4, M5, M6, and M7, at each occurrence, are independently selected C6-C12 arylene, C3-C14 cycloalkylene, 3- to 14-membered heterocyclylene, or 5- to 14-membered heteroarylene, each of which is optionally substituted with one or more independently selected oxo, -CN, halogen, -OH, -OD, C1-C6 alkyl, C3-C6 cycloalkyl, or -C(O)-N(Ra)2; m, at each occurrence, is independently 0 or 1; n, at each occurrence, is independently 0 or 1;, Rx10, Rx11, Rx12, Rx13, Rx14, Rx15, Rx16, Rx17, Ry1, Ry2, Ry3, Ry4, Ry5, Ry6, Ry7, Ry8, Ry9, Ry10, Ry11, Ru1, Ru2, Ru3, Ru4, Ru5, Ru6, Ru7, Ru8, Ru9, Ru10, Ru11, Ru12, Ru13, Ru14, Ru15, Ru16, Ru17, and Ra, at each occurrence, is independently H, deuterium, C1-C6alkyl optionally substituted with one or more independently selected halogen; or C3-C6cycloalkyl optionally substituted with one or more independently selected halogen.

132. The method of any one of claims 111-131, wherein the compound is of any one of claims 1-110, or a pharmaceutically acceptable salt thereof.

133. A pharmaceutical formulation comprising a compound of Formula (Za), (Aa), (Ba), (Y), (Z), (A), or (B), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

134. A pharmaceutical formulation comprising a compound of Formula (Y), (Z), (A), or (B), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

135. A formulation comprising a compound of Formula (Za), (Aa), (Ba), (Y), (Z), (A), or (B), or a pharmaceutically acceptable salt thereof, wherein the composition is sterile.

136. A formulation comprising a compound of Formula (Y), (Z), (A), or (B), or a pharmaceutically acceptable salt thereof, wherein the composition is sterile.

137. A composition comprising a mutant p53 protein and a p53 stabilizer having a covalent bond to the mutant p53 protein, wherein the mutant p53 protein comprises a Y220C mutation,and the covalent bond is formed between a -CN group of the p53 stabilizer and the cysteine at position 220 in the mutant p53 protein.

138. The composition of claim 137, wherein the mutant p53 protein has greater wild-type function compared to a composition comprising the mutant p53 protein without the p53 stabilizer having a covalent bond to the mutant p53 protein.

139. The composition of claim 137 or claim 138, wherein the mutant p53 protein has a greater wild-type conformation compared to a composition comprising the mutant p53 protein without the p53 stabilizer having a covalent bond to the mutant p53 protein.

140. The composition of any one of claims 137-139, wherein the p53 stabilizer is a compound of Formula (Za), (Aa), (Ba), (Y), (Z), (A), or (B), or a compound of any one of claims 1-87, or a pharmaceutically acceptable salt thereof.

141. The composition of any one of claims 137-139, wherein the p53 stabilizer is a compound of Formula (Y), (Z), (A), (B), or a compound of any one of claims 1-110, or a pharmaceutically acceptable salt thereof.

Citation Information

Patent Citations

  • P53-Y220C selective small-molecule reactivator compound, pharmaceutical composition and application of p53-Y220C selective small-molecule reactivator compound

    CN117986235A

  • Hydrazne derivatives for the treatment of cancer

    WO2016123253A1

  • Methods and compounds for restoring mutant p53 function

    WO2021262596A1

Cited By

  • Fused azoles as p53 mutant stabilizer

    WO2025184119A1